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ABSTRACT 
 
Antibody production is a key feature of the adaptive immune response. High affinity 
antibodies neutralise and clear invading pathogens, thereby protecting the host 
against microbial infections. It is now well-established that T follicular helper (Tfh) 
cells – a distinct subset of CD4+ T helper cells – are essential in providing cognate 
help to B cells in the germinal centre (GC) to differentiate into memory and long-lived 
plasma cells that secrete high affinity antibodies. However, stringent control of Tfh 
cell numbers is crucial to produce optimally affinity-matured antibody responses that 
are devoid of self-reactivity. Indeed, excessive number of Tfh cells has been 
associated with autoimmunity. However, our understanding of the molecular 
mechanisms controlling Tfh cell differentiation is still incomplete. This thesis focuses 
on characterising novel post-transcriptional mechanisms that limit Tfh cell numbers.  
 
The data presented in this thesis show that RNA-binding proteins, Roquin and its 
paralogue Roquin-2, cooperate to repress Icos, a key Tfh cell molecule, and limit GC 
reactions. Mutations in the RING or ROQ domain of Roquin disrupted Icos mRNA 
regulation, but, unlike the ROQ mutant that still occupied mRNA-regulating stress 
granules, RING-deficient Roquin failed to localise to stress granules and allowed 
Roquin-2 to compensate in the repression of ICOS. In addition, the data presented 
here show that microRNA-146a is highly expressed in human and mouse Tfh cells 
and its peak expression marks the decline of the Tfh cell response. Loss of miR-146a 
caused cell-autonomous, spontaneous accumulation of Tfh and GC B cells. 
Mechanistically, miR-146a acted in both Tfh and GC B cells to control ICOS-ICOSL 
interactions and limit Tfh and GC B cell numbers. Collectively, Roquin family proteins 
and miR-146a emerge as novel post-transcriptional brakes on ICOS expression, thus 
limiting Tfh cell numbers and GC responses. 
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CHAPTER ONE 
 
 
Introduction 
 
An organism is constantly facing threats from its environment. These threats have 
acted as evolutionary pressures leading to the emergence of various protective 
mechanisms. In vertebrates, physical barriers like skin and mucosa act as a first line 
of defense barring entry to a wide variety of harmful microorganisms, such as 
bacteria, viruses, and parasites. Additionally, secretions from the skin and mucous 
membranes provide an environment that is often hostile to microbes and may also 
contain anti-microbial proteins. Pathogens that manage to breach these barriers must 
contend with a diverse set of specialised immune cells and molecules that have the 
capacity to recognise and eliminate them while mostly sparing the host tissue from 
collateral damage. Bone marrow-derived B cells and thymus-derived T cells are 
examples of such cells and they will be the central focus of this thesis.  
 
T cells are critical mediators of the adaptive immune response. They develop in the 
thymus where immature T cells bearing receptors that can potentially recognise self- 
tissue are censored from the repertoire. This is one of the strategies to maintain 
immunological tolerance (Bluestone, 2011). Naïve T cells then emerge from the 
thymus and differentiate, after stimulated by their cognate antigen presented by 
competent antigen-presenting cells, to become cytotoxic T cells or helper T (Th) cells 
with specialised phenotypes. Mosmann and Coffman initially classified activated Th 
cells into 2 distinct lineages termed Th1 and Th2 cells (Mosmann et al., 1986). Th1 
cells produce interferon-gamma (IFN-γ), which is important for protective response to 
intracellular viral and bacterial infections, whereas secretion of interleukin (IL)-4, IL-5, 
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and IL-13 by Th2 cells are crucial for barrier protection and eliminating extracellular 
parasites including helminths (Zhu and Paul, 2010). The work presented here 
focuses on T follicular helper (Tfh) cells, a distinct subset of activated Th cells, whose 
main role is to help B cells produce high affinity antibodies (Crotty, 2011). Tfh cells 
express a unique combination of effector molecules that are critical in promoting the 
activation, differentiation, and survival of B cells (Crotty, 2011; King et al., 2008; 
Vinuesa et al., 2005b). For instance, CD40 ligand (CD40L) rescues B cells from 
apoptosis and promotes their proliferation (Koopman et al., 1997), and IL-21 
enhances the differentiation of CD40L-stimulated B cells and induces antibody 
production (Avery et al., 2008; Bryant et al., 2007; Ettinger et al., 2005).  
 
Recent studies have shown that Tfh cell numbers have to be tightly regulated for 
optimal production of high affinity antibody responses that are devoid of self-reactivity 
(Schwickert et al., 2011; Victora et al., 2010). A large amount of “molecular rheostats” 
controlling Tfh cell homeostasis have evolved to enable rapid and effective control of 
this population that is crucial for mounting protection against microbes, but can also 
trigger autoimmunity when overactive. Because Tfh cell selection gives rise to long-
lived antibody-secreting B cells that can survive for years or decades in an individual, 
it appears favourable that multiple layers of gene regulation – transcriptional, post-
transcriptional, and post-translational – operate to fine-tune and curtail the Tfh cell 
response. Studies in the past decade have begun to characterise the molecular 
mechanisms required for Tfh cell differentiation (elaborated later in this chapter), 
although this is likely to be just the tip of the iceberg. 
 
The aim of this work is to identify novel post-transcriptional mechanisms that control 
Tfh cell differentiation. Specifically, 1) to understand the contribution of the RNA-
binding proteins Roquin and Roquin-2 in repressing Icos mRNA and Tfh cell numbers 
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and 2) to characterise the role of microRNA-146a, a microRNA that is often 
dysregulated in systemic autoimmune diseases, in limiting the number of Tfh cells. 
 
T CELL-DEPENDENT IMMUNE RESPONSE 
 
Innate vs adaptive immune response 
 
The immune system of higher vertebrates can be divided into two major categories: 
the innate and the adaptive. Whereas the innate immune system recognises non-self 
antigens through germline-encoded receptors, the adaptive immune response relies 
on the activation, expansion, and effector function of lymphocytes with gene-
rearranged receptors. Nonetheless, three basic properties of all immune cells are 
their ability to recognise diverse arrays of pathogens, kill or inactivate those 
pathogens, and discriminate self against non-self tissues. 
 
Innate immunity is the most rapidly acting arm of the immune system mediated in 
large part by myeloid and natural killer (NK) cells. The general strategy of innate 
immune detection is using a limited number of receptors to recognise broadly 
conserved microbial molecules (Kimbrell and Beutler, 2001). These signature 
molecules, known as pathogen-associated molecular patterns (PAMPs), are mostly 
essential for survival and pathogenicity (Akira et al., 2001; Janeway and Medzhitov, 
2002). PAMPs are sensed by evolutionarily conserved, germline-encoded sensors 
known as pathogen recognition receptors (PRRs), which trigger an array of anti-
microbial immune responses such as secretion of inflammatory cytokines and type I 
interferons (Akira et al., 2006). Several families of PRRs, including Toll-like receptors 
(TLRs), RIG-I-like receptors (RLRs), NOD-like receptors (NLRs), and cytosolic 
sensors for DNA, are known to play a crucial role in host defense (Akira et al., 2006; 
Kumar et al., 2011).  
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The main effectors of the adaptive immune response are B and T lymphocytes. Each 
lymphocyte is equipped with a unique antigen receptor that collectively may 
recognise any specific antigen on invading pathogens. This enormous diversity of 
lymphocytes’ antigen receptor repertoire is generated through random genetic 
rearrangements of antigen receptor genes (Tonegawa, 1983), which occur in the 
bone marrow for B cells (Hardy and Hayakawa, 2001) or the thymus for T cells 
(Takahama, 2006). Once stimulated via their antigen receptors, B and T cells can 
elicit potent effector functions, including antibody production by B cells and cytokine 
secretion by T cells, and generate immunological memory. Multiple strategies have 
also evolved to maintain self-tolerance in the immune repertoire and this is crucial to 
protect the body against “friendly fire” from autoreactive lymphocytes (Bluestone, 
2011). 
 
Despite their differences, the innate and the adaptive immune responses are tightly 
connected and function best in conjunction with one another. Myeloid cells, such as 
dendritic cells (DCs) and macrophages, engulf microbes and present their antigens 
to lymphocytes in the presence of costimulatory molecules leading to lymphocyte 
activation (Vyas et al., 2008). Antibodies produced by B cells opsonise bacteria for 
phagocytosis by myeloid cells (Aderem and Underhill, 1999). Innate immune cells 
secrete cytokines to induce differentiation of T cells along a particular lineage (Zhu 
and Paul, 2010), while they are also responsive to cytokines elaborated by the 
adaptive immune system (Soudja et al., 2014; Yang et al., 2008a). The contribution 
of innate immune cells and their soluble factors to T cell differentiation, in particular 
towards the T follicular helper (Tfh) lineage, will be discussed further in this thesis. 
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B cell development in the bone marrow 
 
The development of B cells is characterised by successive rearrangements, first of 
the genes for the immunoglobulin (Ig) heavy chain and then the genes for the light 
chain (Hardy and Hayakawa, 2001). Successfully-rearranged Ig heavy chain is 
paired with a surrogate light chain to form a pre-B cell receptor (BCR) and this 
transduces a signal that triggers the B cells to undergo a rapid proliferative expansion 
(Karasuyama et al., 1996). After this proliferative burst, B cells will lose the 
expression of the surrogate light chain and start to rearrange the light chain genes. 
Cells that productively rearranged their light chain genes will become immature B 
cells, displaying a functional receptor on the surface. These immature B cells will 
then undergo a selection process to remove potentially self-reactive cells. If an 
immature B cell binds strongly to self-antigens, it will downregulate its BCR and B220 
expression and will be suspended from further differentiation (Hartley et al., 1993). 
Recognition of self-antigen can also result in receptor editing, when the immature B 
cell further rearranges the light chain with the chance of creating a non-autoreactive 
receptor and thus avoid negative selection (Gay et al., 1993; Radic et al., 1993; Tiegs 
et al., 1993). To develop into a mature B cell, the immature B cell leaves the bone 
marrow and migrates to the periphery, where it can encounter antigen and 
differentiate into antibody-secreting cells. Interestingly, in spite of the multiple 
mechanisms to purge self-reactive B cells from the repertoire, previous studies 
showed that approximately close to 20% of mature naïve B cells in the peripheral 
circulation retain low levels of self-reactivity (Wardemann et al., 2003). 
 
T cell development in the thymus 
 
T cell progenitors migrate from the bone marrow to the thymus. The function of the 
thymus is to produce T cells capable of responding to foreign antigen while remaining 
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tolerant to self. Immature T cell (termed thymocyte) development is initiated by the 
process of T cell receptor (TCR) gene rearrangements (Davis and Bjorkman, 1988). 
The early CD4- CD8- double-negative (DN) thymocytes begin this process by 
breaking and joining gene segments at the Tcrb locus. Upon successful expression 
of a TCR β-chain, this protein is paired with the germline-encoded pre-TCRα protein. 
The pre-TCRα:TCRβ complex transduces a signal that triggers the DN thymocyte to 
enter an intense proliferation phase before upregulating both CD4 and CD8 co-
receptors (Fehling et al., 1995). Double-positive (CD4+ CD8+; DP) thymocytes will 
then initiate another gene rearrangement process in the Tcra locus to generate the 
TCR α-chain. If a productive TCR α-gene rearrangement occurs, the α-chain can pair 
with the existing TCR β-chain and be expressed on the surface as a functional α:β 
TCR.  
 
The next stage of T cell differentiation entails functional selections of α:β TCR+ 
thymocytes and this requires interactions with distinct thymic epithelial cell subsets 
(Anderson and Jenkinson, 2001). Maturing DP thymocytes interact with the cortical 
thymic epithelial cells, which mediate the process of positive selection, defined as the 
rescue of α:β TCR+ thymocytes capable of engaging self-peptide/major 
histocompatibility complex (MHC) ligand from programmed cell death (Wagner et al., 
1996). Non-positively selected cells, which comprise the bulk (about 90%) of the 
TCR+ DP thymocytes, may continue the process of receptor gene rearrangement to 
generate functional TCRs, but most of them will undergo apoptosis (referred to as 
death by neglect) (Cohen, 1992). Due to the random nature of the TCR gene 
rearrangement process, there are always thymocytes bearing TCR with relatively 
high affinity to self antigens. Most of these self-reactive thymocytes are selectively 
eliminated in the thymic medulla through a process called negative selection (Surh 
and Sprent, 1994), while others proceed to differentiate into regulatory T (Treg) cells 
(Lee et al., 2012a). Whether Treg development and negative selection occur at 
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similar or distinct thresholds of self-reactivity is a topic of ongoing research. 
 
The DP thymocytes that survive positive and negative selection ultimately 
downregulate one of the co-receptors to become single-positive cells (CD4+ or 
CD8+). Those that recognise self-peptide expressed in the context of MHC class I 
(MHCI) will downregulate their CD4 expression and differentiate into CD8+ single 
positive thymocytes whereas engagement of MHC class II (MHCII) will induce 
differentiation into CD4+ thymocytes (Germain, 2002). Once the α:β T cells have 
completed maturation in the thymus, they emerge as naïve cells and migrate to the 
periphery where, upon antigen stimulation, they proliferate and differentiate into 
effector T cells.  
 
Effector T cell subsets 
 
Differentiation of CD4+ effector T cell subsets is established by specific cell-cell 
interactions and cytokines, which drive expression of particular transcription factors. 
The transcription factor produced subsequently regulates the expression of various 
surface-bound and soluble molecules that determine cell function, as well as 
chemokine receptors and adhesion molecules that regulate localisation to specific 
tissues. Thus, distinct effector T cell subsets can be defined by their lineage-specific 
transcription factor expression, cytokine production, and subsequent immune 
function. 
 
Th1, Th2 and Th17 cells 
CD4+ effector cells were initially distinguished as Th1 or Th2 cells based on the 
mutually exclusive production of either IFN-γ or IL-4, respectively (Mosmann et al., 
1986). Cells that produce IL-17 were later demonstrated to represent another effector 
T cell population called Th17 cells (Harrington et al., 2005; Park et al., 2005) and 
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several other subsets have also been described in recent years (Dardalhon et al., 
2008; Eyerich et al., 2009; Veldhoen et al., 2008). Each specific subset has been 
associated with a lineage-defining transcriptional regulator: Th1 cells with T-box 
expressed in T cells (T-bet) (Szabo et al., 2000), Th2 cells with GATA-binding protein 
3 (GATA-3) (Zheng and Flavell, 1997), and Th17 cells with retinoic acid receptor-
related orphan receptor gamma t (RORγt) and RORα (Ivanov et al., 2006; Yang et 
al., 2008b). These transcription factors direct the differentiation, cytokine production, 
and effector function of each distinct Th cell subset. Th1 cells, which produce IFN-γ, 
are important for activating macrophages during intracellular viral and bacterial 
infections. Th2 cells producing IL-4, IL-5, and IL-13 are crucial for barrier protection, 
activation of eosinophils and eliminating extracellular parasites including helminths. 
On the other hand, Th17 cells produce IL-17A and IL-17F, which are essential for 
neutrophil recruitment and activation to protect against fungal and bacterial infections 
(Zhu and Paul, 2010).  
 
Tfh cells and other Tfh-like cells 
Tfh cells were initially discovered based on their expression of chemokine (C-X-C 
motif) receptor 5 (CXCR5) that is required for migration towards B cell follicles in 
response to chemokine (C-X-C motif) ligand 13 (CXCL13) (Ansel et al., 1999; Kim et 
al., 2001), produced by follicular stromal cells. Our group and others have identified 
BCL-6 as a key transcriptional regulator in programming Tfh cell differentiation and 
germinal centre (GC) reactions (Johnston et al., 2009; Nurieva et al., 2009; Yu et al., 
2009). BCL-6 deficiency in CD4+ T cells causes failure in the generation of Tfh cells 
and GC responses in vivo, whereas ectopic expression of BCL-6 drives Tfh cell 
development (Johnston et al., 2009; Nurieva et al., 2009; Yu et al., 2009). Other 
molecules including programmed death-1 (PD-1), inducible T-cell costimulator 
(ICOS), signalling lymphocyte activation molecule (SLAM), B and T-lymphocyte 
attenuator (BTLA), and the cytokine IL-21 are highly expressed in Tfh cells (Crotty, 
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2011) and have been used for the phenotypic identification of Tfh cells.  
 
Other CD4+ T cell subsets with Tfh cell-like characteristics have also been recently 
discovered. The precursors of germinal centre Tfh cells – also referred to as pre-Tfh 
cells – express lower amounts of BCL-6, CXCR5 and PD-1, and are typically located 
at the T:B border where they interact with B cells and trigger their proliferation and 
differentiation along the follicular or extrafollicular pathway (Lee et al., 2011; 
MacLennan et al., 2003). King and colleagues described a population of CCR9+ Th 
cells that support antibody production and express high amounts of IL-21, ICOS, 
BCL-6, and c-Maf, but low CXCR5 (McGuire et al., 2011). Circulating CD4+ CXCR5+ 
Tfh-like cells are found in the blood and share functional properties with Tfh cells 
(Chevalier et al., 2011; He et al., 2013; Locci et al., 2013; Morita et al., 2011). Studies 
on human patients found correlative evidence that circulating CD4+ CXCR5+ T cells 
are related to bona fide Tfh cells (discussed later). In addition, our laboratory and 
others have shown invariant natural killer T (iNKT) cells can quickly migrate into the 
GC and support a distinct type of antibody response – thymus-dependent type 2 – in 
response to lipid antigens (Chang et al., 2012a; King et al., 2012). Also, after protein 
immunisation or infection, thymic-derived Tregs can adopt the Tfh differentiation 
pathway and become T follicular regulatory (Tfr) cells, which can migrate into the GC 
where they exert a suppressive function and control the response (Chung et al., 
2011; Linterman et al., 2011; Wollenberg et al., 2011). 
 
T:B cell collaboration in humoral immunity 
 
T helper cells have a crucial role in helping B cells produce antibodies in response to 
microbes. The interaction between these cell types typically occurs either at 
extrafollicular sites or in GCs, which are histologically distinct structures (Cesta, 
2006) that develop within B cell follicles of secondary lymphoid organs. In recent 
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years, Tfh cells have emerged as the key cell type required for the formation of GCs 
and the generation of long-lasting antibody response (Crotty, 2011; King et al., 2008; 
Vinuesa et al., 2005b). Tfh cells are able to localise to the B cell follicle (Garside et 
al., 1998) and to the GC (Breitfeld et al., 2000; Kim et al., 2001; Schaerli et al., 2000) 
to provide essential help for B cell affinity maturation, class switch recombination, 
and memory B cell and plasma cell generation within the GC (Breitfeld et al., 2000; 
Crotty, 2011; Kim et al., 2001; Schaerli et al., 2000). These features make the GC 
essential for protective humoral immunity against many pathogens and the 
subsequent development of immunological memory. 
 
T cell-dependent humoral immune response is initiated with the individual activation 
of B and T cells. B cells can be activated at extrafollicular sites (Qi et al., 2006) or 
inside the follicles. Within the follicle, B cells may acquire soluble antigen that rapidly 
diffuses from the subcapsullar sinuses (Pape et al., 2007) or they may encounter 
antigen-presenting dendritic cells that migrate into the follicle (Berney et al., 1999). 
Once its cognate antigen is captured, naïve B cells relocate to the interface of the T 
cell zone and the B cell follicle (also called the T:B border) (Garside et al., 1998; 
Okada et al., 2005). At this site, B cells process the captured antigen and present 
them on MHCII, allowing them to engage in cognate interaction with primed CD4+ T 
cells and receive T cell help for subsequent proliferation and differentiation into 
antibody-secreting cells (Jacob et al., 1991; MacLennan et al., 1997). 
 
CD4+ T cell priming occurs in the T cell zone and is typically mediated by DCs 
(Mempel et al., 2004). Naïve T cells carrying receptors specific for the presented 
antigen form a stable contact with DC through TCR-MHCII ligation and costimulatory 
CD28-B7 binding. This leads to a clonal expansion of the antigen-specific T cells and 
differentiation into effector T cells. Following interaction at the T:B border, both cells 
	   23 
enter cell cycle and B cells either migrate to the follicle to seed the GC reaction or 
form the extrafollicular foci. 
 
The extrafollicular antibody response 
In the extrafollicular pathway, activated B cells migrate to the splenic bridging 
channels or junction zones at the border between the T cell zones and red pulp or 
the extramedullary cords in the lymph node, where they form foci of short-lived 
plasmablasts (MacLennan et al., 2003). These plasmablasts do not undergo somatic 
hypermutation and typically have modest affinity to antigens, but they can be critical 
for early protection against infection (Luther et al., 1997). 
 
It has been thought that BCL-6+ T cells are not required for the extrafollicular 
antibody response, as neither DCs nor plasmablasts attract antigen-specific T helper 
cells to these sites, and mice lacking BCL-6 specifically in immune cells can still 
mount an extrafollicular response (Fukuda et al., 1997). However, there is 
increasingly more evidence supporting the role of BCL-6+ T helper cells in these 
responses. Our group previously demonstrated that the interaction of BCL-6-
expressing pre-Tfh cells with B cells at the T:B border are essential for B cell priming 
and the subsequent extrafollicular production of IgG1 in responses to the model 
protein antigens hen egg lysozyme and NP-KLH (4[hydroxy-3-nitrophenyl] acetyl 
keyhole limpet haemocyanin) and for the production of Salmonella enterica–specific 
IgG2c (Lee et al., 2011). Furthermore, a study by Brink and colleagues found 
antigen-specific T cells in close contact with plasmablasts within the extrafollicular 
foci after immunisation with a protein antigen HEL-OVA (Chan et al., 2009). Also, 
there is a subset of BCL-6-dependent T cells within extrafollicular foci of lupus-prone 
MRL/Faslpr mice that may play a role as extrafollicular T helper cells and promote 
autoantibody production (Odegard et al., 2008; Poholek et al., 2010). 
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The germinal centre response 
The GC can be divided into two anatomically distinct areas, called the dark zone and 
the light zone. The dark zone is densely packed with proliferating B cells (or 
centroblasts; defined as CXCR4+ CD83- CD86-) in which somatic hypermutation – a 
process of random genetic mutations, mainly single base substitutions with 
occasional insertions and deletions – is targeted at their immunoglobulin variable (V) 
region genes to improve binding affinity to antigen, whereas in the light zone, 
centrocytes (CXCR4- CD83+ CD86+ B cells), many of which have exited cell cycle, are 
interacting with follicular dendritic cells (FDCs) and Tfh cells. Colocalisation and 
cognate interaction between antigen-specific Tfh cells and antigen-specific B cells is 
critical to provide B cells with key signals for survival and differentiation. This is in 
part mediated by TCR-MHCII engagement and Tfh cell-expressed molecules 
including CD40L and IL-21 (Chtanova et al., 2004; Crotty, 2011; Dong et al., 2001b; 
Kim et al., 2004). Selected B cell clones differentiate, but some migrate back to the 
dark zone to undergo further rounds of proliferation and somatic hypermutation 
(MacLennan, 1994; Victora and Nussenzweig, 2012; Victora et al., 2010).  
 
Understanding Tfh cell differentiation and function is of central importance for rational 
vaccine design, as most vaccines rely on protective T cell-dependent antibody 
responses. It is becoming clear that improving vaccine efficiency will not be 
exclusively a matter of maximising the number of Tfh cells, in fact, too many Tfh cells 
are likely to dampen, or even corrupt, affinity maturation. Restricting Tfh cell numbers 
in GCs is likely to be important for optimal selection. Furthermore, it is likely that an 
appropriate balance between Tfh and Tfr cells at the different stages of the immune 
response will prove critical for optimal induction, function and termination of GCs and 
effective protection against infection. In the next sections, the importance of 
controlling Tfh cell numbers for optimal GC reactions is discussed and an overview of 
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the current knowledge regarding T cell-intrinsic and T cell-extrinsic molecular 
mechanisms regulating Tfh cell homeostasis will be presented. 
 
WHY TFH CELL NUMBERS MATTER? 
 
Since the early ‘90s, mathematical models incorporating observations made in 
mouse and human regarding GC B cell cycling rates, compartmentalisation into dark 
zones and light zones, rates of somatic mutation and clonal-diversification, and 
ongoing B cell selection and exit from GCs proposed that GC T cells had to be the 
limiting factor for optimal affinity maturation (Kepler and Perelson, 1993; MacLennan, 
1994). These models predicted that GC T cells would not only provide signals for B 
cell differentiation, but would also induce some B cells found in the light zone to re-
enter cell cycle and migrate back to the dark zone to undergo further rounds of 
somatic mutation and proliferation. Experimental evidence described below 
(summarised in Figure 1.1) has shown these predictions to be largely true. 
 
Lack of Tfh cells causes abortive germinal centres and immunodeficiency  
 
In the context of protein antigens, T cells – and Tfh cells specifically – are essential 
for the induction of GCs (Johnston et al., 2009; MacLennan, 1994; Nurieva et al., 
2009; Yu et al., 2009). Nevertheless, in exceptional circumstances, GCs can form in 
the absence of T cell help: in response to a T-independent antigen, NP-Ficoll, large 
GCs can form in the absence of T cells, or B cell-helping molecules CD40L and 
CD28 (de Vinuesa et al., 2000; Lentz and Manser, 2001). Although these GCs are 
histologically identical with those induced by T cell-dependent antigens, they 
synchronously abort at a point when the first wave of centrocytes was predicted to 
require selection signals from T cells. This suggested that T cell signals are not only 
required for centrocyte selection (de Vinuesa et al., 2000) but also for the recycling of 
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a defined number of centrocytes to renew the pool of dividing cells and therefore 
maintain the GC reaction.  
 
Not surprisingly, genetic mutations causing reduced Tfh cell numbers lead to primary 
immunodeficiency syndrome, such as X-linked lymphoproliferative syndrome (XLP), 
common variable immunodeficiency (CVID), hyper-IgM, and hyper-IgE syndrome. 
Given the difficulty of accessing and analysing secondary lymphoid organs in human 
patients, the frequency of circulating CD4+ CXCR5+ T cells and antibody titres in the 
serum are frequently used in human studies as biomarkers of GC activity and 
disease severity. Mutations in the gene encoding SLAM-associated protein (SAP), 
SH2D1A, cause XLP (Coffey et al., 1998; Nichols et al., 1998; Sayos et al., 1998). 
SAP mediates signal transduction pathways that are elicited through the SLAM family 
of receptors (Cannons et al., 2011). SAP deficiency leads to lack of GC Tfh cells, 
memory B cells, plasma cells, and specific antibodies in the serum (Crotty et al., 
2003; Ma et al., 2005). This is attributable to an inability to form stable SLAM-
mediated T:B cell conjugates which is essential for GC formation in response to T 
cell-dependent antigens, and production of B cell-helping cytokines IL-4 by Tfh cells 
(Cannons et al., 2010b; Yusuf et al., 2010). 
 
Mutations that affect the genes encoding CD40L and ICOS cause hyper-IgM 
syndrome (Allen et al., 1993; Aruffo et al., 1993; DiSanto et al., 1993; Korthauer et 
al., 1993) and common variable immunodeficiency (Warnatz et al., 2006), 
respectively. Patients with hyper-IgM syndrome (Agematsu et al., 1998) or ICOS-
deficient CVID (Warnatz et al., 2006), display obvious defects in humoral immune 
responses, including reductions in the numbers of circulating CD4+ CXCR5+ T cells, 
memory B cells and serum antibody titres. Also, they display an absence of well-
formed GCs in their secondary lymphoid tissues (Bossaller et al., 2006; Facchetti et 
al., 1995; Warnatz et al., 2006). Such defects are also observed in mice with targeted 
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gene deletion in CD40L or ICOS (Dong et al., 2001b; Xu et al., 1994).  
 
 
Patients with autosomal dominant hyper-IgE syndrome due to STAT3 mutations 
(Holland et al., 2007) also show impaired functional antibody responses (Avery et al., 
2010). They exhibit a modest reduction in the numbers of circulating CD4+ CXCR5+ T 
cells (Ma et al., 2012a). STAT3 acts downstream of several Tfh cell-inducing 
cytokines including IL-6, IL-12, IL-21 and IL-27 (Ma et al., 2012a). Similar reduction in 
circulating CD4+ CXCR5+ T cells numbers is observed in patients with mutations in 
IL12RB1, which encodes the IL-12 receptor β1 subunit (Schmitt et al., 2013). This 
correlates with reduced numbers of memory B cells and abnormal GCs. Taken 
together, these analyses of monogenic immunodeficiencies show that in the 
presence of mutations that severely reduce Tfh cell numbers, GC responses are not 
optimal. 
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Figure 1.1 – Limiting TFH cell number is important for optimal germinal centre (GC) reactions.  
(a) Schematic diagrams illustrating the predicted effect of Tfh cell numbers on GC B cell survival (top) and affinity 
maturation (bottom). (b) Schematic diagrams illustrating GC reactions when Tfh cells are absent (top), present in 
limiting number (middle), or present in excess (bottom). Increasing colour intensity of B cells and plasma cells 
represents increasing B cell receptors’ affinity. Tfh: T follicular helper; GC: germinal centre; FDC: follicular dendritic 
cell; DZ: dark zone; LZ: light zone. 
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Limiting Tfh cell numbers are essential for optimal germinal centre reaction 
 
Recent studies have provided experimental evidence backing up the theories that T 
cells are present in limiting amount in the GCs and this is essential for optimal affinity 
maturation. Increasing the number of antigen-specific T cells in an adoptive transfer 
system resulted in increased proliferation and activation of antigen-specific B cells at 
the early stage of the GC reaction, suggesting that T cell help is indeed a limiting 
factor (Schwickert et al., 2011). Also, developing B cells with highest affinity 
receptors are at a competitive advantage to capture more antigens and present them 
at increased concentrations to cognate T cells, thus being more successful at 
establishing sustained interactions and eliciting survival signals (Figure 1.1). This 
was clearly demonstrated in the recent work of Nussenzweig and colleagues using 
targeted antigen delivery through DEC205, which is a surface lectin	   that efficiently 
delivers antigen to the MHCII processing compartment, to a subset of antigen-
specific B cells resulting in more long-lasting motile T:B cell interactions indicative of 
increased T cell help, and consequently increased B cell proliferation and activation 
(Schwickert et al., 2011; Victora et al., 2010).	   
 
Excessive Tfh cells are associated with autoimmunity 
 
Due to the random nature of the somatic hypermutation of B cell receptors in GCs, B 
cells that enter the peripheral repertoire as non-self-reactive can acquire self-
reactivity in the GC. The suggestion that excessive Tfh cell accumulation or 
overactivity may corrupt positive selection, allowing survival of low affinity and even 
self-reactive B cells (illustrated in Figure 1.1), first came from the analysis of lupus-
prone Roquin-mutant (sanroque) mice (Vinuesa et al., 2005a). The ‘san’ mutation in 
the RNA-binding protein, Roquin, leads to impaired target mRNA decay and 
accumulation of molecules important for Tfh cell development including ICOS, IFN-γ, 
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and OX40 (Lee et al., 2012b; Vinuesa et al., 2005a; Vogel et al., 2013). This causes 
excessive Tfh cell accumulation, spontaneous GC formation, autoantibody 
production and immune-complex-mediated glomerulonephritis (Vinuesa et al., 
2005a). Overactive Tfh cells were shown to be responsible for the systemic lupus 
erythematosus (SLE)-like phenotype in sanroque mice (Linterman et al., 2009b). 
Similar to sanroque mice, BXSB-Yaa mice, which are also prone to systemic 
autoimmunity, have spontaneous GC formation with marked Tfh cell expansion and 
excessive IL-21 production (Ozaki et al., 2004). In MRL/Faslpr mice, extrafollicular T 
helper cells expressing ICOS, CD40L and IL-21, drive class switch recombination 
and promote autoantibody production (Odegard et al., 2008; Rankin et al., 2012). 
Taken together, these studies show that Tfh cells are crucial to the pathogenesis of 
SLE-like disease in mice.  
 
Several studies have since reported increases in circulating CD4+ CXCR5+ T cells in 
patients with SLE (Simpson et al., 2010), Sjögren’s syndrome (Szabo et al., 2013), 
myasthenia gravis (Luo et al., 2013), rheumatoid arthritis (Ma et al., 2012c), juvenile 
dermatomyositis (Morita et al., 2011), and autoimmune thyroid diseases (Zhu et al., 
2012); frequency of the circulating CD4+ CXCR5+ T cells were shown to correlate 
with serum autoantibody titres, frequency of plasma cells, and disease severity. In 
multiple sclerosis and experimental autoimmune encephalomyelitis (EAE), self-
reactive T cells – predominantly Th17 cells – have been shown to acquire a Tfh 
phenotype and give rise to ectopic lymphoid tissues containing GCs (Peters et al., 
2011). These studies suggest that Tfh cell dysregulation contributes to the 
pathogenesis of autoantibody-mediated autoimmune diseases in at least a subset of 
patients potentially by allowing survival of self-reactive B cells.  
 
The paradoxical accumulation of Tfh cells in patients with chronic HIV infection has 
also been suggested to be responsible for the dysgammaglobulinemia, defective T-
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dependent responses (Lindqvist et al., 2012; Petrovas et al., 2012), and even 
potentially the autoimmune phenomena found in these patients (Vinuesa, 2012). 
Despite the ability of HIV to induce the death of virus-specific CD4+ T cells, chronic 
HIV infection appears to promote expansion of the Tfh cell compartment (about 10-
fold increase in Tfh cell frequency), particularly in HIV-specific Tfh cells (Lindqvist et 
al., 2012). Similarly, during chronic simian immunodeficiency virus (SIV) infection, 
there is an 8-fold increase in Tfh cell frequency (Petrovas et al., 2012) and 
approximately a 4-fold increase in Tfh cell number (Hong et al., 2012) in rhesus 
macaques compared with uninfected or acutely infected controls. Interestingly, there 
is no expansion of Tfr cells during SIV infection (Petrovas et al., 2012). Increased IL-
6 production may contribute to the expansion of Tfh cells in this chronic infection 
setting (Kuller et al., 2008). In these studies, the increases in Tfh cells were 
accompanied by parallel increases in GC B cells, plasma cells, and serum IgG 
concentrations, but reduced memory B cells (Lindqvist et al., 2012). Given the 
numerous studies reporting impaired responses of HIV-infected individuals to 
vaccination with protein antigens, it is likely that the lowered threshold for GC B cell 
selection imposed by excessive Tfh cells no longer favours selection of antigen-
specific affinity-matured B cells. 
 
MULTISTAGE PROCESS OF TFH CELL DIFFERENTIATION 
 
The control of Tfh cell numbers is achieved by key checkpoints during their 
formation, migration, expansion, and survival. There has recently been an explosion 
of studies reporting an array of molecules and pathways important for the control of 
Tfh cell formation or homeostasis (summarised in Figure 1.2). Given that many of 
these molecules exert several functions in Tfh cell biology or conversely their precise 
mechanisms of action are not fully elucidated, in this section, they are classified 
according to whether they act T cell-intrinsically or T cell-extrinsically.  
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Tfh cell differentiation requires multiple signals including TCR signalling, 
costimulation, motility/guidance signals, and cytokines (Figure 1.2) (Crotty, 2011; 
Tangye et al., 2013). These signals collectively induce the expression of transcription 
factors, microRNAs, and other regulatory proteins to activate a Tfh lineage-specific 
differentiation programme. Dendritic cells (DCs) and their cytokines (IL-6 and IL-12) 
are crucial for CD4+ T cell priming and initial acquisition of Tfh cell characteristics, 
including the induction of BCL-6 expression (Baumjohann et al., 2011; Liu et al., 
2012). Antigen-primed CD4+ T cells in the T cell zone then reduce chemokine (C-C 
motif) receptor 7 (CCR7) and upregulate CXCR5 expression, which direct them to 
the T:B border (Ansel et al., 1999; Haynes et al., 2007). Antigen-specific CD4+ T cells 
and cognate B cells can then stably interact, forming mobile conjugate pairs leading 
to T cell migration toward the follicle (Qi et al., 2008).  
 
The second stage of signalling for Tfh cell differentiation is required for the 
maintenance and/or further differentiation of these cells and this is mainly mediated 
by B cells (Baumjohann et al., 2011; Choi et al., 2011; Poholek et al., 2010). 
Interaction with antigen-presenting B cells in a SAP- and ICOS-dependent manner 
stimulates a second wave of BCL-6 induction, which leads to stable CXCR5 
expression (Baumjohann et al., 2011; Choi et al., 2011), migration towards the 
follicle, and differentiation into GC Tfh cells. In addition, interactions with non-cognate 
B cells providing ICOS signals help stimulate Tfh cell persistent motility towards the B 
cell follicles (Xu et al., 2013). Thus, GC B cells and Tfh cells are reciprocally 
dependent on each other for survival, proliferation, and differentiation. 
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Figure 1.2 – Molecular mechanisms regulating Tfh cell differentiation.  
Cell-intrinsic mechanisms include a set of transcription factors (highlighted in brown), signalling intermediates (blue), 
and RNA-binding proteins and microRNAs (green), whereas cell-extrinsic mechanisms include cytokines (red), cell-
cell signalling molecules (gray), and regulatory cells. Tfr: T follicular regulatory, IL: interleukin, STAT: signal 
transducer and activator of transcription, IRF: interferon regulatory factor, PI(3)K: phosphoinositide-3 kinase, ICOSL: 
inducible costimulator ligand, PD-L1: programmed cell death 1 ligand 1, CD40L: CD40 ligand. 
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T cell-intrinsic mechanisms controlling Tfh cell numbers 
 
Transcriptional regulation 
BCL-6 B cell lymphoma-6 (BCL-6) is a highly conserved BTB-zinc finger domain-
containing transcriptional repressor that is now recognised as a key transcriptional 
regulator of Tfh cells, in a manner analogous to the roles of T-bet, GATA-3, and 
RORγt and RORα in the differentiation of Th1, Th2, and Th17 cells, respectively 
(Crotty, 2011). As mentioned previously, BCL-6 expression is induced in two waves 
(Baumjohann et al., 2011): after priming by DCs and during interaction with cognate 
B cells. Furthermore, expression of Bcl6 transcript can be upregulated by IL-6 or IL-
21 in vitro (Nurieva et al., 2009). T cell-intrinsic activity of BCL-6 is required for Tfh 
cell development and T cell-dependent GC responses (Johnston et al., 2009; Nurieva 
et al., 2009; Yu et al., 2009) as well as for extrafollicular antibody responses (Lee et 
al., 2011; Poholek et al., 2010). Differentiation of other CD4+ Th subsets is relatively 
unaffected by the loss of BCL-6 (Johnston et al., 2009; Nurieva et al., 2009; Yu et al., 
2009). Ectopic expression of BCL-6 in CD4+ T cells resulted in CXCR5 upregulation 
as well as CCR7 and EBI2 downregulation (Kroenke et al., 2012), all required to 
drive T cell migration to B cell follicles. BCL-6 expression also induced a module of 
protein expression critical for T:B interactions, including SAP, CD40L, PD-1, ICOS, 
and CXCL13 (Kroenke et al., 2012). These findings firmly established a critical role 
for BCL-6 in coordinating Tfh cell formation.  
 
BLIMP-1 The transcription factor B-lymphocyte-induced maturation protein-1 
(BLIMP-1) limits Tfh cell formation by directly repressing BCL-6 (Choi et al., 2011; 
Johnston et al., 2009). Deletion of BLIMP-1 from CD4+ T cells enhances Tfh cell 
formation in response to viral infection. In contrast, BLIMP-1 overexpression severely 
blunts Tfh cell development, and attenuates GC reactions and antibody responses 
(Johnston et al., 2009). BLIMP-1 is induced by IL-2 in CD4+ T cells (Gong and Malek, 
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2007) and hence, repeated administration of IL-2 reduced Tfh cell formation and 
antibody production in an influenza virus infection model (Ballesteros-Tato et al., 
2012). IL-2 signals through STAT5 to limit Tfh cell differentiation (Johnston et al., 
2012; Oestreich et al., 2012). Thus, the IL-2-STAT5-BLIMP-1 axis is likely to limit Tfh 
generation by antagonising the functions of BCL-6. 
 
c-Maf The cellular homologue of avian viral V-maf gene (c-Maf) belongs to the AP-1 
family, containing basic region and leucine zipper domains (Liu et al., 2013). 
Induction of c-Maf is required for the formation of Tfh cells after immunisation, as 
mice lacking c-Maf specifically in immune cells exhibited defective Tfh cell 
differentiation in vivo (Bauquet et al., 2009). c-Maf expression can induce ICOS-
dependent IL-21 production, which is important for Tfh cell formation in vivo (Bauquet 
et al., 2009) and in vitro (Kroenke et al., 2012) and this is through direct binding to 
the Il21 promoter (Hiramatsu et al., 2010). Furthermore, c-Maf overexpression 
upregulates CXCR5 expression and enhances expression of a number of BCL-6-
regulated Tfh cell-associated molecules, such as CXCR5, ICOS and PD-1 (Kroenke 
et al., 2012). c-Maf expression itself can be induced in CD4+ T cells by IL-6 
(Hiramatsu et al., 2010) or IL-27 (Pot et al., 2009). These studies highlight the 
cooperative interplay between c-Maf and BCL-6 in promoting Tfh cell development. 
 
STATs The contributions of the different signal transducer and activator of 
transcription (STAT) proteins to Tfh cell differentiation have been studied in recent 
years. Members of this transcription factor family coordinate responses from certain 
cytokines to either promote (STAT1, STAT3, and STAT4) or dampen (STAT5) Tfh 
cell development. Immunisation of T cell-specific STAT3-deficient mice revealed a 
pronounced reduction of Tfh cells in the absence of STAT3 (Nurieva et al., 2008). In 
addition, patients with STAT3 deficiency showed a significant reduction in the 
generation of circulating CD4+ CXCR5+ Tfh-like cells (Ma et al., 2012a). 
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Mechanistically, STAT3 is required for induction of IL-21 production by murine and 
human CD4+ T cells following stimulation with IL-6, IL-21, IL-23, and IL-27 (Batten et 
al., 2010; Eddahri et al., 2009; Ma et al., 2009; Nurieva et al., 2008; Schmitt et al., 
2009). Furthermore, STAT3 was shown to cooperate with STAT1 in promoting Tfh 
cell differentiation, as the reduction of Tfh cells in IL-6-deficient mice was 
recapitulated only when both STAT1 and STAT3 were deleted from CD4+ T cells 
(Choi et al., 2013). STAT4 also appears to contribute to Tfh cell development: Tfh, 
GC B cells, and IgG2b titres were significantly reduced following immunisation of 
Stat4−/− mice (Nakayamada et al., 2011). This was accompanied by the lack of IL-12-
induced BCL-6 expression (Nakayamada et al., 2011). Taken together, these 
findings show that STAT1, STAT3, and STAT4 positively regulate Tfh cell 
differentiation.  
 
In contrast, STAT5 deficiency greatly enhances the expression of Tfh-signature 
genes in vitro (Johnston et al., 2012; Nurieva et al., 2012) and Tfh and GC formation 
in vivo, also compromising B cell tolerance (Johnston et al., 2012). STAT5 positively 
regulates the expression of BLIMP-1 (Nurieva et al., 2012), which antagonises BCL-6 
expression and in turn inhibits the expression of Tfh-associated genes such as 
Cxcr5, Maf, Bcl6, Batf, and Il21 (Nurieva et al., 2012). STAT5 can also directly bind 
to BCL-6 and suppress its expression (Walker et al., 2007). These studies indicate 
that STAT5 functions to limit Tfh cell development and humoral immunity.  
 
IRF4 Interferon regulatory factor (IRF)-4 is required for Tfh cell differentiation, as Irf4-
/- mice failed to generate Tfh cells due to T cell-intrinsic defect in upregulating BCL-6, 
CXCR5, and ICOS (Bollig et al., 2012). The lack of CXCR5 expression may explain 
the GC phenotype in Irf4-/- mice as T cells failed to migrate to the B cell follicles 
(Bollig et al., 2012). IRF4 may co-operate with STAT3 (Kwon et al., 2009) to bind to 
the Il21 promoter. Given that the phenotype of Irf4-/- mice is much more dramatic than 
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that of Il21-/- mice, it is likely that IRF4 regulates the expression of other transcription 
factors required for Tfh cell development.  
 
BATF Basic leucine zipper transcription factor, ATF-like (BATF) is an AP-1 
superfamily member capable of partnering with Jun. BATF was first demonstrated to 
bind to the Il21 promoter in Th17 cells (Schraml et al., 2009). BATF deficiency 
causes a severe defect in Tfh cells, GC development, and B cell somatic 
hypermutation due to a cell-intrinsic requirement for BATF in both Tfh and B cells 
(Betz et al., 2010; Ise et al., 2011). BATF has been shown to promote the expression 
of BCL-6 and c-Maf (Betz et al., 2010; Ise et al., 2011).  
 
ASCL2 Achaete-scute complex homologue 2 (ASCL2) was initially identified as 
being preferentially expressed in Tfh cells (Liu et al., 2012; Vinuesa et al., 2005a). 
Ectopic expression of ASCL2 was found to induce CXCR5 and repress CCR7 
expression on activated CD4+ T cells independently of BCL-6 in vitro, enhancing 
follicular migration and Tfh cell development in vivo (Liu et al., 2014). Genome-wide 
analysis indicated that ASCL2 directly promoted expression of Tfh-related genes, 
including Cxcr5 and Cxcr4, whereas it inhibited expression of Th1 and Th17 
signature genes (Liu et al., 2014). Deficiency of ASCL2 specifically in CD4+ T cells 
led to impaired Tfh cell development and virus-specific antibody response in an 
influenza virus infection model (Liu et al., 2014). Thus, ASCL2 drives Tfh cell 
differentiation particularly in its early phases.   
 
NF-κB The nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) 
family of transcription factors has been shown to regulate various aspects of T cell 
development, activation, differentiation, and survival. The NF-κB family is comprised 
of five subunits: RelA (p65), RelB, c-Rel, NF-κB1 (p105), and NF-κB2 (p100). In NF-
κB1-deficient mice, Tfh cell development was defective upon immunisation with 
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protein antigens, particularly due to impaired CXCR5 expression (Serre et al., 2011). 
Also, IL-21 production was diminished in c-Rel-deficient mice, inhibiting the 
development of Tfh and GC B cells (Chen et al., 2010). Furthermore, c-Rel was 
shown to directly bind to the Il21 promoter to regulate its expression (Chen et al., 
2010).  
 
Post-transcriptional regulation 
Roquin family Members of this family include Roquin (Rc3h1) and Roquin-2 
(Rc3h2), which exhibit high sequence homology, particularly in their N-termini 
spanning the RING, ROQ, and CCCH-type zinc finger domains. As described 
previously, sanroque mice homozygous for a loss-of-RNA-regulating function 
mutation in Roquin exhibit Tfh cell accumulation, spontaneous formation of GCs and 
systemic autoimmunity (Vinuesa et al., 2005a). Naive and activated T cells from 
Rc3h1san/san mice exhibited increased ICOS expression compared to wild-type cells.  
Using mixed bone marrow chimeras, our group previously showed that the Tfh cell 
accumulation and ICOS phenotypes were due to T cell-intrinsic defects (Linterman et 
al., 2009b; Vinuesa et al., 2005a). Mechanistically, Roquin binds to Icos 3’ 
untranslated region (UTR) via its ROQ domain and represses Icos mRNA through 
post-transcriptional gene regulation (Yu et al., 2007). Induction of mRNA decay 
occurs through removal of the mRNA 5’ cap (Glasmacher et al., 2010; Yu et al., 
2007). Furthermore, mRNA degradation through deadenylation has also been 
recently proposed as an additional mechanism utilised by Roquin to limit mRNA 
expression, and this is dependent on a distinct RNA secondary structure, called the 
constitutive decay element, in the target mRNA 3’UTR (Leppek et al., 2013).   
 
Excessive IFN-γ signalling due to the loss of Roquin-mediated Ifng repression is 
involved in the pathogenic accumulation of Tfh cells and spontaneous GC formation 
in Rc3h1san/san mice (Lee et al., 2012b). OX40 overexpression comparable to those of 
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sanroque mice was also observed in mice with compound (but not single) deletion of 
Roquin and Roquin-2 proteins specifically in T cells (Vogel et al., 2013). OX40 is a 
potent inducer of NF-κB signalling that also promotes Irf4 expression (Vogel et al., 
2013). The collaboration between Roquin and Roquin-2 in controlling Icos mRNA 
expression and GC responses will be discussed further in Chapter 3 of this thesis.  
 
MicroRNAs These are short (20-22 nucleotide) non-coding RNAs that together with 
an assembly of associated proteins known as the RNA-induced silencing complex 
(RISC) bind to sites of complementarity in the 3’UTR of mRNAs. There is 
accumulating evidence that miRNAs regulate the Tfh cell gene expression 
programme. BCL-6 itself was shown to repress numerous miRNAs, suggesting that 
this may be important for some aspects of Tfh cell function (Yu et al., 2009). 
Deficiency in the miRNA biogenesis factor DGCR8, leading to the absence of 
miRNAs, reduced Tfh cell differentiation following immunisation with protein antigens 
(Baumjohann et al., 2013a).  
 
The microRNA cluster 17~92, encoding six miRNAs (miR-17, miR-18a, miR-19a, 
miR-20a, miR-19b-1, and miR-92-1), was recently identified to be required for Tfh cell 
development (Baumjohann et al., 2013a; Kang et al., 2013). Mice lacking miR-17~92 
in T cells had a selective reduction of Tfh cell formation and defective long-lived 
antibody responses to viral infection and protein immunisation (Baumjohann et al., 
2013a; Kang et al., 2013). MiR-17~92 act cell-intrinsically to indirectly upregulate 
essential Tfh lineage-inducing molecules, BCL-6, CXCR5, and IL-21 (Baumjohann et 
al., 2013a; Kang et al., 2013). Overexpression of miR-17~92 in T cells caused SLE-
like autoimmune symptoms, with spontaneous accumulation of Tfh and GC B cells, 
and production of autoantibodies (Baumjohann et al., 2013a; Kang et al., 2013). MiR-
17~92 directly repress Pten, Phlpp2, and Rora mRNAs (Baumjohann et al., 2013a; 
Kang et al., 2013). PTEN and PHLPP2 are phosphatases that antagonise the 
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phosphoinositide 3-kinase [PI(3)K] signalling pathway, which is the only known 
pathway downstream of ICOS required for the development of Tfh cells and GCs 
(Gigoux et al., 2009; Rolf et al., 2010). RORα, as mentioned previously, is a lineage-
defining transcription factor for Th17 cells driving the expression of IL-17 and other 
Th17-signature genes (Yang et al., 2008b). Hence, miR-17~92 cluster promotes Tfh 
cell differentiation directly by activating the PI(3)K pathway and indirectly by 
repressing non-Tfh cell gene-expression programmes.  
 
MicroRNAs can also limit the plasticity of Tfh cells, exemplified by the ability of miR-
10a to repress Bcl6 mRNA and prevent conversion of induced regulatory T cells into 
Tfh cells (Takahashi et al., 2012). The role of miR-146a that is highly expressed in 
Tfh and GC B cells (Kuchen et al., 2010) and is often dysregulated in autoantibody-
mediated autoimmune diseases (Li et al., 2010; Lofgren et al., 2012; Luo et al., 2011; 
Pauley et al., 2008) in repressing Tfh cell differentiation will be presented in Chapters 
4 and 5 of this thesis. 
 
Post-translational regulation 
Cullin-3 A recent study showed that Cullin-3, an E3 ubiquitin ligase, could bind to the 
BTB-ZF domain-containing transcription factor BCL-6 (Mathew et al., 2012). Cell-
intrinsic accumulation of Tfh cells and spontaneous GC were observed in aged 
Cullin-3-deficient mice (Mathew et al., 2012). As observed with BCL-6 deficiency, 
Cullin-3 appears to act selectively in Tfh cells since other CD4+ effector subsets 
appeared unperturbed in Cullin-3-deficient mice (Mathew et al., 2012). Although 
ubiquitylation of BCL-6 by Cullin-3 was not formally demonstrated, it is likely that the 
binding of Cullin-3 to BCL-6 in Tfh cells results in the repression of BCL-6 or BCL-6 
co-factors, and as a consequence, repression of Tfh-associated genes. 
 
Itch Liu and colleagues recently revealed that another E3 ubiquitin ligase, Itch, 
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promotes the differentiation of Tfh cells and GC responses following viral infection 
(Xiao et al., 2014). Itch was found to act in the early stages of the Tfh cell 
development process and upstream of BCL-6 expression. Itch-mediated 
ubiquitylation and degradation of Foxo-1 was crucial for optimal Tfh cell 
differentiation (Xiao et al., 2014). 
 
T cell-extrinsic mechanisms controlling Tfh cell numbers 
 
Regulation of Tfh cell numbers by cytokines 
Multiple cytokines produced by both innate and adaptive immune cells appear 
capable of inducing, enhancing, or sustaining Tfh cell-like phenotypes, and these 
include IL‑6, IL‑21, IL-12, IL-23, and IL-27. These cytokines act through 
phosphorylation of STAT1, STAT3, or STAT4 to regulate the Tfh cell programme of 
gene expression (Avery et al., 2010; Johnston et al., 2012; Leonard, 2001; Parham et 
al., 2002; Schmitt et al., 2009). In contrast, cytokines like IL-2 acting through STAT5 
(Johnston et al., 2012) and IL-10 (Cai et al., 2012) have been shown to suppress Tfh 
cell development at least in mice.  
 
IL-6 Deficiency of this cytokine has been reported to have mild to moderate effect on 
Tfh cell numbers (Eto et al., 2011; Harker et al., 2011; Nurieva et al., 2008). A more 
severe decrease in Tfh cell formation and protective IgG antibody production 
occurred in the absence of both IL-6 and IL-21 (Eto et al., 2011; Karnowski et al., 
2012). This suggests that a significant functional redundancy exists between these 
cytokines. This requirement for IL-6 and IL-21 is consistent with reductions in the 
number of Tfh cells in the absence of functional STAT3 (Ma et al., 2012a; Nurieva et 
al., 2008), which acts downstream of both cytokines. Supporting the interplay 
between IL-6 and IL-21, stimulation by IL-6 has been shown to induce IL-21 
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production by CD4+ T cells in vitro (Karnowski et al., 2012). IL-6 is derived from 
activated B cells (Karnowski et al., 2012) or follicular DCs (Harker et al., 2011). A late 
wave of IL-6 production appears to be critical for the formation of Tfh cells and 
subsequent viral clearance in chronic LCMV infection model (Harker et al., 2011). 
Increased production and responsiveness to IL-6 also appears to contribute to the 
aberrant Tfh cell accumulation seen during chronic HIV infection (Kuller et al., 2008). 
 
IL-21 It is expressed in high amounts by Tfh cells, and high levels of IL-21R are 
present on the surface of most B cells (Chtanova et al., 2004), including GC B cells. 
IL-21 promotes B cell proliferation and maturation in coordination with BCR and 
CD40 ligation (Ettinger et al., 2005; Jin et al., 2004; Kuchen et al., 2007; Ozaki et al., 
2004), and is important for GC maintenance and subsequent development of 
antibody-secreting plasma cells (Eto et al., 2011; Linterman et al., 2010; Zotos et al., 
2010). Through its ability to induce BCL-6, IL-21 can also drive Tfh cell formation 
(Vogelzang et al., 2008). Deficiency of this cytokine has also been reported in other 
studies to have mild to moderate effect on Tfh cell numbers (Eto et al., 2011; 
Linterman et al., 2010).  
 
IL-12 and IL-23 Both cytokines signal through the common IL-12Rβ1 receptor. 
Previous in vitro studies have shown that IL-12 induces human naïve CD4+ T cells to 
express several characteristic Tfh molecules, such as IL-21, CXCR5, ICOS, and 
BCL-6 (Ma et al., 2009; Schmitt et al., 2009). Both IL-12 and IL-23 were also found to 
promote the expression of BCL-6, BATF, and c-Maf, which are key transcription 
factors for Tfh cell formation (Bauquet et al., 2009; Betz et al., 2010; Kroenke et al., 
2012; Schmitt et al., 2013). Two recent studies of patients lacking functional IL-
12Rβ1 have shown variable results in terms of the number of circulating Tfh-like cells 
and memory B cells (Ma et al., 2012a; Schmitt et al., 2013). However, both studies 
confirmed that IL-12-induced IL-21 production was impaired in IL-12Rβ1-deficient 
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individuals (Ma et al., 2012a; Schmitt et al., 2013). In addition, IL-12-mediated 
induction of CXCR5, ICOS, and BCL6 in Tfh cells was unaffected in patients with 
STAT3 deficiency (Ma et al., 2012a), suggesting that IL-12 signalling may involve 
other signal transducers, such as STAT4 (Jacobson et al., 1995). 
 
IL-27 The requirement of IL-27 has not been widely studied, but it was previously 
described that Tfh cell differentiation was impaired in mice lacking IL-27R, although 
this is likely via indirect effects of diminished IL-21 production (Batten et al., 2010). 
Recently, IL-27 was found to promote ongoing survival of antigen-specific CD4+ T 
cells (most of which were Tfh cells) after viral infection but did not appear to control 
Tfh differentiation or BCL-6 expression (Harker et al., 2013). 
 
IL-2 It is a negative regulator of Tfh cell formation. The frequency and number of Tfh 
cells were reduced in mice after viral infection in conjuction with exogenous IL-2 
treatment relative to control mice (Ballesteros-Tato et al., 2012). Further analysis 
showed that IL-2 acts early during Tfh differentiation to suppress the commitment of 
activated CD4+ T cells to the Tfh lineage (Ballesteros-Tato et al., 2012). Strong IL-2-
signalling promoted the binding of STAT5 (Johnston et al., 2012), in place of Tfh-
inducing STAT3, to the Bcl6 promoter, which directly inhibited Bcl6 expression 
(Oestreich et al., 2012). STAT5 can also directly bind Prdm1 (the gene encoding 
BLIMP-1) promoter in CD4+ T cells after IL-2 stimulation (Yang et al., 2011). Also, an 
inverse correlation exists between the expression of IL-2 receptor-α (CD25) and the 
expression of BCL-6 in CD4+ Tfh cells (Choi et al., 2011). Blocking both CD25 and 
CD122 subunits of the IL-2 receptor enhanced BCL-6 (Oestreich et al., 2012).  
 
IL-10 Human tonsillar Tfh cells with high expression of ICOS were shown to also 
secrete IL-10 (Lohning et al., 2003), suggesting that IL-10 may play a role in 
promoting B cell differentiation (Chevalier et al., 2011). In contrast, IL-10 appears to 
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suppress Tfh cell formation in mice: IL-10R-deficient (Il10rb-/-) mice had increased 
Tfh cell formation and IL-21 production and treatment with exogenous IL-10 reduced 
Tfh cells (Cai et al., 2012). DCs lacking IL-10Rβ produced more IL-6, IL-23 and IL-12, 
which contributed to the increase in Tfh cell numbers (Cai et al., 2012). Supporting 
the repressive role of IL-10 in mice, a recent study found that IL-10 reduced the 
production of autoantibodies in mouse models of SLE (Wu et al., 2008). It is possible 
that human and mouse studies are not entirely contradictory once the cellular 
sources and targets of IL-10 are carefully analysed since, at least in mice, Tfr cells 
have also been shown to be a source of this cytokine (Linterman et al., 2011). 
 
Regulation of Tfh cell numbers by neighbouring cells in the GCs 
 
Antigen-presenting cells (DCs and B cells) 
Cell-cell interactions via multiple cell surface molecules between developing Tfh cells 
and GC B cells or DCs are vital for Tfh cell development. Initial priming by DCs 
(through TCR-MHCII interaction and costimulatory molecules) is crucial for 
upregulation of CXCR5 (Ansel et al., 1999). In addition, many reports have 
demonstrated that mice lacking B cells or those with B cells deficient in functional 
molecules (CD19, CD40, MHCII, ICOSL, and CD86) exhibited decreased numbers of 
Tfh cells after immunisation or infection (Deenick et al., 2010; Haynes et al., 2007; 
Johnston et al., 2009; Poholek et al., 2010; Salek-Ardakani et al., 2011). In this 
section, the contribution of the CD28-family proteins, CD40L, and SLAM-family 
proteins in controlling Tfh cell numbers will be discussed. 
 
CD28-B7 B7.1 (CD80) and B7.2 (CD86) expressed on DCs bind to CD28 on T cells 
to provide an important costimulatory signal for T cell activation and subsequent 
differentiation into all effector subsets (Linterman et al., 2009a; Walker et al., 2003). 
Analysis of mice deficient in CD28 showed an absence of Tfh cells (Ferguson et al., 
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1996) and blocking of CD28 inhibited upregulation of CXCR5 and thus migration to B 
cell follicles (Walker et al., 1999). While CD28 seems to be important at the initial 
stages of CD4+ T cell activation, a CD28-homologue, CTLA-4, plays additional roles 
in later stages of GC reaction to limit the number of Tfh cells (Walker et al., 2003). 
Interestingly, deficiency of CD86, but not CD80, recapitulated the Tfh defect seen in 
CD28-deficient mice in response to viral infection (Salek-Ardakani et al., 2011), 
suggesting that ligation of CD28 by CD86, rather than CD80, has a preferential role 
in Tfh cell development. However, another study showed that Tfh cell frequency was 
decreased in Cd80-/- mice in response to protein immunisation (Good-Jacobson et 
al., 2012). Also, in the absence of CD80, there was a decrease in the surface 
expression PD-1 and ICOS, as well as Il21 mRNA on Tfh cells (Good-Jacobson et 
al., 2012).  
 
ICOS-ICOSL Costimulatory signals through ICOS are required for optimal Tfh cell 
formation but are not essential for the development of other T cell subsets (Bauquet 
et al., 2009). Mice in which ICOS-ICOSL interactions are disrupted, or patients with 
mutations in ICOS (which result in CVID), have decreased Tfh cells (Akiba et al., 
2005; Bauquet et al., 2009; Bossaller et al., 2006; Dong et al., 2001a; Dong et al., 
2001b; Gigoux et al., 2009). ICOS ligand (ICOSL) on DCs and B cells have been 
shown to be important for the early (T cell priming) and late (T:B interaction at the 
T:B border) BCL-6 upregulation, respectively (Choi et al., 2011; Nurieva et al., 2008). 
Indeed, mice that lack ICOSL expression on B cells showed specific reduction in Tfh 
cells numbers (Nurieva et al., 2008). The expression of ICOSL is regulated by 
members of the NF-κB and B cell-activating factor receptor (BAFFR) protein families. 
Expression of BAFFR and NF-κB-inducing kinase (NIK; a downstream molecule in 
BAFFR signalling pathway) on B cells was found to be required for their constitutive 
expression of ICOSL. NIK deficiency on B cells compromises Tfh cell induction (Hu 
et al., 2011). In contrast to BAFFR, transmembrane activator and CAML interactor 
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(TACI; a member of BAFFR family) negatively regulates Tfh cell development, as 
Taci-/- mice have increased ICOSL expression on B cells and consequently, 
expanded populations of Tfh cells and GC B cells (Ou et al., 2012). The non-
canonical NF-κB members RelB and NF-κB2 have also been shown to bind Icoslg 
promoter and drive its expression (Hu et al., 2011).  
 
Several studies have demonstrated that ICOS signals via the recruitment of PI(3)K to 
the tyrosine residue within its cytoplasmic YFMF motif (Bauquet et al., 2009; Coyle et 
al., 2000; Gigoux et al., 2009; Rolf et al., 2010). Mice expressing ICOS with mutated 
PI(3)K-binding residue in its cytoplasmic tail (Gigoux et al., 2009) or lacking the 
p110δ isoform of PI(3)K in T cells (Rolf et al., 2010) showed decreased Tfh cell 
numbers. In addition, p110δ is required for ICOS-mediated upregulation of Il21, Il4, 
and Maf mRNAs (Rolf et al., 2010). These observations are in accordance with ICOS 
ligation regulating c-Maf expression, which in turn drives IL-21 (Bauquet et al., 2009) 
and IL-4 (Ho et al., 1996).  
 
Recently, another study described a novel role for ICOS as a regulator of persistent 
directional motility and follicular recruitment of activated CD4+ T cells (Xu et al., 
2013). This role does not involve BCL-6 as an intermediate nor ICOSL-mediated 
ligation with cognate B cells (Xu et al., 2013). Instead, developing Tfh cells acquire 
ICOSL signals from bystander follicular B cells, which do not present antigen to these 
T cells but collectively form an ICOS-engaging field that facilitates directional 
persistent movement (Xu et al., 2013). This effect is also likely to be mediated by 
PI(3)K signalling. 
 
PD-1-PD-L1 PD-1 was initially shown to exert an inhibitory role in Tfh cell differen-
tiation, as mice with impaired PD-1 signalling showed increased Tfh (CXCR5+ 
ICOShigh or CCR7low ICOShigh) cell numbers as a result of increased proliferation and 
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reduced apoptosis (Good-Jacobson et al., 2010; Hams et al., 2011; Kawamoto et al., 
2012). These PD-1-deficient Tfh cells expressed higher amounts of BCL-6 
(Kawamoto et al., 2012) but produced less IL-21 (Good-Jacobson et al., 2010). As a 
result, there was reduced antibody-secreting plasma cells in mice lacking PD-1 or its 
ligands (Good-Jacobson et al., 2010). A closer analysis of the PD-1-deficient mice 
recently revealed a specific increase of Tfr cells, which do not produce IL-21 (Sage et 
al., 2013). This may explain the previous observations (Kawamoto et al., 2012) of 
reduced IL-21 by total CXCR5high cells (that include both Tfh and Tfr cells) in these 
mice. 
 
CD40-CD40L CD40L expressed by T cells is known to activate DCs via CD40, 
allowing the DCs to support ongoing T cell activation (Cella et al., 1996). The 
absence of CD40 expression on DCs inhibited upregulation of CXCR5 and homing to 
the follicle (Fillatreau and Gray, 2003). CD40-CD40L interactions are also crucial for 
the B cell-helping capacity of Tfh cells. As Tfh cell and GC B cell are mutually 
dependent on each other for their survival, the lack of CD40 expression on B cell 
prevents activation of B cells and GC formation, which in turn, results in decreased 
Tfh cell numbers (Choi et al., 2011). Consistent with the requirement of these 
interactions for Tfh cell homeostasis, circulating CD4+ CXCR5+ Tfh-like cells are 
absent in patients with mutations in CD40LG (Bossaller et al., 2006) and mice with 
CD40L deficiency fail to form GCs after immunisation (Xu et al., 1994).  
 
SLAM family This family of receptors includes SLAM (also known as SLAMF1), 
CD84, natural killer cell receptor 2B4, T lymphocyte surface antigen Ly9, and Ly108. 
They are expressed highly on both activated B cells and CD4+ T cells, including Tfh 
cells (Cannons et al., 2010a; Cannons et al., 2011; Chtanova et al., 2004; Ma et al., 
2009). They are homotypic receptors and facilitate prolonged interactions between 
activated antigen-specific T and B cells via the recruitment of SAP to their 
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cytoplasmic tails for downstream signalling (Cannons et al., 2011). The importance of 
SAP on Tfh cell development has been established from analysis of SAP-deficient 
mice and patients suffering from XLP (Cannons et al., 2010a; Cannons et al., 2011; 
Linterman et al., 2009b). Although SAP-deficient mice were capable of generating 
CXCR5+ PD-1+ Tfh cells at day 4 post-immunisation, these could not be retained in 
GCs (Cannons et al., 2010a) and did not differentiate further into GC Tfh cells 
(Linterman et al., 2009b). Analysis of gene-targeted mice has failed to show a 
requirement for individual SLAM family members, except for CD84, in Tfh cell 
formation (Cannons et al., 2011). Also, the Tfh cell deficiency in Cd84-/- mice was 
less severe than in SAP-deficient mice (Cannons et al., 2010a). In vitro experiments 
have suggested that CD84 and Ly108 collectively contribute to T:B cell interaction 
and thus promoting Tfh cell phenotypes (Cannons et al., 2010a). This indicates that 
the severe effect of SAP deficiency in Tfh cells reflects the requirement of signals 
from multiple SLAM receptors during Tfh cell differentiation. 
 
Apoptotic cells  
The clearance of apoptotic cells is necessary to maintain immune tolerance to self-
antigen. Inefficient clearance of apoptotic cells results in the development of 
autoantibodies and autoimmunity (Ravichandran and Lorenz, 2007). Large numbers 
of low-affinity and self-reactive B cells are thought to die in the GCs. A specialised 
subset of macrophages in GCs, called tingible body macrophages, express Mer (a 
surface receptor that facilitates apoptotic cell clearance), and is associated with the 
clearance of apoptotic cells within GCs (Rahman et al., 2010). Mer-deficient mice 
were found to develop SLE-like symptoms, and this was due to significantly 
increased activation and proliferation of GC B cells and CD4+ effector T cells, 
including Tfh cells (Khan et al., 2013). In addition, there was a significant increase in 
IFN-γ production by CD4+ T cells obtained from Mer-/- mice (Khan et al., 2013); this 
can contribute to aberrant Tfh cell formation by inducing overexpression of BCL-6 
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(Lee et al., 2012b).  
 
Regulatory T cells  
Tfr cells Our group and others have recently shown that a subset of Foxp3+ cells 
migrates into the follicles to restrain Tfh cell differentiation; these cells are called the 
T follicular regulatory (Tfr) cells (Chung et al., 2011; Linterman et al., 2011; 
Wollenberg et al., 2011). Tfr cells show characteristics of both Tfh and Treg cells 
(e.g. BCL-6, Foxp3, CXCR5, PD-1, ICOS, CTLA-4), but they lack expression of the B 
cell-helping molecules CD40L, IL-4 and IL-21 (Linterman et al., 2011). Deletion of Tfr 
cells or impairing their follicular localisation led to increased numbers of Tfh and GC 
B cells (Chung et al., 2011; Linterman et al., 2011; Wollenberg et al., 2011). 
However, the mechanisms by which Tfr cells limit Tfh cell differentiation remain to be 
determined. They may repress Tfh cells directly or attenuate GC B cell development, 
which in turn will impair Tfh cell numbers. The contribution of non-follicular Tregs to 
the repression of Tfh cells is unclear.  
 
CD8+ regulatory cells A subset of Qa1-restricted CD8+ T cells has been found to 
dampen Tfh cell development. These cells express CXCR5 and hence are able to 
migrate to B cell follicles (Kim et al., 2010). Furthermore, these regulatory CD8+ T 
cells do not express Foxp3 or CTLA-4, and they are dependent on Helios, IL-15 and 
perforin to execute their suppressive role. Disrupting the interaction between Tfh cells 
and regulatory CD8+ T cells resulted in a dramatic expansion of Tfh cells and the 
development of a lethal SLE-like disease (Kim et al., 2010). 
 
Plasma cells  
Antigen-specific plasma cells appear to retain their capacity to present antigens to 
naïve CD4+ T cells but are unable to induce expression of Bcl6 and Il21 (Pelletier et 
al., 2010), suggesting that plasma cells can prime T cells to differentiate into effector 
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cells other than Tfh cells. Moreover, co-cultures of plasma cells with differentiated Tfh 
cells resulted in the reduction of Bcl6 and Il21 expression on Tfh cells (Pelletier et al., 
2010). Plasma cell-mediated inhibition of Tfh cell differentiation may constitute a 
negative feedback mechanism to limit the GC reaction after sufficient end products of 
this process (i.e. antigen-specific plasma cells) have been generated. The 
mechanism by which plasma cells repress Tfh cells remains elusive.  
 
Regulation of Tfh cell numbers by antigen availability 
A recent study showed that the percentage of Tfh cells was significantly higher with 
increased amounts of available antigen (Baumjohann et al., 2013b). Also, chronic 
antigenic stimulation through multiple immunisations led to a larger increase in the 
frequencies of Tfh and GC B cells as compared to a single injection (Baumjohann et 
al., 2013b). These findings may contribute to explain aberrant Tfh cell formation in 
chronic infection settings, such as chronic HIV infection, which leads to selection of 
low-affinity B cells and failure to clear the virus.  
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THESIS OBJECTIVES 
 
The body has evolved a rich and diverse army of specialised cells to protect against 
infection and to eliminate disease. T follicular helper (Tfh) cells constitute a distinct 
effector CD4+ T cell subset that provides essential help for B cell proliferation and 
differentiation within the germinal centres (GCs). However, data from clinical and 
experimental studies have shown that the number of Tfh cells needs to be tightly 
regulated, as too many Tfh cells may corrupt B cell affinity maturation often leading to 
autoimmune disease. This chapter has attempted to give an up-to-date overview of 
the known molecular signals and pathways governing Tfh cell differentiation. Within 
Tfh cells, most of these molecules were shown to regulate gene expression at the 
transcriptional level, whilst our knowledge of post-transcriptional and post-
translational mechanisms is still lacking. The work presented here aims to discover 
novel post-transcriptional mechanisms that control Tfh cell numbers and hence the 
magnitude and/or quality of GC responses. In the long term, this could prove 
essential for rational design of efficacious vaccines. 
 
The first demonstration that Tfh cell dysregulation leads to autoantibody formation 
and development of SLE-like disease was from the analysis of sanroque mice, which 
carry a single point (M199R) mutation in the gene Rc3h1, encoding an RNA-binding 
protein called Roquin (Linterman et al., 2009b). However, unlike the sanroque mice, 
Roquin-deficient mice did not show accumulation of effector CD4+ T cells or Tfh cells 
(Bertossi et al., 2011), potentially indicating a functional compensation by another 
protein. In mammals, there is one clear Roquin paralogue, called Roquin-2, which 
shares a high sequence similarity across the N-terminus and is largely 
uncharacterised in terms of its role in immune cells. Hence, the function of Roquin-2 
and possible functional redundancies between Roquin and Roquin-2 in repressing 
mRNAs important for Tfh cell development will be investigated.  
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A closer analysis of T cells from the lupus-prone sanroque mice revealed a 
significant accumulation of several microRNAs (miRNAs), among which is miR-146a. 
This miRNA was shown to be highly expressed in Tfh and GC B cells (Kuchen et al., 
2010) and dysregulation of miR-146a was also associated with several systemic 
autoimmune diseases (Li et al., 2010; Lofgren et al., 2012; Luo et al., 2011; Pauley et 
al., 2008). These lead us to hypothesise that miR-146a may play a role in Tfh cells 
and potentially also in GC B cell homeostasis. Hence, the humoral immune response 
in mice lacking miR-146a will be assessed and identification of potential miR-146a 
targets in controlling Tfh cell numbers and GC responses will be performed. 
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CHAPTER TWO 
 
 
Materials and methods 
 
Antibodies 
 
Antibodies for flow cytometry 
All antibodies used for flow cytometry are listed in Table 2.1 below: 
 
Table 2.1 – Antibodies used for flow cytometry. The clone designations, 
fluorochrome conjugates (if any), and vendors are listed for each antibody. Each 
antibody was titrated and used at the minimal concentration required for saturation.  
Antibody Clone Conjugate Vendor 
Anti-hen egg lysozyme* Hy-HEL9 - A gift from 
Robert Brink, 
Garvan 
Institute, 
Sydney  
Anti-human CD185 (CXCR5) RF8B2 Alexa Fluor 647 BD Biosciences 
Anti-human CD25 BC96 PE-Cy7 Biolegend 
Anti-human CD279 (PD-1) MIH4 PE eBioscience 
Anti-human CD4 RPA-T4 APC-Cy7 BD Biosciences 
Anti-human CD44 IM7 Alexa Fluor 700 Biolegend 
Anti-mouse CD11b M1/70 APC-Cy7 Biolegend 
Anti-mouse CD11c HL3 PerCP-Cy5.5 BD Biosciences 
Anti-mouse CD150 
(SLAMF1) 
TC15-
12F12.2 
PE Biolegend 
Anti-mouse CD184 (CXCR4) 2B11/CXCR4 Biotin^ BD Biosciences 
Anti-mouse CD185 (CXCR5)  2G8 Biotin^ BD Biosciences 
Anti-mouse CD21/35 7G6 Biotin^ BD Biosciences 
Anti-mouse CD25 PC61 Alexa Fluor 647 Biolegend 
Anti-mouse CD275 (ICOSL) HK5.3 PE Biolegend 
Anti-mouse CD278 (ICOS) 7E.17G9 PE eBioscience 
Anti-mouse CD279 (PD-1) RMP1-30 PE BD Biosciences 
Anti-mouse CD279 (PD-1) 29F.1A12 Brilliant Violet 
421 
Biolegend 
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Anti-mouse CD31 MEC13.3 PE BD Biosciences 
Anti-mouse CD4 RM4-5 Alexa Fluor 700 BD Biosciences 
Anti-mouse CD4 RM4-5 APC-Cy7 Biolegend 
Anti-mouse CD44 IM7 APC BD Biosciences 
Anti-mouse CD44 IM7 Alexa Fluor 700 Biolegend 
Anti-mouse CD44 IM7 PE-CF594 BD Biosciences 
Anti-mouse CD45.1 (Ly5a) A20 Pacific Blue Biolegend 
Anti-mouse CD45.1 (Ly5a) A20 Alexa Fluor 700 Biolegend 
Anti-mouse CD45.2 (Ly5b) 104 Alexa Fluor 700 BD Biosciences 
Anti-mouse CD45.2 (Ly5b) 104 PerCP BD Biosciences 
Anti-mouse CD45R (B220) RA3-6B2 PerCP BD Biosciences 
Anti-mouse CD84 mCD84.7 PE Biolegend 
Anti-mouse CD95 (Fas) Jo2 PE-Cy7 BD Biosciences 
Anti-mouse Foxp3 FJK-16s FITC eBioscience 
Anti-mouse Foxp3 FJK-16s eFluor 450 eBioscience 
Anti-mouse GL-7 GL7 FITC BD Biosciences 
Anti-mouse gp130 (IL6ST) 125623 APC R&D Systems 
Anti-mouse gp38 eBio8.1.1 Alexa Fluor 488 eBioscience 
Anti-mouse IFN-γ XMG1.2 FITC BD Biosciences 
Anti-mouse IgG1 A85-1 PE BD Biosciences 
Anti-mouse IL-17A TC11-18H10 Alexa Fluor 700 BD Biosciences 
Anti-mouse IL-21R 4A9 APC Biolegend 
Anti-mouse IL-4 11B11 PE-Cy7 BD Biosciences 
Anti-mouse Ly108 (SLAMF6) eBio13G3-
19D 
APC eBioscience 
Anti-mouse Notch1 HMN1-12 PE Biolegend 
Anti-mouse STAT1 1/STAT1 Alexa Fluor 647 BD Biosciences 
Anti-mouse STAT1 (pY701) 14/P-STAT1 Pacific Blue BD Biosciences 
Anti-mouse STAT3 (pY705) 4/P-STAT3 PE BD Biosciences 
Anti-mouse Vβ5.1/5.2 TCR MR9-4 FITC BD Biosciences 
 
Note: 
* Anti-HEL (Hy-HEL9) was conjugated in house to Alexa Fluor 647 using a Protein 
Labelling Kit (Molecular Probes, Life Technologies) as per manufacturer’s protocol.  
^ Biotinylated antibodies were detected using Streptavidin PE-Cy7 (BD Biosciences) 
in most experiments.  
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Antibodies for Western blot 
Antibody against V5-tag was purchased from AbD Serotec and antibody against 
FLAG-tag was from Sigma-Aldrich. Antibody against hemagglutinin (HA)-tag (Sigma-
Aldrich) was used as an isotype control. Secondary antibodies conjugated to 
horseradish peroxidase were purchased from Jackson ImmunoResearch. 
 
Antibodies for immunofluorescence 
Antibodies against TIA-1 and eIF3η were obtained from Santa Cruz Biotechnology, 
antibody against Roquin (NB100-655) was purchased from Novus Biologicals, rabbit 
antisera against Roquin-2 was a gift from Steven Hefeneider (Oregon Health and 
Science University, USA), and antibody against Dcp1a was a gift from Jens Lykke-
Andersen (University of California San Diego, USA). Antibody against V5-tag was 
purchased from AbD Serotec and antibody against FLAG-tag was from Sigma-
Aldrich. Secondary antibodies conjugated to Alexa Fluor 568 and Alexa Fluor 488 
were purchased from Molecular Probes (Life Technologies).  
 
Antibodies for in vivo treatments 
Monoclonal blocking antibody against ICOSL (MIL-5733) was provided by Andreas 
Hutloff (DRFZ, Germany). Blocking antibody against IL-6R (15A7) and isotype control 
(LTF-2) were purchased from BioXCell.  
 
Antibodies for in vitro cell culture 
For Tfh-like cell differentiation, mouse anti-CD3 (500A2) and anti-CD28 (37.51) were 
purchased from BD Biosciences, whereas anti-IFN-γ (XMG1.2), anti-IL-12 (C17.8), 
anti-IL-4 (11B11), and anti-TGF-β (TW7-20B9) were from Biolegend. For B cell 
stimulation, mouse anti-CD40 (FGK4.5) was obtained from BioXCell. 
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Buffers, solutions, and media 
Common buffers, solutions, and media were sourced and/or prepared as described 
in Table 2.2 below: 
 
Table 2.2 – Common buffers, solutions, media, and their respective sources. 
Buffer/ solution/ medium Composition/ vendor 
PBS, RPMI-1640, DMEM  Purchased from Gibco (Life Technologies) 
Lymphocyte culture 
medium (complete RPMI) 
RPMI-1640 supplemented with 10% (v/v) heat-
inactivated foetal calf serum (Sigma-Aldrich), 10 mM 
HEPES, pH 7.4 (Sigma-Aldrich), 0.1 mM non-
essential amino acid solution (Gibco), 1 mM sodium 
pyruvate (Sigma-Aldrich), 55 µM beta-
mercaptoethanol (Gibco), 2 mM L-glutamine, and 
100 U penicillin-streptomycin (Gibco) 
Cell line culture medium 
(complete DMEM) 
DMEM supplemented with 10% (v/v) heat-
inactivated foetal calf serum (Sigma-Aldrich), 2 mM 
L-glutamine, and 100 U penicillin-streptomycin 
(Gibco) 
FACS buffer 2% HyClone bovine serum and 0.1% sodium azide 
in PBS 
Magnetic cell separation 
(MACS) buffer 
0.5% bovine serum albumin and 2 mM EDTA in PBS 
TNE lysis buffer 1% NP-40, 150 mM NaCl, 20 mM Tris-base, 1 mM 
EDTA and Complete EDTA-free protease inhibitory 
cocktail tablet (Roche) 
SDS-PAGE running buffer 
(10X) 
250 mM Tris-base, 1.92 M glycine and 1% SDS in 
water. Buffer was diluted with water to 1X before use 
SDS-PAGE transfer buffer  25 mM Tris-base, 192 mM glycine and 20% 
methanol dissolved in water 
Red blood cell lysis buffer 
(10X) 
1.55 M ammonium chloride, 100 mM potassium 
bicarbonate, 1 mM sodium EDTA in water. Buffer 
was adjusted to pH 7.2 and diluted with water to 1X 
concentration before use 
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Mice and immunisations 
C57BL/6 (B6), B6-Ly5a, Lck-Cre, Rag1-/-, Cd28-/-, Sap-/-, OT-II, Rc3h1san/san 
(sanroque), Rc3h1rin/rin (Roquin ringless), Rc3h2rin/rin (Roquin-2 ringless), Rc3h1flox/flox, 
Rc3h2flox/flox, Mir146a-/-, Stat1fae/+, Icos+/-, SWHEL-Ly5a, Foxo1flox/flox mice were housed 
in specific pathogen-free conditions at the Australian Phenomics Facility, ANU, and 
NOD.Nkrp1b.Tg(Slamf1)1 and NOD.Nkrp1b.Tg(Slamf1)2 mice at the Immuno-
genetics Research Facility, James Cook University. All mice had access to food and 
water ad libitum. 
 
Roquin ringless and Roquin-2 ringless mice were generated by Ozgene, LoxP sites 
that flanked or ‘floxed’ Rc3h1/2 exon 2, encoding the start codon and RING motif 
were introduced via homologous recombination in B6 mouse embryonic stem (ES) 
cells. Recombinant ES cell clones were implanted into foster mothers to yield 
chimeras. Heterozygote progeny were screened for germline transmission before 
crossing to Rosa26-Flp1 mice to remove the NeoR cassette. Floxed Rc3h1 and 
Rc3h2 mice were then crossed to mice expressing Cre under the control of the 
endogenous Rosa26 promoter. Removal of Cre expression by backcrossing to B6 
yielded germline deletions of Rc3h1/2 exon 2 (i.e. Rc3h1rin/rin or Rc3h2rin/rin mice). A 
conditional Roquin RING-deficient strain (called Tringless) was generated by 
crossing Roquinflox/flox mice to Lck-Cre breeders to remove Roquin exon 2 specifically 
in T cells. Rc3h1san mice were generated as previously described (Vinuesa et al., 
2005a). 
 
Mir146a-/- mice were generated on the B6 background and provided by David 
Baltimore (Caltech, USA). Stat1-face (Stat1fae) mice were derived from an N-ethyl, N-
nitrosourea (ENU) mutagenesis screen and kindly donated by Christopher C. 
Goodnow (ANU, Australia). SWHEL mice carry a Vκ10-κ light chain transgene and a 
knocked-in VH10 Ig heavy chain in place of the JH segments of the endogenous IgH 
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gene that encodes a high affinity antibody for hen egg lysozyme (Phan et al., 2003). 
Foxo1flox/flox mice (Paik et al., 2007) were donated by Ronald A. DePinho (Dana-
Farber Cancer Institute, USA) and were backcrossed seven times with B6 mice. The 
NOD.Nkrp1b.Tg(Slamf1) mice carry a Slamf1 transgene as described previously 
(Jordan et al., 2011). Mir146a-/-, Mir146a-/- Stat1fae/+, NOD.Nkrp1b.Tg(Slamf1)1, and 
NOD.Nkrp1b.Tg(Slamf1)2 mice were taken down at 12-16 weeks old unless 
otherwise stated. All experiments were approved by the Australian National 
University Animal Experimentation Ethics Committee and the James Cook University 
Animal Ethics Committee.  
 
To generate thymus-dependent germinal centre responses, where mentioned, mice 
were immunised intravenously with 2 x 108 sheep red blood cells (SRBC) (Applied 
Biological Products Management, Australia) and were taken down on day 7 post-
immunisation. 	  
Human tonsils 
Human tonsils were obtained from consenting patients undergoing routine 
tonsillectomy at the Canberra Hospital (Australia) with the approval from the 
institutional human research ethics committee. Tonsillar cells were isolated by 
mechanical disruption and Ficoll-Paque (GE Healthcare) density gradient 
centrifugation. 
 
Adoptive transfers  
To study the kinetics of miR-146a expression in a T-dependent germinal centre 
response, 5 x 105 sorted naïve OT-II CD4+ T cells were adoptively transferred into 
Ly5a+ wild-type B6 recipient mice intravenously. To limit miR-146a deficiency to T 
cells, 1 x 105 sorted naïve Mir146a-/- OT-II or control OT-II T cells were adoptively 
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transferred into Cd28-/- recipient mice. The recipients were immediately immunised 
intraperitoneally with 100 µg OVA (Sigma-Aldrich) in alum. To study the contributions 
of miR-146a deficiency in T and B cells, 4 x 106 CD4+ T cells and 6 x 106 B cells from 
Mir146a+/+ or Mir146a-/- mice were adoptively transferred into Rag1-/- mice. The 
recipients were immunised with SRBC 14 days after transfer and they were sacrificed 
7 days post-immunisation. Additionally, to examine the contribution of ICOS 
overexpression specifically in Tfh cell precursors to Tfh cell accumulation, 7.5 x 105 
naïve CD4+ T cells from either Mir146a-/- Icos+/+ or Mir146a-/- Icos+/- donor mice were 
co-transferred with 3 x 106 Mir146a-/- Icos+/+ B cells and 7.5 x 104 Mir146a+/+ Icos+/+ 
Tregs into Rag1-/- recipients and immunised with SRBC as above. To study the 
affinity maturation process in Mir146a-/- mice, 1 x 105 Ly5a+ SWHEL B cells and 2 x 108 
SRBCs conjugated to low affinity HEL3X antigen were injected intravenously into 
Ly5b+ Mir146a+/+ or Mir146a-/- mice as described previously (Phan et al., 2006). 
 
Bone marrow chimeras  
Chimeras were generated by sub-lethally irradiating Rag1-/- recipient mice (500 cGy, 
X-rad) and reconstituting their immune system by transferring 4 x 106 bone marrow 
cells from donor mice.  
 
Lymphocyte isolation, culture, and stimulation  
Single cell suspensions were prepared from spleens of unimmunised and/or 
immunised mice. Red blood cells were lysed using 1X red blood cell lysis buffer 
(Table 2.2). Lymphocyte suspensions were then prepared in lymphocyte culture 
media (Table 2.2) by mechanical disruption and gentle pipetting through 70 µm nylon 
mesh filters (BD Biosciences).  
 
For cytokine staining (IFN-γ, IL-4, and IL-17), cells were cultured for 4 hours in a 
37oC/ 5% CO2 incubator with 50 ng/ml phorbol-12-myristate-13-acetate (or PMA) 
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(Sigma-Aldrich) and 1 µM ionomycin (Sigma-Aldrich) in the presence of Golgi Stop 
(BD Biosciences). To study the effect of IL-6 and IL-21 on Tfh cell differentiation in 
vitro, naive CD4+ T cells and T cell-depleted antigen-presenting cells from Mir146a+/+ 
or Mir146a-/- mice were purified from splenocytes using flow cytometry. Differentiation 
of Tfh-like cells was modified from a published protocol (Lu et al., 2011). In brief, 2 x 
105 naive sorted CD4+ T cells were co-cultured with 1 x 106 APCs at 1 ml/well in a 6-
well plate, in the presence of soluble anti-CD3 (5 µg/ml) and anti-CD28 (2 µg/ml) for 
3 days in lymphocyte culture media under different skewing conditions: Th0: anti-IFN-
γ, anti-IL-12, anti-IL-4 (10 µg/ml); and Tfh-like: anti-IFN-γ, anti-IL-4, anti-IL-12, anti-
TGF-β (20 µg/ml), IL-6 and IL-21 (Peprotech).  
 
For ICOSL induction, B220+ cells and combined CD11b+/CD11c+ cells were isolated 
from SRBC-immunised Mir146a+/+ or Mir146a-/- mice by negative and positive 
selection respectively using MACS separation columns (Miltenyi Biotec) according to 
the manufacturer’s instructions. 5 x 105 B cells or CD11b+/CD11c+ cells were cultured 
per well in a 96-well plate (Corning) with different conditions: complete RPMI only 
(unstimulated), 1 µg/ml lipopolysaccharides (LPS) from E. coli (Sigma-Aldrich), 10 
µg/ml rat IgG2a (2A3) isotype control antibody (BioXCell), 10 µg/ml rat anti-mouse 
CD40 antibody (BioXCell) for 8 hours in a 37oC/ 5% CO2 incubator. 
 
To induce IL-6 expression, purified CD11b+ cells from mixed bone marrow chimeras 
were stimulated overnight with 100 ng/ml LPS (Sigma-Aldrich) in a 37oC/ 5% CO2 
incubator. 
 
Flow cytometry  
For lymphocyte analysis, single cell suspensions were prepared as described above. 
For myeloid cell population analysis, spleens were treated with Collagenase P 
(Roche) and DNase I (BD Biosciences) before preparing single cell suspensions for 
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staining. Follicular dendritic cells were isolated as described previously (Harker et al., 
2011). To stain for surface markers, cells were incubated with antibodies (Table 2.1) 
diluted in ice-cold FACS buffer (Table 2.2) for 30 minutes in the dark at 4oC and 
washed thoroughly with FACS buffer between each antibody layer. Staining for 
CXCR5 was done for 1 hour at 4oC. Cell viability was assessed using 7AAD (Life 
Technologies). Intracellular staining was performed using the Foxp3 staining buffer 
set (eBioscience) according to the manufacturer’s instructions.  
 
Detection of phosphorylated STAT3 and phosphorylated STAT1 was adapted from a 
previous protocol (Schulz et al., 2012). Briefly, total splenocytes were stimulated with 
recombinant mouse IL-6 or IL-21 (20 ng/ml) for 15 minutes in a 37oC/ 5% CO2 
incubator and levels of STAT3 and STAT1 phosphorylation were analysed using flow 
cytometry. For staining HEL3X-binding B cells, cells were initially incubated with 50 
ng/ml HEL3X, followed by Hy-HEL9 conjugated to Alexa Fluor 647. Serum IL-6 and 
TNF were measured using BD Cytometric Bead Array (CBA) Kit (BD Biosciences) 
following the manufacturer’s instructions. A BD LSRII Flow Cytometer with FACSDiva 
software was used for flow cytometry acquisition and FlowJo version 8 (Tree Star) 
was used for analysis. FACS Aria (BD Biosciences) was used for cell sorting. 
 
Histology 
Tissues were fixed in 10% neutral-buffered formalin and embedded in paraffin. 100 
µm thick sections were stained with haematoxylin and eosin (H&E) or Luxol Fast 
Blue-Cresyl Violet (LFB-CV) where indicated. Tissue sectioning and staining were 
performed by Anne Prins, ANU. 
 
ANA Assessment 
Serum was obtained from 8- to 16-week-old mice by eye or cardiac bleed. 
Concentration of autoantibodies in serum was measured with Mouse anti-dsDNA 
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Total Ig ELISA kit (Alpha Diagnostic) according to the manufacturer’s instructions. 
Plates were read at 405 nm using the Infinite 200 Pro microplate reader (Tecan). The 
ANA Ig autoantibodies concentration was calculated relative to the ANA standards. 
 
Cell lines and transfection 
HEK293T, Phoenix, and NIH3T3 cells (American Type Culture Collection) were 
grown in DMEM cell line culture media in a 37oC/ 5% CO2 incubator. Semiconfluent 
cells were transfected in 6-well plates using Lipofectamine 2000 (Life Technologies) 
according to the manufacturer’s protocol.  
 
Plasmids 
To construct the N-terminal V5-tagged full length Roquin, the cDNA was PCR-
amplified from plasmid Roquin-GFP3 using primers Roquin1F1: 5’- 
GGCTCTAGAATTCCGCAATGCCTGTACAAGCTCC-3’ and SR-DownNotI: 5’- 
CGCGAATGCGGCCGCCGGGAGCAGAATTGGAAACAAC-3’. The amplicon was 
cloned into the EcoRI-NotI sites of the entry vector pENTR3C (Life Technologies). 
This was recombined into the destination vector pcDNA3.1/nV5-DEST (Life 
Technologies). The RINGLESS version of Roquin was generated using site-directed 
mutagenesis (Quikchange, Agilent Technologies)  to create a second EcoRI site 
immediately upstream of the ATG codon at amino acid position 133 (5’- 
ACTACTCAGAGTGTTCTGGAATTCCCAATGCAGAGGAAACTT-3’) in the full length 
Roquin pENTR3C clone described above.  This construct was cut using EcoRI to 
excise the RING domain region and the vector religated. The resulting pENTR3C 
construct was recombined into the destination vector pcDNA3.1/nV5-DEST (Life 
Technologies) generating V5-Rc3h1RINGLESS. The untagged RoquinRINGLESS retroviral 
construct was constructed by cutting the RoquinRINGLESS pENTR3C vector with SalI 
and EcoRV and subcloned into the XhoI-blunted EcoRI sites of pKMV. The N-
terminal V5-tagged human RC3H2 cDNA was subcloned from MNAB-GFP 
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(Athanasopoulos et al., 2010) as an XbaI-NotI fragment and cloned into the same 
sites of pBluescriptII SK+.  The fragment was excised using BamHI-NotI and cloned 
into the same sites of pENTR2B before recombination into pcDNA3.1/nV5-DEST 
using the Gateway recombination system (Life Technologies). To construct the C-
terminal FLAG-tagged Roquin, the cDNA was excised from plasmid Roquin-GFP 
(Athanasopoulos et al., 2010) and cloned into the XbaI-NotI sites of the vector 
pMZS3F  (kind gift from J.F. Greenblatt, University of Toronto). The full length or 
CDS of Icos mRNA were amplified by PCR and inserted into the pR-IRES-hCD4 
retroviral vector. Rc3h1 and RC3H2 cDNA were also amplified and inserted into the 
pR-IRES-GFP retroviral vector. 
 
Wild-type and mutated putative miR-146a minimal target sequences (inserted into 
pmirGLO vector) used in luciferase reporter assays are provided in Table 2.3 below: 
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Table 2.3 – Putative miR-146a minimal target regions used in luciferase 
reporter assays. 
Target gene Sequence (sense strand) Sequence (antisense strand) 
Wt-Icos  
 
aaactagcggccgctagt  
ttcttcagtctagacagttctcttct  
tagtggtagtaaacatttctcagt  
ctagactgagaaatgtttactaccactaa
gaagagaactgtctagactgaagaaac
tagcggccgctagttt 
Mut-Icos  
 
aaactagcggccgctagt  
ttcttcagtctagacagaagacttct  
tagtccaagtaaacatttgagagt  
ctagactctcaaatgtttacttggactaag
aagtcttctgtctagactgaagaaacta  
gcggccgctagttt 
Wt-Slamf1 aaactagcggccgctagt  
ggaccccgggtcccaagttctctgtgac  
gaacttttgaatttaagttctctgttt  
ctagaaacagagaacttaaattcaaaa
gttcgtcacagagaacttgggacccggg
gtccactagcggccgctagttt 
Mut-Slamf1 aaactagcggccgctagt  
ggaccccgggtcccaaaaaaaatgtgac  
gaacttttgaatttaaaaaaaatgttt  
ctagaaacattttttttaaattcaaaagttc
gtcacattttttttgggacccggggtccact
agcggccgctagttt  
Wt-Slamf6 aaactagcggccgctagt  
caactaaacagtcagagttctgatggac  
agattgattccgcaagtaatcacttctccttct  
ctagagaaggagaagtgattacttgcgg
aatcaatctgtccatcagaactctgactgt
ttagttgactagcggccgctagttt 
Mut-Slamf6 aaactagcggccgctagtcaactaaacagt
cagaaaaaaaatggacagattgattccgca
agtaatcaaaaaaacttct 
ctagagaagtttttttgattacttgcggaat
caatctgtccattttttttctgactgtttagttg
actagcggccgctagttt  
Wt-Cd84 aaactagcggccgctagt  
aactcagctatctatagttctaagtatc  
agtggctgctctctgatttctcttctt  
ctagaagaagagaaatcagagagcag
ccactgatacttagaactatagatagctg
agttactagcggccgctagttt 
Mut-Cd84 aaactagcggccgctagt  
aactcagctatctataaaaaaaagtatc  
agtggctgctctctgaaaaaaattctt  
ctagaagaatttttttcagagagcagcca
ctgatacttttttttatagatagctgagttact
agcggccgctagttt  
Wt-Il21r aaactagcggccgctagt  
tgtattgtaatgctaaattctctacccaa 
agttctaggcctacgagtgaattctcatgttt  
ctagaaacatgagaattcactcgtaggc
ctagaactttgggtagagaatttagcatta
caatacaactagcggccgctagttt 
Mut-Il21r aaactagcggccgctagttgtattgtaatgct
aaaaaaaatacccaaaaaaaaaggccta
cgagtgaaaaaaaatgttt 
ctagaaacattttttttcactcgtaggcctttt
tttttgggtattttttttagcattacaatacaa
ctagcggccgctagttt  
Wt-Il6st aaactagcggccgctagt  
tccagagtagctggaattctccttcaa  
cccagttaggactgagttttctatgt  
ctagacatagaaaactcagtcctaactg
ggttgaaggagaattccagctactctgg
aactagcggccgctagttt 
Mut-Il6st aaactagcggccgctagt  
tccagagtagctggaaaaaaacttcaa  
cccagttaggactgaaaaaaatatgt  
ctagacatatttttttcagtcctaactgggtt
gaagtttttttccagctactctggaacta  
gcggccgctagttt 
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Immunofluorescence 
Transfected HEK293T cells were fixed in 3.7% formaldehyde, permeabilised with 1% 
Triton X-100 for 5 minutes, and washed in PBS. Cells were then incubated with 
antibodies for 1 hour at room temperature and washed with PBS containing 0.05% 
Tween-20 (Sigma-Aldrich). For TIA-1 staining, cells were fixed for 10 minutes in 3% 
paraformaldehyde, permeabilised in 0.5% Triton X-100, washed in PBS and blocked 
in 5% foetal calf serum or 5% BSA for 1 hour at room temperature. Cells were 
counter-stained with 4′,6-diamidino-2-phenylindole (DAPI) for 5 minutes before 
mounting in Vectashield (Vector Laboratories). Images were collected using an 
Olympus IX71 microscope with DP Controller software (Olympus) and compiled 
using Adobe Photoshop software. 
 
Retroviral transductions 
Packaging of retroviruses, virus titrations, transduction of NIH3T3 cells, and 
quantification of target mRNA expression relative to empty vector expression were 
performed as previously described (Swift et al., 2001; Yu et al., 2007). In brief, 
retroviral supernatants were harvested from packaging Phoenix cells transfected with 
individual retroviral constructs. NIH3T3 cells were transduced by retroviruses via 
spinoculation.  
 
Immunoprecipitation and Western blotting  
Whole-cell lysates were prepared using TNE lysis buffer (Table 2.2). To 
immunoprecipitate proteins, antibody was added to pre-cleared lysates and mixed 
with Protein G Sepharose 4 Fast Flow (GE Healthcare) for 12 hours then washed. 
For western blotting, lysates were separated by sodium dodecyl sulphate-
polyacrylamide gel electrophoresis (SDS-PAGE), transferred to nitrocellulose 
membrane, blocked in 5% BSA Tris-buffered saline containing 0.05% Tween-20 
(Sigma-Aldrich), probed with primary antibodies and detected with horseradish 
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peroxidase-conjugated secondary antibodies. Blots were developed using the 
Western Lightning Plus Enhanced Chemiluminescence reagent (Perkin Elmer). 
 
Luciferase reporter assay  
HEK293T cells were co-transfected with pmirGLO (Promega) luciferase reporter 
plasmids containing either wild-type or mutated putative miR-146a minimal target 
sequences (Table 2.3) and mirVana miR-146a mimic or mirVana negative control #1 
“scramble” (Life Technologies) according to the manufacturer’s instructions. After 24 
hours, 3 x 105 transfected cells were transferred into opaque flat-bottom 96-well 
plates and incubated for another 24 hours. Cells were then harvested and luciferase 
activity was assessed using Dual-Glo Luciferase Assay System (Promega) according 
to the manufacturer’s protocol.   
 
Microarray  
Total RNA extraction from sorted tonsillar cells or mouse splenocytes was done 
using the RNeasy Kit (QIAGEN) according to the manufacturer’s protocol. RNA 
quantity and quality were determined using Nanodrop 1000 and Agilent 2100 
Bioanalyzer respectively. Hybridisations on Agilent Human miRNA Microarray (V1) 
Kit, 8x15K (for human miRNA array), Agilent Mouse miRNA Microarray (V1) Kit, 
8x15K (for Rc3h1san/san miRNA array), and Affymetrix GeneChip Mouse gene 1.0 ST 
Array (for Mir146a-/- microarray) were performed at The Ramaciotti Center for 
Genomics (University of New South Wales, Australia). Data were analysed using 
GeneSpring 10.0 software (Affymetrix). Triplicates (for human miRNA array) and 
duplicates (for mouse microarray) of each population were collected and averaged in 
GeneSpring. 
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Real-time PCR analysis 
RNA was extracted using TRIzol reagent (Life Technologies) according to the 
manufacturer’s protocol, and complementary DNA (cDNA) was synthesised using the 
miScript II reverse transcription (RT) Kit (QIAGEN) following the manufacturer’s 
instructions. Quantitative PCR to assess miR-146a expression was performed using 
the miScript SYBR Green PCR Kit and miScript Primer Assays (QIAGEN) to amplify 
mature Mir146a and the U6 small nuclear RNA. Other gene-specific primers were 
purchased from Origene. Quantitative PCR was performed on the ABI Prism 7900 
(Applied Biosystems). Fluorescence signals were measured over 40 PCR cycles and 
the cycle (Ct) at which signals crossed a threshold set within the logarithmic phase 
was recorded. The relative gene expression was calculated using the 2-ΔΔCt method.  
 
Transcription factor analysis 
The genome-wide nuclear run-on (Gro-Seq) assay was performed according to a 
published protocol (Chiarle et al., 2011). The genome-wide DNase I protection assay 
and the chromatin interaction analysis-paired end tag sequencing (ChIA-PET) assay 
were performed as previously described (Kieffer-Kwon et al., 2013). The binding of 
Foxo-1 to the Mir146a enhancer region on Treg cells was determined using 
chromatin immunoprecipitation-sequencing (ChIP-Seq) as previously described 
(Ouyang et al., 2012). 
 
Statistical analysis  
Statistical significance was determined using the non-parametric Mann-Whitney U 
test unless specified otherwise. All statistical analyses were performed using the 
Prism software version 5.0 (GraphPad Software). Statistically significant differences 
are indicated as: ns = not significant, * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 
0.0001. 
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CHAPTER THREE 
 
 
Roquin shares overlapping functions with its paralogue 
Roquin-2 in the repression of Icos mRNA to limit germinal 
centre reactions  
 
INTRODUCTION 
 
Roquin (or Roquin-1) is a RING (really interesting new gene)-domain containing 
protein encoded by the Rc3h1 gene with an important function in controlling T 
follicular helper (Tfh) cells. It was discovered and revealed as a crucial regulator of 
self-tolerance when homozygosity for the Rc3h1 ‘san’ allele in mice, which causes an 
M199R amino acid substitution within a unique ROQ domain of the protein, was 
found to segregate with excessive formation of Tfh cells, spontaneous autoantibody 
production and end-organ pathology typical of systemic lupus erythematosus 
(Vinuesa et al., 2005a). Roquin is expressed ubiquitously, but little is known about its 
other cellular actions, including within the innate immune system. 
 
Roquin binds mRNA targets such as Icos promoting their decay through the ROQ 
domain and an adjacent CCCH-type zinc finger (Athanasopoulos et al., 2010; Chang 
et al., 2012b; Glasmacher et al., 2010; Yu et al., 2007). Consistent with this function, 
Roquin localises to cytoplasmic stress granules (SGs) and processing bodies (P-
bodies), forming part of the mRNA decapping complex within P-bodies through its 
ability to interact with RCK and the enhancer of decapping EDC4 (Glasmacher et al., 
2010). In Rc3h1san/san mice, the mutant protein fails to repress target mRNAs, leading 
to overexpression of the T cell inducible costimulator (ICOS) and interferon-gamma 
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(IFN-γ) (Lee et al., 2012b; Yu et al., 2007). Both of these molecules contribute to the 
accumulation of Tfh cells that sustain and aberrantly select germinal centre (GC) B 
cells and cause autoimmunity (Lee et al., 2012b; Linterman et al., 2009b; Yu et al., 
2007). 
 
Unlike Rc3h1san/san mice, Rc3h1-null mice showed no accumulation of effector CD4+ T 
cells or Tfh cells (Bertossi et al., 2011), suggesting the possibility of the existence of 
a related protein with redundant functions. A family of Rc3h1-like genes and proteins 
can be traced in evolution from mammals to invertebrates. While C. elegans and D. 
melanogaster have a single ancestral gene, humans and mice have one clear 
Roquin paralogue called Roquin-2 [also known as MNAB, membrane-associated 
nucleic acid binding protein (Siess et al., 2000)]. Roquin-2 is encoded by the Rc3h2 
gene. The two paralogues – Roquin and Roquin-2 – appear to have arisen by ancient 
gene duplication and lie on different chromosomes. The N-termini of Roquin and 
Roquin-2 share high sequence similarity across the RING, ROQ and CCCH domains 
(Figure 3.1). While the function of Roquin-2 remains unknown, both Roquin and 
Roquin-2 are expressed ubiquitously and localise to RNA-regulating SGs 
(Athanasopoulos et al., 2010). If the function of Roquin can be shared by another 
protein, Roquin-2 is an obvious candidate.  
 
This study sets out to investigate the function of Roquin-2 and possible functional 
redundancies between Roquin and Roquin-2 by analysing single and double RING 
mutant mice. The experiments reveal that these paralogues share overlapping 
mRNA targets and Roquin-2 can compensate for Roquin’s RNA repression activity 
when Roquin is not localised to SGs. These results establish an important role for the 
RC3H family as regulators of Tfh cell homeostasis and GC responses. 
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RESULTS 
 
Roquin-2 localises to stress granules and represses Icos mRNA 
 
Given the striking sequence similarity between Roquin and Roquin-2 (Figure 3.1), it 
is likely that they might have similar functions. Since Roquin localises to cytoplasmic 
SGs and processing bodies (P-bodies), we tested whether Roquin-2 could also be 
found in these subcellular compartments. A cDNA encoding Roquin-2 was fused to a 
V5 tag and introduced into HEK293T cells. Staining cells for the SG and P-body 
markers eIF3 and Dcp1a, respectively, revealed that Roquin-2 localised within both 
SGs (Figure 3.2a) and P-bodies (Figure 3.2b) upon oxidative stress induced by 
arsenite treatment.  
 
We next asked whether Roquin-2 could repress Icos mRNA, a known target of 
Roquin (Yu et al., 2007). Roquin-2 and Roquin were expressed in NIH3T3 cells using 
pR-IRES-GFP retroviral vectors, together with a pR-IRES-CD4 retroviral vector 
expressing either full length (FL) Icos or only the protein-coding sequence (CDS), 
thus lacking the 3’UTR sequences recognised by Roquin (Figure 3.3). In this system, 
cell to cell differences in Roquin and Roquin-2 expression are inferred from 
differences in GFP fluorescence, since they are encoded by a single bicistronic 
mRNA, and human CD4 (HuCD4) fluorescence is an indicator of Icos mRNA 
expression within individual cells. 
 
When NIH3T3 cells were co-transduced with RC3H2-IRES-GFP and Icos FL-IRES-
CD4, cells expressing high amounts of RC3H2-IRES-GFP repressed HuCD4 
expression by ~50%, indicating Roquin-2 represses Icos mRNA, albeit possibly to a 
lesser extent than Roquin (Figures 3.4a,b). As shown previously for Roquin, Roquin-
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2 did not repress Icos mRNA in cells transduced with Icos CDS-IRES-CD4 (Figures 
3.4a,c), suggesting that mRNA repression by Roquin-2 occurs via 3’UTR targeting.  
 
The possibility that Roquin and Roquin-2 form dimers or interact to jointly repress 
shared mRNA targets was also considered. Reciprocal co-immunoprecipitation of 
Roquin-FLAG and V5-Roquin-2 ectopically expressed in HEK293T cells failed to 
reveal an interaction between Roquin and Roquin-2 (Figure 3.5). It is nevertheless 
possible that the molecular tags may interfere with dimerisation, thus this possibility 
cannot be completely ruled out. In the future, a repeat of the co-immunoprecipitation 
experiment needs to be conducted on endogenous Roquin and Roquin-2 to eliminate 
possible artefact caused by the tags. Collectively, these data indicate that Roquin-2 
and Roquin have independent, overlapping ability to destabilise Icos mRNA when 
their expression is enforced in vitro. 
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Roquin-2 
Hydrophobic 
Roquin 
RING CCCH Coiled Coil Proline-Rich Region ROQ 
82% 
Sequence 
similarity: 99% 81% 45% 51% 
Figure 3.1 – Schematic diagram of Roquin and Roquin-2 proteins.  
The amino acid sequence similarity for each domain is calculated and expressed as a 
percentage.  
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Figure 3.2 – Roquin-2 localises to stress granules (SG) and P-bodies.  
HEK293T cells were transfected with V5-RC3H2WT (shown in green), treated with 1 mM sodium 
arsenite (+AS) for 1 hour to induce SG formation, then fixed and stained with anti-eIF3 (a) or left 
untreated and stained with anti-Dcp1a (b) antibody (shown in red). DNA was stained with 4’,6-
diamidino-2-phenylindole (DAPI, shown in blue). Images in a and b were all taken at the same 
magnification and the scale bar represents 50 µm. 
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Figure 3.3 – Schematic diagram of retroviral vectors used to investigate the repression of 
full-length (FL) Icos mRNA (including protein-coding sequence (CDS) and 3’UTR) or Icos 
CDS by Roquin or Roquin-2. LTR, long terminal repeats; Ψ, retroviral packaging element; 
HuCD4, human CD4; GFP, green fluorescent protein; IRES, internal ribosome entry site.  
Icos FL IRES CD4 5’LTR 3’LTR 
Ψ 
Icos CDS IRES CD4 5’LTR 3’LTR 
Ψ 
Rc3h1 IRES GFP 5’LTR 3’LTR 
Ψ 
RC3H2 IRES GFP 5’LTR 3’LTR 
Ψ 
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Figure 3.4 – Roquin-2 represses Icos mRNA through its 3’UTR.  
(a) Flow cytometric analysis of NIH3T3 cells following retroviral co-transduction of Rc3h1 (left) 
or RC3H2 (right) with either Icos FL mRNA (top) or Icos CDS mRNA (bottom). Expression of 
Roquin or Roquin-2 was assessed by GFP fluorescence, whereas that of ICOS was assessed 
by human CD4 (HuCD4) reporter. (b) Quantification of HuCD4 (normalised to empty vector) on 
NIH3T3 cells co-transduced with Icos FL mRNA and either Rc3h1 or RC3H2. (c) Similar to b, 
but NIH3T3 cells were co-transduced with RC3H2 and either Icos FL mRNA or Icos CDS 
mRNA. The vertical axes in b and c show the fold difference in HuCD4 expression on NIH3T3 
cells transduced with either Rc3h1 or RC3H2 relative to empty vector. The dashed lines in b and 
c indicate full (unrepressed) expression of HuCD4. Data are representative of three independent 
experiments.  
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IB: 
250 
150 
250 
150 
FLAG 
kDa: 
V5 
IP: 
Rc3h1-FLAG + V5-RC3H2 
Figure 3.5 – No direct interaction between Roquin and Roquin-2.  
Reciprocal co-immunoprecipitation of Rc3h1-FLAG and V5-RC3H2 ectopically expressed in 
HEK293T cells.  
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In vivo targeted deletion of the Roquin and Roquin-2 RING domains 
 
To compare the role of Roquin and Roquin-2 as regulators of mRNA decay in vivo, 
gene targeting was used to produce mice with loss-of-function mutations that 
eliminated the RING domain from Roquin or Roquin-2. The Cre-LoxP methods were 
used to ablate Rc3h2 exon 2, encoding the translation start site and RING domain, 
upon crosses with Rosa26-Cre transgenic mice to generate a germline deficiency 
(Figure 3.6). This allele has been designated Rc3h2rin (rin = ringless). In the resulting 
Rc3h2rin mRNA, skipping of exon 2 resulted in a smaller transcript due to splicing of 
exon 1 to exon 3 (Figure 3.7), yielding an alternative in-frame Kozak translation 
initiation site at Met130.  
 
Homozygous Rc3h2rin/rin mice, which lacked the Roquin-2 RING domain in all cell 
types, were viable and did not display ICOS overexpression (Figures 3.8a,b). 
Enumeration of effector CD4+, Tfh, and GC B cells before or 6 days after sheep red 
blood cells (SRBC) immunisation did not reveal any differences with control mice 
(Figures 3.8a,c).  
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Figure 3.6 – Schematic diagram showing the strategy to generate the Roquin-2 ringless 
mice. Deletion of Rc3h2 exon 2 through homologous recombination with a targeting vector 
containing loxP sites and crossing to the Rosa26-Cre transgenic strain. White boxes, non-
coding exons; black boxes, protein-coding exons; NeoR, Neomycin resistance cassette.  
Wild-type allele 
5 3 Targeting  
vector 
5’ arm 
loxP loxP 
loxP loxP 
loxP loxP 
Targeted (floxed) allele 
Homologous recombination  
Cross to Rosa26-Flp1 mice 
loxP 
Primers: 
Cross to Rosa26-Cre mice ringless allele 
3’ arm 
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Figure 3.7 – Rc3h2 exon 2 is skipped in the Rc3h2rin/rin cells.  
Deletion of Rc3h2 exon 2 detected in mouse embryonic fibroblasts (MEFs) by PCR (a) and 
sequencing of cDNA (b). Position of primers used for the PCR in a is indicated as arrowheads in 
Figure 3.6. M, DNA marker; bp, base pairs; +/+. Rc3h2+/+; rin/rin, Rc3h2rin/rin.  
a 
bp 
+/+ rin/rin M b 
…C T A G A A C A G T T T G A A A A A… C C C 
Rc3h2rin 
…CAAACATTAGCTTAAAAAAC…TGGAGCCCAGGTACCAGATCA…   
Exon 1 Exon 3 
Exon 1 Exon 3 Exon 2 
Rc3h2WT 
250 
500 
750 
1000 
1500 
2000 
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Figure 3.8 – No obvious T and B cell phenotypes in the Rc3h2rin/rin mice.  
(a) Contour plots showing the gating strategy of naïve (CD44low), effector (CD44high) and Treg 
(CD25high) cells gated on CD4+ T cells (left), Tfh (CXCR5high PD-1high) cells gated on CD4+ T 
cells (middle), and GC B (Fas+ GL-7+) cells gated on B220+ cells (right). (b) ICOS geometric 
mean fluorescence intensity (MFI) on naïve (left) or effector (right) CD4+ T cells from mice 
sufficient (Rc3h2+/+) or deficient (Rc3h2rin/rin) in the Roquin-2 RING domain. (c) Proportions of 
effector cells (left), Tfh cells (middle) and GC B cells (right) in Rc3h2+/+ and Rc3h2rin/rin mice. MFI 
values and percentages before (d0) and 6 days after SRBC immunisation (d6) are shown. ns = 
not significant. Each dot represents an individual mouse and bars represent median values in 
each group. Data are representative of two independent experiments.  
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A similar strategy was used to produce mice with a germline or T cell-specific 
deletion of Rc3h1 exon 2, which encodes the translation start codon and RING 
domain. Like the Rc3h2rin allele, the resulting Rc3h1 ringless (Rc3h1rin) mRNA also 
spliced exon 1 to exon 3 yielding an alternative in-frame Kozak translation initiation 
site at Met133 that produced an N-terminally truncated protein. Unlike the Rc3h2rin 
allele, however, homozygosity for the germline Rc3h1rin resulted in perinatal lethality 
and a phenotype similar to that described in mice lacking Rc3h1, including a lung 
inflation defect (Figure 3.9a) and an incomplete closure of the neural tube (Figure 
3.9b) The phenotypic similarity between Rc3h1rin/rin and Rc3h1-/- suggests that the 
Rc3h1rin allele results in a severe loss-of-function of Roquin (Bertossi et al., 2011). 
 
To circumvent perinatal lethality and investigate the consequences of the Rc3h1rin 
mutation on ICOS regulation in T cells, mice with a T cell-specific deletion of Roquin 
RING (Rc3h1flox/flox Lck-Cre) were generated. Similar to mice lacking Rc3h1 (Bertossi 
et al., 2011), there was no spontaneous accumulation of activated CD4+ and Tfh cells 
in Rc3h1flox/flox Lck-Cre (Tringless) mice (Figure 3.10a). GC B cell frequencies were 
also comparable to those of Rc3h1flox/flox control mice (Figure 3.10b). ICOS 
expression on naïve (CD44low) and effector (CD44high) CD4+ T cells was increased 
slightly in Roquin Tringless mice similar to mice heterozygous for the Rc3h1san allele 
analysed in parallel, but much less than in homozygous Rc3h1san/san mice (Figure 
3.11).  
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Figure 3.9 – Roquin RING deficiency causes lung defect and improper closure of the 
neural tube. Histological assessments of lung by haematoxylin and eosin (H&E) staining (a) 
and lumbar neural tube by Luxol Fast Blue-Cresyl Violet (LFB-CV) staining (b) of embryos 
sufficient (Rc3h1+/+) (left) or deficient (Rc3h1rin/rin) (right) in the Roquin RING domain at 
embryonic day 19 (E19). Scale bar on the lung photomicrograph (a) represents 100 µm, and 
that on the vertebrae photomicrograph (b) represents 500 µm. This experiment was performed 
by Roy R. Ramiscal, ANU. 
a 
b 
Rc3h1+/+ Rc3h1rin/rin 
	   83 
0.00
0.05
0.10
0.15
0.0
0.1
0.2
0.3
0
5
10
15
Rc3h1flox/flox Rc3h1flox/+ Lck-Cre Rc3h1flox/flox Lck-Cre (Tringless) 
G
C
 B
 (%
 o
f B
22
0+
 c
el
ls
)  
Tf
h 
(%
 o
f C
D
4+
 c
el
ls
)  
E
ffe
ct
or
 (%
 o
f C
D
4+
 c
el
ls
)  
Figure 3.10 – Roquin RING deficiency does not cause accumulation of effector T and Tfh 
cells. Proportions of effector (CD44high) cells (left), Tfh (CXCR5high PD-1high) cells (middle) and 
GC B cells (right) in Rc3h1flox/flox, Rc3h1flox/+ Lck-Cre, and Rc3h1flox/flox Lck-Cre mice. Each dot 
represents an individual mouse and bars represent the median value in each group. This 
experiment was performed by Roy R. Ramiscal, ANU. 
 
	   84 
Effector 
Rc3h1flox/flox 
Rc3h1flox/+ Lck-Cre 
Rc3h1flox/flox Lck-Cre (Tringless) 
Rc3h1+/+ 
Rc3h1san/+ 
Rc3h1san/san 
Naïve 
IC
O
S
 M
FI
 
Figure 3.11 – Roquin RING deficiency minimally impairs ICOS repression.  
ICOS MFI on naïve or effector CD4+ T cells from mice with T cell-conditional deletion of Rc3h1 
RING (Rc3h1flox/flox Lck-Cre) or littermate controls (Rc3h1flox/+ Lck-Cre and Rc3h1flox/flox) and from 
mice with the Roquin M199R point mutation (Rc3h1san/san) or littermate controls (Rc3h1san/+ and 
Rc3h1+/+). Each dot represents an individual mouse and bars represent the median value in 
each group. This experiment was performed by Jessica Fitch, ANU. 
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Roquin-2 compensates for RING-deficient Roquin 
 
We next tested the possibility that the apparent loss of function of RoquinRINGLESS 
protein allowed its Icos-regulating function to be compensated by wild-type Roquin-2 
in Roquin Tringless mice. Supporting this hypothesis, Roquin-2 was found to localise 
normally to SGs in Rc3h1rin/rin mouse embryonic fibroblasts (Figure 3.12). The RING 
domains were ablated from both Roquin and Roquin-2 in T cells by breeding Lck-Cre 
transgenic mice bearing homozygous Rc3h1flox/flox and Rc3h2flox/flox alleles. Double 
Roquin-1/2 Tringless mice (Rc3h1flox/flox Rc3h2flox/flox Lck-Cre) had elevated ICOS 
expression on effector (CD44high) CD4+ and Tfh (CXCR5high PD-1high) cells compared 
to control Rc3h1flox/flox Rc3h2flox/flox mice that did not inherit the Lck-Cre transgene or 
to their single Tringless counterparts (Figure 3.13). This was accompanied by 
increased formation of Tfh and GC B cells and increased IFN-γ-producing cells upon 
SRBC immunisation (Figure 3.14). The Ifng mRNA was shown previously to be a 
target of Roquin (Lee et al., 2012b). Nevertheless, ICOS expression, Tfh and GC B 
cell numbers were still higher in Rc3h1san/san mice than in double Roquin-1/2 
Tringless mice (Figure 3.14). 
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Figure 3.12 – Roquin-2 localises to stress granules in Rc3h1rin/rin cells.  
Mouse embryonic fibroblasts (MEFs) were prepared from Rc3h1+/+ (a) or Rc3h1rin/rin (b) mice 
and transduced with retroviruses expressing wild-type Roquin-2 (RC3H2-IRES-GFP; as 
described in Figure 3.3).  Cells were pre-treated with 1 mM sodium arsenite for 1 hour to induce 
stress granules (+AS) stained with anti-Roquin-2 antibody (green) and the stress granule 
marker eIF3 (red). DNA is stained with DAPI (blue). Boxed inserts magnify one particular region. 
This experiment was performed by Vicki Athanasopoulos, ANU.   
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Figure 3.13 – Partially overlapping functions of Roquin and Roquin-2 in the repression of 
ICOS and germinal centre responses. Flow cytometric analysis on Lck-Cre expressing double 
Rc3h1 and Rc3h2-floxed (Roquin-1/2 Tringless) mice and controls examined 6 days post-SRBC 
immunisation showing ICOS MFI on effector and Tfh cells, and proportions of Tfh cells and GC 
B cells. Control groups include double Roquin-1/2 floxed (Rc3h1flox/flox Rc3h2flox/flox), Rc3h2rin/rin 
(Roquin-2 ringless), and Rc3h1flox/flox Lck-Cre (Roquin Tringless) mice. ns = not significant, * P < 
0.05; ** P < 0.01. Data are representative of two independent experiments.  
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Figure 3.14 – Phenotypes of the Roquin-1/2 Tringless mice are not as severe as those of 
the Roquin sanroque mice. Flow cytometric analysis on the double RING-domain mutant 
(Roquin-1/2 Tringless) mice and the Roquin ROQ-domain mutant (Rc3h1san/san) mice, showing 
ICOS MFI on Tfh cells, proportions of IFNγ-producing CD4+, Tfh and GC B cells. MFI values and 
percentages before (d0) and 6 days after SRBC immunisation (d6) are shown.  Data are 
representative of two independent experiments.  
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Deletion of the RING domain affects localisation to stress granules 
 
The data above suggests that Roquin-2 can compensate for RoquinRINGLESS but not 
RoquinSAN mutations. There are two possible interpretations for this difference. First, 
the ‘san’ missense mutation is either a neomorphic or antimorphic allele, where the 
M199R substitution results in a protein with novel or dominant negative activity. To 
test if the requirement for homozygosity of the Rc3h1san allele was due to a gain-of-
function or antimorphic effect that only occurred with a double gene dosage of point 
mutant protein, we compared mice that carried a single copy of the Rc3h1san allele 
but carried, on the other chromosome, either a normal Rc3h1 gene (san/+) or the 
loss-of-function Rc3h1rin allele (san/rin). T cells in the resulting compound 
heterozygous Rc3h1san/rin mice displayed increased CD44high CD4+ and Tfh cells and 
exaggerated ICOS expression on naïve CD4+ cells comparable to T cells from 
Rc3h1san/san mice with a double genetic dose of the point mutant protein (Figure 
3.15). This result indicates that the recessive ICOS dysregulation caused by 
Rc3h1san reflects a loss of Roquin’s RNA-regulating function. 
 
The second interpretation for the inability of Roquin-2 to compensate for RoquinSAN is 
that the ‘san’ allele may act recessively to encode a “niche-filling” protein, where 
assembly into the mRNA regulating complex is preserved but the normal mRNA-
repressing function of Roquin is lost. Previous evidence has been presented that 
RoquinSAN localises normally to SGs (Athanasopoulos et al., 2010). Repression of 
mRNAs such as Icos by Roquin correlates with localisation of the protein to 
cytoplasmic P-bodies, subcellular cytoplasmic compartments where 5’-3’ mRNA 
decay is thought largely to occur (Glasmacher et al., 2010). P-bodies and SGs have 
been shown to be dynamically linked structures and their fusion promoted and even 
stabilised by RNA-binding proteins such as TTP and BRF1 (Kedersha et al., 2005). 
Localisation of RoquinSAN in the correct niche could then prevent compensatory 
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substitution by related proteins with overlapping functions. This type of compensation 
for null but not missense alleles has previously been demonstrated for the Ikaros 
protein family (Papathanasiou et al., 2003).  
 
We therefore looked at the ability of an N-terminal RING domain-deleted Roquin 
(Roquin133—1130; RoquinRINGLESS) to localise to P-bodies and to SGs. When ectopically 
expressed in HEK293T cells, V5-tagged RoquinRINGLESS was still able to localise to P-
bodies, but only co-localised with eIF3 (a SG marker) in 5% of arsenite-treated cells 
compared to RoquinWT, which co-localised with eIF3 in 91% of stressed cells (Figure 
3.16). Additional tests using a different marker for SG co-localisation, TIA-1, 
confirmed that RoquinRINGLESS localised outside of, but adjacent to, SGs (Figure 
3.17). Even though Roquin-2 still localised to SGs in the presence of RoquinSAN 
(Figure 3.18), the latter, although not functional, is likely to retain its scaffold position 
within RNA granules. Thus, unlike RoquinRINGLESS, RoquinSAN may not create a void in 
the multi-molecular RNA-regulating assembly in SGs for Roquin-2 to occupy (Figure 
3.19). 
 
We also investigated the possibility that the altered localisation of the RoquinRINGLESS 
(133-1130) mutant studied here was related to the fusion tag. Retrovirally expressed 
untagged RoquinRINGLESS (133-1130) also failed to localise to SGs (Figure 3.16e) in 
HEK293T cells. Similar to RoquinRINGLESS, the RING-deficient Roquin-2 protein 
(Roquin-2RINGLESS) localised outside SGs upon stress induction (Figure 3.20a) but 
retained its normal P-body localisation (Figure 3.20b). These results demonstrate 
that the mutation engineered in the mice, which selectively removes the RING 
domain from an otherwise full-length protein, results in a failure of the protein to 
localise to SGs. 
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Figure 3.15 – RoquinRINGLESS protein is unable to complement the ROQ M199R mutant 
protein to regulate Icos mRNA in T cells. Proportions of effector cells (left), Tfh cells (middle) 
and ICOS MFI on naïve or effector CD4+ T cells (right) from Rc3h1+/+, Rc3h1rin/+, Rc3h1san/+, 
Rc3h1san/rin and Rc3h1san/san mice. Data are pooled from two experiments. Each dot represents 
an individual mouse and bars represent the median value in each group. This experiment was 
performed by Jessica Fitch, ANU. 
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Figure 3.16 – RING-deficient Roquin is unable to localise to eIF3+ stress granules.  
(a,b) HEK293T cells transfected with V5-Rc3h1WT (a) and V5-Rc3h1RINGLESS (b) were fixed and 
co-stained with V5 antibody (green), and the P-body (PB) marker Dcp1a (red). (c-e) HEK293T 
cells were transfected with V5-Rc3h1WT (c), V5-Rc3h1RINGLESS (d), or untagged Rc3h1RINGLESS 
(e), treated with 1 mM sodium arsenite for 1 hour to induce SG formation. Cells were fixed and 
stained with eIF3 antibody (red) and either V5 antibody (green in c,d) or Roquin-specific 
antibody (green in e). Ectopically expressed V5-Rc3h1WT localises to eIF3+ SGs (yellow 
arrowheads). White arrowheads show V5-Rc3h1RINGLESS with impaired localisation to eIF3+ 
granules. Boxed inserts magnify one particular region. DNA was stained with DAPI (blue). This 
experiment was performed by Vicki Athanasopoulos, ANU. 
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Figure 3.17 – RING-deficient Roquin is unable to localise to TIA-1+ granules.  
HEK293T cells transfected with V5-Rc3h1WT (a) or V5-Rc3h1RINGLESS (b,c) were fixed and co-
stained with anti-V5 antibody (green), and with the SG/PB marker TIA-1 (red). Cells were pre-
treated with 1 mM sodium arsenite for 1 hour to induce stress granules (+AS). DNA was stained 
with DAPI (blue). Boxed inserts magnify one particular region. This experiment was performed 
by Vicki Athanasopoulos, ANU. 
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Figure 3.18 – Roquin-2 SG localisation is unaffected by the presence of RoquinSAN. 
HEK293T cells were co-transfected with V5-RC3H2WT and either V5-Rc3h1WT (a) or V5-
Rc3h1SAN (b,c) and treated with 1 mM sodium arsenite for 1 hour to induce stress granules 
(+AS). Cells were stained with anti-eIF3 antibody (red) or with anti-Roquin-2 antibody (shown in 
green in a,b) or with anti-Roquin antibody (shown in green in c). DNA was stained with DAPI 
(blue). Boxed inserts magnify one particular region. This experiment was performed by Vicki 
Athanasopoulos, ANU. 
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Figure 3.19 – Schematic diagram illustrating the plausible cooperation between Roquin 
and Roquin-2 in their RNA-regulating function in physiological condition (wild-type) or in 
Roquin RING-domain (RoquinRINGLESS) or ROQ-domain (RoquinSAN) mutant cells. In wild-
type cells, Roquin and Roquin-2 collaborate to repress target mRNAs, with Roquin being the 
more efficient family member. In mutant cells, RoquinRINGLESS, but not RoquinSAN, appears to 
vacate its niche in the RNA-regulating granules thereby allowing Roquin-2 to compensate its 
functional defect. 
Roquin 
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Figure 3.20 – RING-deficiency causes impaired Roquin-2’s SG localisation.  
(a) HEK293T cells were transfected with V5-RC3H2RINGLESS (stained with anti-V5, green), 
treated with 1 mM sodium arsenite for 1 hour to induce SG formation (+AS), then fixed and 
stained with anti-eIF3 (red). (b) Non-stressed transfected cells were stained with anti-Dcp1a 
antibody (red). Scale bar represents 50µm. Boxed inserts magnify one particular region. DNA 
was stained with DAPI (blue).  
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Roquin-2 RING deficiency exacerbates immune pathology in sanroque mice 
 
In order to further understand the functional overlap between the two Roquin-family 
proteins and also test whether there are any unique functions of Roquin-2, we 
examined the effects of Roquin-2 RING deficiency on the pathology caused by 
homozygous Rc3h1san/san mutation. Rc3h1san/san mice were crossed to Rc3h2rin/rin mice 
to generate Rc3h1san/san Rc3h2rin/rin mice and the relevant littermate controls. Roquin-
2 RING deficiency caused premature and fully penetrant mortality of Rc3h1san/san 
mice, with no mice surviving beyond 22 weeks (Figure 3.21a).  
 
Examination of the double-mutant mice revealed more severe inflammatory infiltrates 
in the kidney (Figure 3.21b) and other organs (data not shown) and elevated 
percentages of Tfh cells (Figure 3.21c). Double-mutant mice also exhibited 
increased susceptibility to low-dose lipopolysaccharide (LPS): 2.5 µg/g body weight 
LPS injection was lethal for 3 out of 4 double mutants but all single mutant controls 
survived; interestingly, the amount of tumour necrosis factor (TNF) in the serum of 
the surviving mouse 72 hours post-injection was 100-fold higher than in the controls 
(Figure 3.22). Similar susceptibility to LPS was also observed in irradiated Rag1-/- 
recipient mice transplanted with Rc3h1san/san Rc3h2rin/rin bone marrow: 1.2 µg/g body 
weight LPS was lethal in 4 out of 5 mice while mice in single mutant control groups 
(Rc3h1san/san and Rc3h2rin/rin) remained healthy. This indicates that Roquin and 
Roquin-2 act within haematopoietic cells to control inflammation, at least in part by 
limiting the production of pro-inflammatory cytokines. Further investigations revealed 
that Roquin and Roquin-2 act within myeloid cells to repress Tnf mRNA and TNF-
mediated responses such as septic shock and antibody-induced arthritis (Pratama et 
al., 2013). Collectively, these results suggest that Roquin and Roquin-2 have partially 
but not completely overlapping roles in controlling GC reactions and systemic 
inflammation.
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Figure 3.21 – RING deficiency in Roquin-2 causes early lethality and exacerbated tissue 
damage in Rc3h1san/san mice. (a) Survival curve of weaned Rc3h1san/san Rc3h2rin/rin double-
mutant mice and control littermates with the indicated genotypes. (b) Haematoxylin and eosin 
stains of kidneys from 13-week old Rc3h1san/san (left) and Rc3h1san/san Rc3h2rin/rin (right) mice. 
Arrows indicate tissue infiltrates. Scale bar represents 100 µm. (c) Percentages of Tfh cells 
amongst total CD4+ T cells from foetal liver chimeras reconstituted with wild-type (Rc3h1+/+ 
Rc3h2+/+), Rc3h2rin/rin, Rc3h1san/san, and Rc3h1san/san Rc3h2rin/rin cells. Each dot represents 
individual mouse and bars represent median values in each group.  
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Figure 3.22 – Exaggerated TNF response in the Rc3h1san/san Rc3h2rin/rin mice following 
LPS injection. Serum TNF levels in Rc3h1san/san Rc3h2rin/rin mice and control groups (including 
Rc3h1san/san, Rc3h2rin/rin, and wild-type mice) measured 0, 1, and 72 hours after LPS (2.5 µg/g 
body weight) injection. Each symbol represents mean and error bar represents s.d. 
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DISCUSSION	  
 
Data presented in this chapter illuminate the function of Roquin and Roquin-2, 
showing that these evolutionarily paralogous proteins act in concert to dampen 
autoimmunity and inflammation. Both Roquin-family proteins localise to mRNA-
regulating SGs and P-bodies in the cytoplasm, and both repressed Icos mRNA in a 
3’UTR-dependent fashion in overexpression studies. The RING domain of both 
proteins is shown here to be critical for their localisation to SGs and their function. In 
the absence of its RING domain, RoquinRINGLESS protein behaved like a complete 
loss-of-function allele in causing perinatal lethality and vertebral malformations. 
RoquinRINGLESS protein was also unable to complement the ROQ M199R point mutant 
protein to regulate Icos mRNA in T cells of compound heterozygous Rc3h1san/rin mice. 
These in vivo results confirm overexpression data from Heissmeyer and colleagues 
(Glasmacher et al., 2010) that showed a Roquin construct lacking the RING domain 
had impaired ability to repress Icos mRNA in vitro, and establish that the ROQ 
M199R point mutation in the Rc3h1san mice is also a loss-of-function allele with 
respect to Icos repression. Wild-type Roquin-2, but not Roquin-2RINGLESS, was able to 
compensate for loss of RING domain from Roquin to control Icos mRNA in T cells. 
Loss of the RING domain from Roquin-2 cooperated with the Roquin M199R mutant 
to increase pro-inflammatory cytokines, organ inflammation, and mortality.   
 
These results provide evidence for overlapping functions of the two proteins, as the 
phenotypes conferred by defects in Roquin can be amplified by defects in Roquin-2. 
Since the Rc3h1ringless mutation behaves like a Roquin null allele with respect to 
perinatal lethality and pathology, this poses two key questions: 1) Why does 
Rc3h1ringless cause so little dysregulation of ICOS or Tfh cells compared to the 
Rc3h1san mutation; and 2) Why does the Rc3h1san mutation not cause perinatal 
lethality? Analysis of compound heterozygous Rc3h1san/rin mice revealed pronounced 
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dysregulation of ICOS and CD4+ T cells, indicating that the RING and ROQ domain 
mutations each disrupt Icos mRNA repression. The two mutations nevertheless differ 
in their effects on SG localisation, since this step is disrupted by the RING domain 
mutation but not the ROQ domain point mutation. The RoquinRINGLESS mutant protein, 
but not the RoquinSAN protein, vacates its subcellular niche within SGs; however, both 
proteins still localise to P-bodies. As shown here, Icos repression is preserved in 
Rc3h1ringless T cells provided there is normal Roquin-2, but this is impaired when the 
RING domain of Roquin-2 is also mutated. Hence the simplest explanation for the 
loss of Icos repression caused by the Rc3h1san mutation, despite the presence of 
normal Roquin-2 in SGs, is that the ROQ-domain mutant protein still occupies its 
niche within these subcellular compartments and blocks the opportunity for functional 
compensation by Roquin-2. Similar differences between recessive null mutants and 
niche-filling loss-of-function point mutants have been described for other proteins that 
are members of potentially redundant families of paralogues, such as the MAP 
kinases in yeast (Madhani et al., 1997) and the Ikaros transcription factor family in 
mice (Papathanasiou et al., 2003).  
 
In this study, we did not see evidence of physical interaction between Roquin and 
Roquin-2 when epitope-tagged versions of these proteins were overexpressed in 
HEK293T cells and assayed using co-immunoprecipitation. Although ectopic protein 
expression and epitope tags permit the detection of proteins when high-quality 
protein-specific antibodies are not available, they can also introduce experimental 
artifacts by altering the protein’s structure and/or function (Margolin, 2012). Recent 
structural data from our laboratory showed that Roquin can form homodimers 
through its ROQ domain, therefore it is not improbable that Roquin may also form 
heterodimers with Roquin-2, which has a very similar ROQ domain. If proven true, 
this can provide an alternative explanation to the severe autoimmune phenotypes of 
sanroque mice: the mutation in the ROQ domain in Rc3h1san/san mice may change the 
	   102 
structural conformation of the domain and in turn, abolish the interaction with Roquin-
2 that may be important in target mRNA repression. With better reagents in the 
future, this protein-protein interaction assay needs to be repeated using untagged, 
endogenous proteins. 
  
On the other hand, both tagged and untagged full-length Roquin protein failed to 
localise normally to SGs, marked either by eIF3 or TIA-1 staining, when the RING 
domain was selectively eliminated. Since the ringless mutation has very similar in 
vivo consequences to complete loss of the Roquin protein, the defect in SG 
localisation is a clear and important finding of the current study because it 
demonstrates a striking correlation between Roquin function and localisation. As 
discussed above, it may explain why the RoquinRINGLESS mutant is more effectively 
compensated by Roquin-2 than the RoquinSAN mutant. It is interesting to compare the 
failure of the ringless (133-1130) protein to localise to SGs with the earlier finding 
from our group that fragments of Roquin (138-337 or 138-484) that lacked both the 
RING domain and the C-terminal half of the protein could localise to SGs 
(Athanasopoulos et al., 2010). This suggests that SG localisation driven by the ROQ-
CCCH domains is regulated by the interplay between the N-terminal RING domain 
and the C-terminal domains that contain numerous potential sites for protein-protein 
interaction. 
 
It is possible that the inability of RoquinRINGLESS to localise to SGs is not in itself the 
direct cause of failed ICOS repression, given that Icos mRNA is found in SGs and 
also in P-bodies (Yu et al., 2007) and Icos mRNA decay occurs in P-bodies 
(Glasmacher et al., 2010). Indeed, RoquinRINGLESS was found in P-bodies when over-
expressed in HEK293T cells. Instead, failure to localise to SGs may simply be an 
indicator of a severe functional defect in the protein. It is also possible that RNA-
regulating processes in P-bodies may be perturbed following defects in RNA-sorting 
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pathways including impaired shuttling of RNA-binding proteins between SGs and P-
bodies. 
 
ICOS expression, Tfh and GC B cell numbers were still higher in Rc3h1san/san mice 
than in double Roquin-1/2 Tringless mice. There are several non-mutually exclusive 
explanations for this observation. First, it is possible that either one or both the RING 
mutant proteins have not completely lost the RNA-regulating activity; this is 
particularly plausible in the case of Roquin-2 given the reported early lethality of 
Rc3h2-/- mice (Vogel et al., 2013), which differs from the Rc3h2rin/rin mice used here 
that are viable and healthy. Second, the ROQ mutant’s actions in non-lymphoid cells, 
such as those in myeloid cells (Pratama et al., 2013), may exacerbate the T and B 
cell phenotypes. It is also possible that, at least in the regulation of some targets, 
RoquinSAN exerts antimorphic effects – i.e. new or interfering activities that do not 
reflect the normal function of Roquin. Although this was not obvious in the case of 
ICOS regulation, RoquinSAN appeared to aberrantly stabilise Tnf mRNA (Pratama et 
al., 2013). In support of this hypothesis, previous data from our laboratory showed 
that RoquinSAN binds Icos mRNA with 3-fold higher affinity than RoquinWT in vitro 
(Athanasopoulos et al., 2010). Finally, the absence of perinatal lethality or vertebral 
malformation in Rc3h1san/san homozygotes indicates that the ROQ domain mutation 
disrupts Icos repression but preserves an apparently independent Roquin activity in 
embryonic development that requires the RING domain.  
 
The experiments here reveal that although Roquin and Roquin-2 share some 
functional redundancies, their activities are not completely overlapping. This 
conclusion is based on the exaggerated TNF production by Rc3h2rin/rin macrophages 
and MEFs with normal Roquin (Pratama et al., 2013), and the lethal inflammatory 
disease and LPS-induced shock when the Rc3h2ringless mutation was combined with 
Rc3h1san/san. Roquin and Roquin-2 may play non-redundant roles either by acting on 
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the same mRNA targets (for example Tnf; data not shown) in different cell types 
and/or by acting on different mRNA targets within the same cell. Besides Tnf, Roquin 
also has recently been shown to limit IL6 mRNA, another potent pro-inflammatory 
cytokine (Tan et al., 2014). In T cells, Roquin plays the major role in the repression of 
Icos based on the data from Rc3h1san/rin compound heterozygous mice, and since a 
subtle phenotype is already observed in mice lacking active Roquin [shown here for 
Roquin Tringless mice and by (Bertossi et al., 2011), using T cell-conditional Rc3h1-/- 
mice] that is not fully compensated by Roquin-2. Roquin also facilitates perinatal 
survival in a manner dependent on the RING domain, which cannot be either 
compensated by Roquin-2. These differences between Roquin and Roquin-2 are 
likely to be mediated by their dissimilar C-termini that provide many sites for protein-
protein interaction. Collectively, the RC3H family emerges as a key player of post-
transcriptional regulation of adaptive humoral immunity and the innate inflammatory 
response. 
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CHAPTER FOUR 
 
 
MicroRNA-146a deficiency causes spontaneous accumulation 
of T follicular helper cells and germinal centre B cells 
 
INTRODUCTION 
 
T follicular helper (Tfh) cells provide essential survival and selection signals to 
germinal centre (GC) B cells, which are important for long-lived protective antibody 
responses (Craft, 2012; Crotty, 2011). Increasing evidence suggests that restricting 
Tfh cell numbers in GCs is crucial for optimal GC B cell selection (Schwickert et al., 
2011; Victora et al., 2010). B cells expressing the highest affinity receptors after 
somatic hypermutation can capture more antigen and therefore have a competitive 
advantage in establishing sustained interactions and eliciting survival signals from 
Tfh cells (Victora et al., 2010). Studies of autoimmune mouse models (Linterman et 
al., 2009b; Odegard et al., 2008; Ozaki et al., 2004; Vinuesa et al., 2005a) and 
human patients (He et al., 2013; Ma et al., 2012c; Morita et al., 2011; Simpson et al., 
2010; Szabo et al., 2013) suggest that excessive Tfh cells may contribute to the 
pathogenesis of autoantibody-mediated autoimmune diseases, potentially by 
allowing survival and differentiation of self-reactive B cells. While multiple signals are 
now known to be required for Tfh cell formation and migration (Crotty, 2011; Ma et 
al., 2012b), surprisingly little is known about the mechanisms that limit Tfh cell 
numbers. Cell-extrinsic mechanisms such as the actions of T follicular regulatory (Tfr) 
cells (Chung et al., 2011; Linterman et al., 2011; Wollenberg et al., 2011) and 
follicular CD8+ T cells (Kim et al., 2010) have been reported and to date, only Roquin 
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is known to act in a T cell-autonomous manner to prevent spontaneous accumulation 
of Tfh cells (Yu et al., 2007).  
 
MicroRNA-146a has recently emerged as a key post-transcriptional regulator in 
haematopoietic cells. In the absence of miR-146a, regulatory T (Treg) cells lose their 
suppressive ability due to STAT1 overexpression driving increased IFN-γ secretion 
(Lu et al., 2010). MiR-146a also represses TRAF6 and IRAK1 in myeloid cells (Boldin 
et al., 2011) and T cells (Yang et al., 2012) to control their proliferation and NF-κB 
activation in response to Toll-like receptor and TCR signalling respectively. 
Deficiency of miR-146a leads to excessive production of IL-6 and TNF, 
myeloproliferation, chronic inflammation, and a decline in the number and quality of 
haematopoietic stem cells (Boldin et al., 2011; Etzrodt et al., 2012; Zhao et al., 2013). 
Importantly, approximately 60-fold higher titres of autoantibodies against double-
stranded DNA were detected in the serum of aged miR-146a-null mice compared 
with wild-type littermates (Boldin et al., 2011). This leads us to hypothesise that the 
loss of miR-146a may also affect the antibody selection and maturation process, 
perhaps by deregulating Tfh cell and GC B cell differentiation. 
 
The data presented in this chapter show that miR-146a profoundly represses Tfh cell 
and GC B cell numbers: absence of this miRNA led to spontaneous Tfh cell and GC 
B cell accumulation in 12 to 16-week old mice, which preceded the myeloid cell 
expansion. Furthermore, although deficiency of miR-146a in T cells alone was 
sufficient to initiate the Tfh and GC B cell accumulation, non-T cell factors appeared 
to exacerbate the phenotypes. 
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RESULTS 
 
 
MiR-146a is highly expressed in Tfh cells and its expression peaks at the late 
stage of GC response 
 
To identify miRNAs that might regulate Tfh cell development and/or function, a 
genome-wide screen was performed to identify miRNAs that are highly expressed in 
human Tfh cells. Compared to naïve T cells, miR-146a was the most differentially 
expressed miRNA (upregulated by 8.2-fold) in Tfh cells amongst those that are highly 
expressed in T cells (Figure 4.1). Real-time PCR on T cell subsets from human 
tonsils revealed that Tfh cells expressed the highest amounts of miR-146a compared 
to all other effector CD4+ subsets (Figure 4.2a). Consistent with these results, a 
deep-sequencing survey of the miRNome in mouse tissues showed the highest 
levels of miR-146a in Tfh and GC B cells [Figure 4.2b and (Kuchen et al., 2010)]. 
Lower levels of miR-146a were detected in activated B cells and thymic-derived 
Tregs, while non-haematopoietic tissues displayed little or no miR-146a expression 
(Figure 4.2b). Further supporting the notion that miR-146a may play a role in Tfh cell 
biology, a previous finding from our laboratory showed that miR-146a is the most 
dysregulated miRNA (upregulated by about 20-fold) in T cells from Rc3h1san/san mice 
(Figure 4.3), which are characterised by excessive Tfh cell accumulation (Vinuesa et 
al., 2005a). 
 
 
To study the kinetics of miR-146a expression during a T-dependent immune 
response, 5 x 105 naïve CD4+ T cells from Ly5b+ OT-II TCR-transgenic mice were 
adoptively transferred into Ly5a+ wild-type C57BL/6 recipient mice, which were then 
immunised with ovalbumin (OVA) precipitated in alum, and sacrificed at different time 
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points (Figure 4.4a). The proportion of Tfh cells among donor cells peaked at day 7 
post-immunisation (Figure 4.4b) and started to contract by day 10, coinciding with 
the peak of miR-146a expression in the OT-II cells (Figure 4.4b). This suggests a 
possible role for miR-146a in downsizing the Tfh cell population. 
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1.5-fold 
Figure 4.1 – MiR-146a is amongst the most highly upregulated miRNAs in Tfh cells.  
The scatter plot shows the log2 of averaged (n=3) background-subtracted expression of all 
Agilent Human miRNA Microarray (V1) Kit 8x15K probes by Tfh cells on the x-axis compared 
with naïve CD4+ T cells on the y-axis. Each dot represents one miRNA probe. Probes located 
outside the dotted lines are expressed at greater than 1.5-fold difference. This experiment was 
performed by Robert J. Rigby and Monika Srivastava, ANU. 
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Figure 4.2 – MiR-146a expression is upregulated in both human and mouse Tfh cells.  
(a) Expression of miR-146a, normalised to U6, measured by real-time PCR from human tonsils. 
The heights of the bars represent the mean, and the error bars represent the s.d. of three 
technical replicates. Data are representative of three independent experiments. Statistical 
significance was determined using unpaired Student’s t test. *** P < 0.001, **** P < 0.0001. (b) 
Bar graph showing the expression of miR-146a in mouse immune cell subsets and other non-
haematopoietic tissues analysed by deep sequencing. Data were obtained from R. Casellas’ 
laboratory, as published in Kuchen et al., Immunity, 2010. 
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Figure 4.3 – MiR-146a is the most highly upregulated miRNA in Rc3h1san/san T cells.  
(a) The scatter plot shows the relative expression of all Agilent mouse miRNA Microarray 8x15K 
probes by wild-type naïve CD4+ T cells on the x-axis compared with Rc3h1san/san T cells on the 
y-axis. Each dot represents one miRNA probe. Probes located outside the solid lines are 
expressed at greater than 2-fold difference. (b) Expression of miR-146a, normalised to U6, on 
Rc3h1san/san and wild-type naïve T cells. Each symbol represents one mouse and the heights of 
the bars represent the median. Data are representative of three independent experiments. 
Statistical significance was determined using a Student’s t test. *** P < 0.001. These 
experiments were performed by Monika Srivastava, ANU. 
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Figure 4.4 – Peak miR-146a expression coincides with the decline of the Tfh response.  
(a) Schematic diagram outlining the OT-II cell transfer and immunisation experiment. (b) 
Kinetics of the Tfh cell response (filled circles) and miR-146a expression (open circles) from 
transferred Ly5b+ OT-II cells analysed at different time points according to the strategy shown in 
a. Three recipient mice were sacrificed at each time point. Percentage of Tfh cells among donor 
Ly5b+ cells was measured using flow cytometry staining of CXCR5high PD-1high Foxp3- CD4+ T 
cells. MiR-146a expression was measured by real-time PCR of total Ly5b+ CD4+ T cells and was 
normalised to U6 expression. Filled and open circles in b represent the mean, and error bars 
represent the s.d. of biological replicates (for Tfh cell percentage) or technical replicates (for 
miR-146a expression). 
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MiR-146a expression is regulated by Foxo-1 in T cells 
 
Previous studies reported that the expression of miR-146a is regulated by the 
nuclear factor kappa B (NF-κB) family of transcription factors (Taganov et al., 2006; 
Yang et al., 2012). However, NF-κB activation is a feature of all activated T cells and 
thus regulation of miR-146a by NF-κB alone is unlikely to fully explain the selective 
upregulation of miR-146a in Tfh cells. In order to identify additional transcriptional 
regulators, we examined the genomic regions around the Mir146a locus in mouse 
chromosome 11. DNase I protection mapping was used to locate the specific binding 
sites of proteins (i.e. transcription factors) on DNA (Boyle et al., 2008). The 
chromosomal regions bound by proteins are protected from DNase I-mediated 
hydrolysis and are shown as peaks in the DNase I footprint (Figure 4.5a). These 
regions were sequenced and known transcription factor binding motifs were identified 
by digital footprinting (Neph et al., 2012). We found binding motifs for several 
transcription factors, including the NF-κB subunits, and two known regulators of Tfh 
cells: Foxo-1 and Blimp-1 (encoded by Prdm1) (Figure 4.5a). Using chromatin 
interaction analysis by paired-end tag sequencing (ChIA-PET) (Fullwood et al., 2009; 
Kieffer-Kwon et al., 2013), we found that the genomic region bound by Foxo-1 was 
interacting with the Mir146a promoter region (Figure 4.5a); the promoter region was 
identified as the region with the highest peak in the global run-on sequencing (GRO-
seq) (Core et al., 2008) profile characteristic of promoter-proximal Pol II pausing 
(Figure 4.5a). On the other hand, the regions bound by Blimp-1 did not appear to 
interact with this promoter (Figure 4.5a). Direct binding of Foxo-1 to the Mir146a 
enhancer region identified by the DNase I protection assay, was confirmed using 
chromatin immunoprecipitation and sequencing (ChIP-Seq) on Tregs (Figure 4.5b). 
Together, these data suggest that Foxo-1 directly binds to and may regulate miR-
146a expression in T cells. 
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To further investigate the role of Foxo-1 in regulating miR-146a expression, we 
measured the expression of miR-146a in mice carrying a T cell-conditional deletion of 
Foxo-1 before and 7 days after SRBC immunisation. In Tregs, miR-146a was more 
highly expressed when Foxo-1 was absent (Figure 4.6) suggesting that miR-146a is 
repressed by Foxo-1 in this subset. In Tfh cells however, miR-146a was mildly 
reduced in the absence of Foxo-1 (Figure 4.6). 
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Figure 4.5 – Foxo-1 binds to the Mir146a enhancer region in T cells. 
(a) Analysis of mouse chromosome 11 around the Mir146a locus for putative transcription factor 
binding sites. The Foxo-1 binding site is located between position 43,172,530-43,172,572 
(sequence shown in red). This analysis was performed by Rafael Casellas and colleagues, NIH, 
USA. (b) Chromatin immunoprecipitation-sequencing (ChIP-seq) analysis for the binding of 
Foxo-1 to the Mir146a enhancer region predicted in a (peak indicated by the arrow) in Treg 
(Foxp3+) cells. Gray box marks the region at chromosome 11 between positions 
43,172,000-43,173,000. This experiment was performed by Weiming Ouyang, United States 
Food and Drug Administration, USA. 
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Figure 4.6 – MiR-146a expression in T cells is regulated by Foxo-1.  
Expression of miR-146a, normalised to U6, on T cells sorted from unimmunised (left) or SRBC-
immunised (right) mice lacking Foxo-1 specifically in T cells (filled bars) or wild-type littermates 
(open bars). The heights of the bars represent the mean, and the error bars represent the s.d. of 
three technical replicates. Statistical significance was determined using unpaired Student’s t 
test. ns = not significant, * P < 0.01, ** P < 0.01. 
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Loss of miR-146a causes spontaneous accumulation of Tfh and GC B cells 
 
To test whether miR-146a plays a role in the control of Tfh cell numbers, we studied 
Tfh cells in mice lacking miR-146a. Analysis of total follicular T cells, gated as 
CXCR5high PD-1high (Figure 4.7a,b) or BCL-6high PD-1high (Figure 4.7c,d) cells, 
showed they were expanded in both percentage and total number in unimmunised 
Mir146a-/- mice compared to wild-type littermates. This expansion was not selective to 
either Tfh (CXCR5high PD-1high Foxp3-) or Tfr (CXCR5high PD-1high Foxp3+) cells as 
both subsets increased in parallel (Figure 4.8). However, it seemed to affect Tfh cells 
more severely than the non-follicular effector cell subsets: compared to the 5-fold 
increase in Tfh cells, no statistically significant increases were observed in either Th2 
(IL-4+) or Th17 (IL-17+) cells, while Th1 (IFN-γ+) cells expanded by 1.4-fold, and Treg 
(Foxp3+) cells by 1.5-fold, as previously reported (Lu et al., 2010) (Figure 4.9).  
 
Total GC B cells were also increased by about 20-fold in Mir146a-/- mice compared to 
wild-type littermates, and this was accompanied with a statistically significant 
increase of autoantibody titres in the serum (Figure 4.10). Moreover, the 
spontaneous accumulation of Tfh and GC B cells became more severe with age 
(Figure 4.11). Of note, deletion of miR-146a in sanroque mice appeared to slightly 
exacerbate the expansion of Tfh and GC B cells, but did not affect the autoantibody 
titres (Figure 4.12), suggesting that despite its elevated quantity, the quality of miR-
146a in repressing target mRNAs may have declined significantly in the presence of 
mutant Roquin. 
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Figure 4.7 – Loss of miR-146a causes spontaneous accumulation of Tfh cells.  
(a-d) Flow cytometric contour plots and dot plots showing percentages and absolute cell 
numbers of follicular T cells gated as CXCR5high PD-1high cells (a,b) or BCL-6high PD-1high cells 
(c,d) in miR-146a-sufficient (+/+) and -deficient (-/-) mice. Contour plots shown in a and c are 
gated on CD4+ cells. Mice were sacrificed at 12-16 weeks old without any immunisation. Each 
symbol represents one mouse and the horizontal lines represent the median values. Data are 
representative of five independent experiments. ** P < 0.01.  
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Figure 4.8 – Parallel increases of Tfh and Tfr cells in mice lacking miR-146a.  
Flow cytometric plots showing the gating strategy for Tfh (CXCR5high PD-1high Foxp3-) and Tfr 
(CXCR5high PD-1high Foxp3+) cells and dot plots showing their percentages in miR-146a-
sufficient (+/+) and -deficient (-/-) mice. Contour plot shown is gated on CD4+ cells. Each symbol 
represents one mouse and the horizontal lines represent the median values. Data are 
representative of five independent experiments. ** P < 0.01.  
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Figure 4.9 – MiR-146a deficiency affects Tfh cells more severely than the other effector 
cell subsets. Percentages of Th1 (IFN-γ+), Th2 (IL-4+), Th17 (IL-17+), Treg (Foxp3+), and Tfh 
(CXCR5high PD-1high Foxp3-) cells amongst total CD4+ cells in miR-146a-sufficient (+/+) and -
deficient (-/-) mice. Each symbol represents one mouse and the horizontal lines represent the 
median values. Data are representative of three independent experiments. ns = not significant,  
* P < 0.01, ** P < 0.01.  
Mir146a: 
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Figure 4.10 – Loss of miR-146a causes spontaneous accumulation of GC B cells and 
elevated autoantibody titres. (a,b) Flow cytometric contour plots and dot plots showing the 
percentages and absolute numbers of germinal centre (GC) B cells in miR-146a-sufficient (+/+) 
and -deficient (-/-) mice. Contour plots shown in a are gated on B220+ cells. (c) Relative 
amounts of anti-nuclear antibodies (ANA) in the serum. Each symbol represents one mouse and 
the horizontal lines represent the median values. Data are representative of five independent 
experiments. a.u. arbitrary unit. * P < 0.05, ** P < 0.01. 
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Figure 4.11 – Age-dependent accumulation of Tfh cells in Mir146a-/- mice.  
Percentages of Tfh (left) and GC B (right) cells in mice lacking miR-146a (-/-) or wild-type (+/+) 
littermates with different age brackets at steady-state. w.o. = weeks old. Each symbol represents 
one mouse and the horizontal lines represent the median values. 
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Figure 4.12 – Ablation of miR-146a does not rescue the autoimmune phenotypes in 
sanroque mice. Percentages of Tfh (left) and GC B (middle) cells and relative amounts of anti-
dsDNA autoantibodies measured by ELISA (right) in unimmunised 8-week old Mir146a+/+ 
Rc3h1+/+, Mir146a+/+ Rc3h1san/san, and Mir146a-/- Rc3h1san/san mice, and 16-week old Mir146a-/-
mice. Each symbol represents one mouse and the horizontal lines represent the median values. 
Data are representative of three independent experiments. a.u. = arbitrary unit. 
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Cell-intrinsic regulation of Tfh and GC B cells by miR-146a 
 
To examine whether the accumulation of Tfh cells in Mir146a-/- mice was due to T 
cell-intrinsic factors, mixed bone marrow chimeras were generated by transferring 
equal amounts of either Ly5a+.Mir146a+/+:Ly5b+.Mir146a+/+ (WT:WT) or 
Ly5a+.Mir146a+/+:Ly5b+.Mir146a-/- (WT:KO) bone marrow cells into sub-lethally 
irradiated Rag1-/- recipients. Four months after reconstitution, the spleens were 
harvested and the percentage of CD4+ T cells, effector cells, Tfh cells, B220+ cells 
and GC B cells derived from the Ly5a+ or Ly5b+ donor marrow in each mouse were 
determined.  
 
There was a higher percentage of total follicular T cells in the WT:KO chimeras 
compared to the WT:WT chimeras (Figure 4.13a). This was due to cell-autonomous 
expansions of Tfh and Tfr cells derived from Ly5b+.Mir146a-/- marrow (Figure 4.13b). 
In each mouse, there was a 2- to 4-fold increase in Ly5b+ Tfh cells compared to 
Ly5a+ Tfh cells, whereas this was not observed in control WT:WT chimeras, in which 
the percentages of Ly5a+ and Ly5b+ Tfh cells were comparable (Figure 4.13b). 
Importantly, the percentages of non-follicular effector CD4+ cells were comparable 
between Ly5a+ and Ly5b+ cells in both WT:WT and WT:KO mixed chimeras. Similar 
to a previous report (Lu et al., 2010), there was a cell-autonomous expansion of non-
follicular Tregs derived from Ly5b+.Mir146a-/- marrow in the WT:KO chimeras (Figure 
4.13b). 
 
We also observed a significant increase in the percentage of GC B cells derived from 
Ly5b+.Mir146a-/- marrow compared with those derived from Ly5a+.Mir146a+/+ bone 
marrow (Figure 4.14), suggesting that miR-146a also acts cell-autonomously in GC 
B cells. Intriguingly, despite the significant total increase in the proportion of follicular 
T cells in the WT:KO chimeras (Figure 4.13a), we only observed expansion of the 
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Ly5b+.Mir146a-/- GC B cells, while the percentage of the neighbouring 
Ly5a+.Mir146a+/+ GC B cells was comparable to that in the WT:WT chimeras (Figure 
4.14). This may suggest that GC B cell expansion requires concerted actions of miR-
146a in T cells and B cells, perhaps through regulation of a receptor-ligand pair in 
each cell type, and this is explored further in the next chapter. Collectively, these 
results suggest that miR-146a acts in T cells and B cells to prevent Tfh and GC B cell 
accumulation. 
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Figure 4.13 – Cell-autonomous accumulation of Mir146a-/- Tfh cells.  
(a) Flow cytometric contour plots showing the gating strategy for follicular T cells in 50:50 mixed 
bone marrow chimeras gated on all CD4+ (top), on Ly5a+ CD4+ (middle), or on Ly5b+ CD4+ 
(bottom) cells. Chimeric mice were generated by sub-lethally irradiating Rag1-/- mice and 
reconstituting their immune system with a 1:1 ratio of bone marrow cells from Ly5a+.Mir146a+/+ 
and Ly5b+.Mir146a-/- or control Ly5a+.Mir146a+/+ and Ly5b+.Mir146a+/+ mice and analysed 16 
weeks post-reconstitution. (b) Percentages of Tfh, Tfr, non-follicular effector, and non-follicular 
Tregs in the mixed chimeras. Each symbol represents one mouse and the connecting lines 
between percentages in Ly5a+ and Ly5b+ in b indicate that they are from the same chimeric 
mouse. Data are representative of three independent experiments. ns = not significant, ** P < 
0.01, *** P < 0.001, **** P < 0.0001. 
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Figure 4.14 – Cell-autonomous accumulation of Mir146a-/- GC B cells.  
(a,b) Flow cytometric contour plots and dot plot showing the percentages of GC B cells in the 
50:50 mixed chimeras as described in Figure 4.13. Contour plots in a are gated on Ly5a+ B220+ 
and Ly5b+ B220+ cells as indicated. Each symbol represents one mouse and the connecting 
lines between percentages in Ly5a+ and Ly5b+ in b indicate that they are from the same 
chimeric mouse. Data are representative of three independent experiments. ns = not significant, 
*** P < 0.001.  
1.59 1.49 
1.12 5.97 
105 
104 
103 
102 
0 
105 104 103 102 0 
G
L-
7 
Fas 
105 
104 
103 
102 
0 
105 104 103 102 0 
105 
104 
103 
102 
0 
105 104 103 102 0 
105 
104 
103 
102 
0 
105 104 103 102 0 
Mir146a: 
 
	   128 
Non-T cells lacking miR-146a contribute to Tfh cell accumulation 
 
We next investigated whether accumulation of Tfh cells could occur independently of 
neighbouring Mir146a-/- B cells and myeloid cells in the same mice. To this end, we 
transferred purified naïve CD4+ T cells from Mir146a+/+ or Mir146a-/- OT-II TCR-
transgenic mice into Cd28-/- recipients, which were then immunised with OVA 
precipitated in alum and sacrificed 7 days later (Figure 4.15a). There was a 
statistically significant increase in the percentage of OVA-specific Vβ5+ Tfh cells and 
in the percentage of total GC B cells in mice that received Mir146a-/- OT-II cells 
although the magnitude of the increases was smaller than that observed in intact 
Mir146a-/- mice (Figure 4.15b), suggesting that non-T cells, including B cells and 
myeloid cells, enhance these effects. 
 
In a separate experiment, four different combinations of Mir146a+/+ or Mir146a-/- CD4+ 
T cells and B cells were co-transferred into Rag1-/- mice, which were immunised 14 
days later with sheep red blood cells (SRBC) (Figure 4.16a). Similar to the OT-II 
transfer experiment, we found that in the presence of wild-type B cells and myeloid 
cells, miR-146a-deficiency in T cells alone was sufficient to cause Tfh cell 
accumulation, although the magnitude was again more modest than that observed in 
intact Mir146a-/- mice (Figure 4.16b). The presence of Mir146a-/- B cells appeared to 
exacerbate the effect, but this did not reach statistical significance. Similar trends 
were observed for the percentage of GC B cells (Figure 4.16b). In summary, our 
data show that deficiency of miR-146a in T cells is sufficient to initiate Tfh and GC B 
cell accumulation, but T cell-extrinsic factors contribute to exacerbate these 
phenotypes. 
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Figure 4.15 – Deficiency of miR-146a in T cells alone is sufficient to initiate Tfh cell 
accumulation. (a) Schematic diagram outlining the OT-II cell transfer experiment. (b) 
Percentages of OVA-specific (Vβ5+) Tfh cells (left) and total GC B cells (right) in Cd28-/- 
recipient mice following adoptive transfer of Mir146a+/+ or Mir146a-/- naïve T cells and 
immunisation as described in a. Each symbol represents one mouse and horizontal lines 
represent median values. Data are representative of three independent experiments. * P < 0.05, 
** P < 0.01.  
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Figure 4.16 – Contributions of miR-146a deficiencies in T cells and B cells to the 
accumulation of Tfh and GC B cells. (a) Schematic diagram outlining the adoptive transfer of 
purified CD4+ T cells and B cells from Mir146a+/+ or Mir146a-/- donor mice into Rag1-/- recipients. 
The recipient mice were immunised with sheep red blood cells 14 days after transfer and they 
were sacrificed 7 days post-immunisation. (b) Percentages of Tfh and GC B cells in Rag1-/- 
recipient mice. Each symbol represents one mouse and the horizontal bars represent the 
median values. ns = not significant, * P < 0.05.  
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Contribution of IL-6 signaling to Tfh and GC B cell accumulation 
 
In view of the reported increased proliferation of myeloid cells in 6 to 8-month old 
Mir146a-/- mice (Boldin et al., 2011; Zhao et al., 2011), we asked whether expanded 
myeloid compartment could be one of the T cell-extrinsic factors contributing to the 
Tfh and GC B cell expansion. Assessments of 12 to 16-week old mice, when the Tfh 
cell accumulation is obvious (Figure 4.11), revealed no significant accumulation of 
myeloid cell subsets in Mir146a-/- mice (Figure 4.17).  
 
Myeloid cells and T cells have been reported to produce more IL-6 cytokine in 6 to 
10-month old miR-146a-null mice (Boldin et al., 2011; Zhao et al., 2013). Since IL-6 
contributes to Tfh cell differentiation (Harker et al., 2011; Nurieva et al., 2009), we 
tested whether IL-6 production was elevated in 12 to 16-week old Mir146a-/- mice. No 
significant increase of IL-6 was observed in the serum of these mice (Figure 4.18a), 
and we also did not find increased amount of Il6 transcripts in CD11chigh splenic 
dendritic cells (Figure 4.18b). Next, we used Ly5a+.Mir146a+/+:Ly5b+.Mir146a-/- mixed 
bone marrow chimeras to investigate the possibility that during the course of a T-
dependent immune response, IL-6 might be expressed at increased levels by 
Mir146a-/- GC B cells, Tfh cells or myeloid cells. Despite the expected cell-
autonomous accumulation of Mir146a-/- Tfh cells in the mixed chimeric mice (Figure 
4.19a), no differences in Il6 mRNA expression were found between miR-146a-
sufficient and -deficient cells in any of the subsets examined (Figure 4.19b-d).  
 
Finally, we also tested the possibility that follicular dendritic cells (FDCs), which are 
of non-haematopoietic origin, expressed more IL-6 in the absence of miR-146a; it 
has been suggested that FDC-derived IL-6 is important for the late-stage 
maintenance of Tfh cells during LCMV infection (Harker et al., 2011). We isolated 
FDCs according to published protocols by gating on CD45- CD31- CD21/35+ cells 
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from Mir146a+/+ or Mir146a-/- mice. As both gp38-expressing (Jarjour et al., 2014) and 
non-gp38-expressing (Link et al., 2007) FDCs have been identified, we separated 
these two cell subsets and measured the expression of IL-6 (Figure 4.20a). Again, 
we did not find evidence of increased Il6 transcripts in either gp38+ or gp38- FDCs 
from miR-146-deficient mice (Figure 4.20b). On the other hand, a complete blockade 
of IL-6R using a dose of monoclonal antibody previously reported to inhibit Tfh cell 
formation (Harker et al., 2011) significantly reduced Tfh cell accumulation in Mir146a-
/- mice (Figure 4.21). Collectively, these results indicate that increased IL-6 
expression is unlikely to be the cause of Tfh cell accumulation in young miR-146a-
deficient mice, although according to the IL-6R blockade results, there still remains 
the possibility that miR-146a-deficient T cells are more responsive to IL-6 signalling. 
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Figure 4.17 – No excessive myeloid cell accumulation in 12 to 16-week old Mir146a-/- 
mice. Gating strategy and percentages of myeloid cell subsets in 12 to 16-week old miR-146a-
sufficient (+/+) and -deficient (-/-) mice. Data are representative of three independent 
experiments. Each symbol represents one mouse and the horizontal lines represent the median 
values. ns = not significant. 
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Figure 4.18 – No elevated production of pro-inflammatory IL-6 in 12 to 16-week old 
Mir146a-/- mice. (a) Serum concentration of IL-6 in unimmunised Mir146a+/+ and Mir146a-/- mice. 
(b) Relative amount of Il6 mRNA (normalised to β-actin) in unimmunised Mir146a+/+ and 
Mir146a-/- splenic CD11chigh conventional dendritic cells. Each symbol represents one mouse 
and the horizontal lines represent the median values. Height of bar graph represents mean and 
error bar represents s.d. Statistical significance was determined using a Mann-Whitney U test 
(a) or unpaired Student’s t test (b). ns = not significant, * P < 0.05. 
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Figure 4.19 – Similar expression of Il6 mRNA between miR-146a-deficient and -sufficient 
cells in the mixed bone marrow chimeras. (a) Flow cytometric contour plots showing the 
percentages of Tfh cells from the Ly5a+.Mir146a+/+:Ly5b+.Mir146a-/- and control mixed bone 
marrow chimeras. Analysis of WT:WT and WT:KO chimeras were performed on different days. 
(b) Flow cytometric contour plots showing the gating strategy used to isolate the different cell 
subsets. (c) Relative amounts of Il6 mRNA in GC B (B220+ GL-7+ Fas+), non-GC B (B220+ GL-7- 
Fas-), Tfh (CXCR5high PD-1high), and CD11b+ cells from Ly5a+ and Ly5b+ cells analysed directly 
after isolation. n.d. = not detectable. (d) Relative amounts of Il6 mRNA in LPS-stimulated  
CD11b+ cells from the same set of chimeric mice as in c. Chimeric mice were immunised with 
sheep red blood cells and analysed 14 weeks post-reconstitution. Height of bar graph 
represents mean and error bar represents s.d.  
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Figure 4.20 – No increased expression of Il6 transcripts in miR-146a-deficient follicular 
dendritic cells. (a) Flow cytometric contour plots showing the gating strategy used to isolate 
follicular dendritic cells. (b) Relative amounts of Il6 mRNA in gp38+ and gp38- FDCs (CD45- 
CD31- CD35+) from Mir146a+/+ or Mir146a-/- mice at 12 to 16 weeks old. Height of bar graph 
represents mean and error bar represents s.d. Statistical significance was determined using 
unpaired Student’s t test. ns = not significant, ** P < 0.01.  
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Figure 4.21 – The effect of IL-6R blockade on the Tfh and GC B cell accumulation in 
miR-146a-deficient mice. Percentages of Tfh (left) and GC B (right) cells in wild-type and 
miR-146a-deficient mice after administration of anti-IL6R antibody or isotype control. Animals 
were treated with 150 µg anti-IL-6R blocking antibody or isotype control i.p. every 5 days for 8 
weeks since they were 8 weeks old. Each symbol represents one mouse and the horizontal 
lines represent the median values. Data are representative of two independent experiments. * P 
< 0.05, ** P < 0.01. 
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Effects of miR-146a deficiency on the affinity maturation of GC B cells 
 
To determine whether the accumulation of Tfh cells in Mir146a-/- mice affects the 
process of affinity maturation of GC B cells, 1 x 105 Ly5a+ SWHEL B cells expressing a 
BCR specific for hen egg lysozyme (or HEL) (Phan et al., 2003) were adoptively 
transferred into Ly5b-marked wild-type or Mir146a-/- mice. The recipients were also 
immunised with either unconjugated SRBC (control) or SRBC conjugated to HEL3X 
that binds with 10,000-fold less affinity to Ig receptors on SWHEL B cells compared to 
native HEL (Phan et al., 2006), allowing affinity maturation to proceed normally. The 
percentage of donor B cells expressing high affinity BCRs to HEL3X (HEL3X high IgG1+) 
indicating the acquisition of mutations that confer higher affinity for the immunising 
antigen, and the percentage of total HEL3X+ IgG1+ donor B cells were determined 10 
days post-immunisation. Although the results did not reach statistical significance, 
there was a consistent trend towards a lower percentage of donor B cells expressing 
high affinity receptors to HEL3X in Mir146a-/- recipients compared to wild-type 
controls, in the presence of comparable percentages of total HEL3X+ IgG1+ donor B 
cells in both groups (Figure 4.22). Together, these results indicate that miR-146a 
acts in T cells to limit the magnitude and possibly the quality of the Tfh cell response.  
	   139 
a 
HEL3X-SRBC SRBC control  
HEL3X-SRBC SRBC control  c 
Figure 4.22 – The effect of miR-146a deficiency on affinity maturation of GC B cells.  
(a,c) Flow cytometric contour plots of donor Ly5a+ SWHEL B cells from the spleens of wild-type 
recipient mice 10 days after adoptive transfer and immunisation with HEL3X-SRBC or 
unconjugated SRBC. Contour plots show concatenated samples of all mice in the respective 
group (n=6 for HEL3X-SRBC; n=2 for unconjugated SRBC control) and are gated on Ly5a+ 
B220+ cells. (b,d) Percentages of Ly5a+ HEL3X high IgG1+ cells (top gate in a,c) amongst total 
HEL3X-binding IgG1+ cells (left) and percentages of total HEL3X-binding IgG1+ cells amongst all 
Ly5a+ B220+ cells (right) in miR-146a-sufficient (+/+) and -deficient (-/-) mice. Each symbol 
represents one mouse and the horizontal lines in b,d represent the median values. Data shown 
in a,b and c,d are from two independent experiments.  
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DISCUSSION 
 
We have shown that miR-146a represses Tfh and GC B cell accumulation. In the 
absence of miR-146a, there was a spontaneous, cell-intrinsic expansion of Tfh and 
GC B cells. Amongst effector CD4+ cell subsets, loss of miR-146a seemed to affect 
Tfh cells more severely than the other subsets. This was perhaps due to the higher 
expression of miR-146a in Tfh cells compared with non-Tfh effector cells. MiR-146a 
therefore emerges as the first miRNA to negatively regulate Tfh cell accumulation. It 
opposes the action of the miR-17~92 cluster, recently shown to promote Tfh cell 
differentiation (Baumjohann et al., 2013a; Kang et al., 2013). Not surprisingly, 
dysregulated expression of miR-146a has been found to correlate with increased 
incidence of autoimmune diseases, such as lupus (Lofgren et al., 2012; Luo et al., 
2011; Tang et al., 2009; Wang et al., 2010) and rheumatoid arthritis (Li et al., 2010; 
Nakasa et al., 2008; Pauley et al., 2008; Stanczyk et al., 2008). 
 
Restricting miR-146a deficiency to Tfh precursor cells resulted in a modest 
expansion of Tfh and GC B cells. This indicates that Tfh cell-extrinsic factors 
contribute to exacerbate these phenotypes. Although miR-146a deficiency in B cells 
appeared to enhance the Tfh and GC B cell accumulation in the Rag1-/- recipients, 
the results did not reach statistical significance. Another potential contributor to the 
Tfh cell phenotype is the incomplete GC regulation by T follicular regulatory (Tfr) 
cells. Tfr cells derive from Foxp3+ thymic Tregs and are required to control Tfh cells 
and GC B cells (Chung et al., 2011; Linterman et al., 2011; Wollenberg et al., 2011). 
Rudensky and colleagues previously demonstrated that Tregs are less functional in 
Mir146a-/- mice due to STAT1 overexpression (Lu et al., 2010). Thus, despite their 
accumulation, it is likely that Tfr cells are also defective (this can be tested in future 
studies) in Mir146a-/- mice and this may exacerbate the spontaneous Tfh cell 
accumulation.  
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In addition, IL-6, which was increased at the mRNA and protein levels in aged miR-
146a-deficient mice (Boldin et al., 2011; Zhao et al., 2013), did not appear to be 
upregulated in any of the cell types examined in 12 to 16-week old mice; although the 
role of IL-6 derived from other haematopoietic cells and/or non-haematopoietic cells 
cannot be completely excluded. In the future, experiments using Mir146aflox/flox Lck-
Cre mice, which would eliminate the effects of miR-146a-deficient non-T cells, may 
be used to complement the present findings. Collectively, these miR-146a-mediated 
effects in various cell types are likely to act cooperatively to cause the severe 
accumulation of Tfh cells. 
 
The accumulation of Tfh and GC B cells in miR-146a-deficient mice became more 
severe with age. This is similar to the age-dependent myeloid cell hyperproliferation 
and expansion reported previously in these mice (Boldin et al., 2011). The molecular 
mechanisms contributing to this observation remain unclear. It is possible that long 
exposure to chronic antigenic stimulation, perhaps towards self-peptide or 
commensal microbiota, leading to progressive expansion of particular Tfh cell clones 
is required. Accumulation of CD4+ CD8+ double-positive T cells with certain TCR 
specificity in peripheral blood of elderly people has been reported elsewhere (Ghia et 
al., 2007). Future studies to elucidate the TCR specificity of Tfh cells in the miR-
146a-null mice may shed more light on this subject. Alternatively, miR-146a-deficient 
Tfh cells may become increasingly resistant to Treg-mediated suppression over time. 
A similar mechanism has been proposed for the age-dependent onset of diabetes in 
non-obese diabetic (NOD) mice (You et al., 2005). This may act in concert with the 
low repressive ability of Mir146a-/- Tregs to enhance the Tfh cell accumulation. 
Additionally, although we did not see myeloid cell accumulation in 12 to 16-week old 
miR-146a-null mice, it is still possible that these cells are functionally altered (in 
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terms of antigen-presentation capacity or cytokine production), which may again 
contribute to the Tfh cell phenotype. 
 
It is also intriguing that miR-146a is present at increased levels in Rc3h1san/san T cells, 
and yet the sanroque mice exhibit Tfh cell accumulation (Vinuesa et al., 2005a) – 
similar to the miR-146a-deficient mice. One plausible explanation is that miR-146a is 
less functional in the absence of wild-type Roquin. Additional data from our 
laboratory support this notion: the expression of a validated miR-146a target, Stat1, 
was elevated in Rc3h1san/san T cells (Srivastava et al., 2014). A combined loss of miR-
146a and wild-type Roquin in Mir146a-/- Rc3h1san/san mice did however result in a 
more exaggerated accumulation of Tfh and GC B cells compared with the 
corresponding single mutant controls, suggesting that miR-146a is still partially 
functional in the presence of mutant Roquin. Data presented in the next chapter help 
explain some of these findings by revealing that Roquin and miR-146a share (and 
are likely to co-regulate) a common mRNA target, Icos, which has been previously 
shown to be a target of Roquin (Glasmacher et al., 2010; Yu et al., 2007) and plays 
important roles in Tfh cell differentiation (Akiba et al., 2005; Bauquet et al., 2009; 
Bossaller et al., 2006; Choi et al., 2011; Dong et al., 2001a; Xu et al., 2013). 
 
Our work has also identified Foxo-1 as a transcriptional repressor of miR-146a, 
although more prominently in Tregs. The balance between NF-κB-mediated induction 
of miR-146a transcription (Taganov et al., 2006) and Foxo-1-mediated miR-146a 
repression is likely to be important in setting T cell activation thresholds and 
contribute to guiding T cell specification towards effector versus regulatory subsets 
(S. Hedrick, personal communication). Our data also show a modest decline in Tfh-
cell expressed miR-146a in the absence of Foxo-1. It is possible that Foxo-1 
promotes miR-146a expression to limit Tfh cells, which would be consistent with the 
need to inactivate Foxo-1 to allow Tfh cell formation (S. Hedrick, personal 
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communication). Our collaborator Rafael Casellas (NIH, USA) also found evidence of 
a Blimp-1 footprint at two DNase I hypersensitivity sites at the Mir146a locus, thus it 
is tempting to speculate that miR-146a may also cooperate with this well-known 
repressor of Tfh cells. However, unavailability of good quality chromatin 
immunoprecipitation (ChIP) reagents for Blimp-1 made it difficult to confirm direct 
binding of Blimp-1 to these regions. 
 
MiR-146a has been demonstrated to play crucial roles in limiting inflammation (Hou 
et al., 2009; Tang et al., 2009) and autoimmunity (Boldin et al., 2011; Lu et al., 2010). 
This report identifies yet another immune process regulated by miR-146a: Tfh and 
GC B cell homeostasis. Both T cell-intrinsic and T cell-extrinsic effects play a role in 
this process. The molecular mechanisms contributing to this regulation will be 
discussed in the next chapter. Collectively, miR-146a emerges as a novel post-
transcriptional brake on the magnitude of GC responses. 
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CHAPTER FIVE 
 
 
MicroRNA-146a acts via T cell-intrinsic and T cell-extrinsic 
mechanisms to limit germinal centre reactions 
 
INTRODUCTION 
 
Naïve CD4+ T cells become activated as a result of interaction of TCR, and CD4 co-
receptors, with cognate peptide-MHC Class II (pMHC) complexes on the surface of 
professional antigen-presenting cells. TCR activation induces a cascade of 
downstream signalling pathways that eventually lead to the proliferation of naïve T 
cells and their differentiation into effector cells. Lineage-specific differentiation into 
distinct effector subsets depends on the cytokine milieu of the microenvironment, as 
well as on the concentration and nature of antigens (i.e. self vs. foreign), avidity of 
TCR-pMHC interaction, type of antigen-presenting cells, and costimulatory molecules 
(Constant and Bottomly, 1997; Zhu et al., 2010). 
 
Tfh cell differentiation is known to be driven by a number of transcription factors 
including ASCL2 (Liu et al., 2014), BATF (Betz et al., 2010), c-Maf (Bauquet et al., 
2009), but largely by the expression of BCL-6, a transcriptional regulator that is 
necessary and sufficient to direct Tfh cell differentiation (Johnston et al., 2009; 
Nurieva et al., 2009; Yu et al., 2009). BCL-6 is induced very early during T cell 
activation and is further upregulated in developing Tfh cells (Baumjohann et al., 
2011) in conjunction with upregulation of CXCR5 expression and downregulation of 
CCR7 expression (Ansel et al., 1999). Such changes in the expression of homing 
receptors allow developing Tfh cells to migrate to the boundary between the T cell 
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zone and B cell follicles of secondary lymphoid organs, where they encounter 
antigen-specific B cells (Crotty, 2011). IL-6 and IL-21 cytokines contribute to promote 
Tfh cell differentiation (Nurieva et al., 2008; Vogelzang et al., 2008) and their 
downstream signalling is mediated by the activation of STAT3 and STAT1 
transcription factors (Choi et al., 2013; Ma et al., 2012a). Continued cognate 
interactions with antigen-presenting B cells further polarise Tfh cells (Yusuf et al., 
2010) and help to maintain the Tfh cell phenotype (Baumjohann et al., 2013b). Of 
note, the interaction of ICOS on Tfh cells with ICOSL on dendritic cells and B cells 
plays important roles in multiple stages of Tfh cell differentiation: it provides critical 
early costimulatory signals (Choi et al., 2011), controls follicular recruitment of 
activated T cells (Xu et al., 2013), and promotes Tfh-inducing IL-21 production 
through c-Maf upregulation (Bauquet et al., 2009). 
 
Over the last decade, a fundamental role for microRNA-mediated post-transcriptional 
regulation of gene expression has garnered attention due to its increasingly 
recognised importance in development and disease (Kloosterman and Plasterk, 
2006; Sayed and Abdellatif, 2011). MiRNAs can repress translation and/or reduce 
mRNA stability by targeting the 3′ untranslated region (UTR) of target mRNAs 
(Bartel, 2004). An explosion of high-throughput sequencing efforts has uncovered 
over 900 miRNA genes in the human genome and more than half of all mammalian 
transcripts are predicted to be targets of miRNAs (Sayed and Abdellatif, 2011). Not 
surprisingly, many reports indicate that miRNAs play important roles in regulating 
virtually all biological processes including T cell differentiation (Baltimore et al., 2008; 
Xiao and Rajewsky, 2009). 
 
There is some evidence that miRNAs regulate the Tfh cell gene-expression program 
(Yu et al., 2009) and the plasticity of Tfh cells (Takahashi et al., 2012). Importantly, 
two recent studies reported that miRNAs of the miR-17~92 family act as critical 
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positive regulators of Tfh cell differentiation. The first study described a role for miR-
17~92 in controlling the migration of CD4+ T cells into B cell follicles, and identified 
the phosphatase PHLPP2 as an important mediator in this process (Kang et al., 
2013). The second study used a viral infection model to discover that miR-17~92 
repressed the expression of genes encoding molecules associated with the function 
of effector subsets other than Tfh cells, including Rora, which encodes the Th17-
associated transcription factor RORα (Baumjohann et al., 2013a). Hence, miRNAs 
positively contribute to Tfh cell differentiation. 
 
Here we identify miR-146a as the first miRNA that limits Tfh cell numbers. MiR-146a 
repressed several Tfh cell-expressed mRNAs, and of these, ICOS was the most 
strongly and cell-autonomously upregulated target in miR-146a-deficient T cells. 
Partial blockade of ICOS signalling, either by injections of sub-optimal dose of 
blocking antibody or by halving the gene dose of Icos in miR-146a-deficient Tfh cell 
precursors, prevented the Tfh and GC B cell accumulation. Additional factors 
including STAT1 overexpression in T cells, mildly enhanced T cell sensitivity to IL-6 
signalling, and increased ICOS ligand (ICOSL) expression on GC B cells and other 
antigen-presenting cells, may collectively exacerbate the expansion of Tfh and GC B 
cells in miR-146a-deficient mice. 
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RESULTS 
 
MiR-146a represses multiple Tfh cell mRNAs 
 
To uncover mRNA targets of miR-146a in T cells, we performed a microarray 
analysis on sorted naïve CD4+ T cells from Mir146a-/- mice and wild-type littermates. 
A number of differentially-expressed genes were identified and for further validation, 
we selected putative targets based on: 1) known roles in Tfh and/or germinal centre 
biology, 2) the presence of target sites for miR-146a seed region within their 3’UTR, 
and 3) upregulated mRNA expression in Mir146a-/- T cells. The selected mRNA 
targets were Stat1, Cxcr4, Notch1, Slamf1, Slamf6, Cd84, Icos, Il6st, and Il21r 
(putative miR-146a binding sites are shown in Figure 5.1; previously validated target 
sites in Cxcr4, Notch1, and Stat1 are not shown). 
 
Next we assessed whether the proteins encoded by these putative RNA targets were 
upregulated in miR-146a-deficient T cells using flow cytometry. STAT1, a validated 
target of miR-146a in Tregs (Lu et al., 2010) and an important signalling intermediate 
downstream of the Tfh-inducing cytokines IL-6, IL-12, IL-21, and IL-27, was 
upregulated in Mir146a-/- naïve CD4+, Tfh cells (Figure 5.2) and, as shown previously 
(Lu et al., 2010), in Tregs (Figure 5.3). The validated miR-146a targets CXCR4 
(Labbaye et al., 2008), known to regulate dark zone versus light zone partitioning in 
GCs (Allen et al., 2004; Victora et al., 2012; Victora et al., 2010), and Notch1 (Mei et 
al., 2011), shown to promote Tfh cell differentiation (Auderset et al., 2013), were both 
upregulated in Mir146a-/- effector CD4+, Tfh cells (Figure 5.2) and Tregs (Figure 
5.3). Importantly, we also observed ICOS overexpression in Mir146a-/- naïve, effector 
CD4+, Tfh cells (Figure 5.2) and Tregs (Figure 5.3) compared to wild-type cells.  
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Members of the SLAM family of receptors (SLAMF1, SLAMF6, and CD84) mediate 
prolonged interactions between activated antigen-specific T and B cells and signal 
via the recruitment of SAP to promote terminal Tfh cell differentiation (Cannons et al., 
2011). SLAMF1, SLAMF6, and CD84 were upregulated in Mir146a-/- naïve and 
effector CD4+ T cells compared to their wild-type counterparts (Figure 5.2). CD84 
was upregulated in Mir146a-/- Tfh cells (Figure 5.2) and SLAMF1 and CD84 were 
also upregulated in Mir146a-/- Tregs (Figure 5.3). IL-21R and IL6ST are subunits of 
receptors for IL-21 and IL-6 respectively. IL-21R was upregulated in Mir146a-/- naïve 
(Figure 5.2) and Tregs (Figure 5.3), while IL6ST was upregulated in Mir146a-/- naïve 
and effector CD4+ T cells, but not in Tfh cells (Figure 5.2) or Tregs (Figure 5.3) 
compared to their wild-type counterparts.  
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Figure 5.1 – Alignments of the selected putative miR-146a targets.  
The minimal RNA sequences of Slamf1, Slamf6, Cd84, Icos, Il6st, and Il21r 3’ untranslated 
regions (UTRs) that are predicted to bind to miR-146a are shown 5’ to 3’, whereas mature 
miR-146a sequence is shown from 3’ to 5’. Vertical lines indicate possible base pairing.  
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Naïve  Tfh Effector Naïve  Tfh Effector Naïve  Tfh Effector 
Figure 5.2 – Elevated protein expression of the putative miR-146a targets in Mir146a-/- T 
cells. Geometric mean fluorescence intensity (MFI) values of STAT1, CXCR4, Notch1, ICOS, 
SLAMF1, SLAMF6, CD84, IL-21R, and IL6ST on naïve (CD44low), effector (CD44high) CD4+, and 
Tfh (CXCR5high PD-1high Foxp3-) cells from mice lacking miR-146a (-/-) or wild-type (+/+) 
littermates. Each symbol represents one mouse and the horizontal lines represent the median 
values. Data are representative of at least two independent experiments. ns = not significant, * P 
< 0.05, ** P < 0.01. 
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Figure 5.3 – Increased expression of the putative miR-146a targets in Mir146a-/- Tregs. Dot 
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The selected miR-146a targets that had not been previously validated (Slamf1, 
Slamf6, Cd84, Icos, Il6st, and Il21r) were further tested for direct repression by miR-
146a using luciferase reporter assays. The predicted target sequence from Stat1 
revealed a 25% repression (data not shown), similar to that reported by Rudensky 
and colleagues (Lu et al., 2010). Similar repression was observed using luciferase 
reporters containing the minimal target sequences from Icos, Slamf1, Slamf6, or 
Cd84. All of these targets were specifically repressed by miR-146a, but not by the 
“scramble” miRNA control (a commercially available random sequence miRNA 
mimic) (Figure 5.4). Luciferase reporter constructs containing mutations in the 
sequences recognised by the miR-146a seed region were no longer repressed by 
miR-146a. This not only validated the sequence specificity of the miRNA-mRNA 
binding but also mapped the miRNA recognition sequence in the 3’UTR (Figure 5.4). 
By contrast, luciferase reporter constructs containing the predicted target sequences 
from Il21r and Il6st were not repressed by miR-146a (Figure 5.4). Hence, Icos, 
Slamf1, Slamf6, and Cd84, but not Il21r and Il6st, are likely to be novel direct targets 
of miR-146a. 
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Scramble
miR-146a
Figure 5.4 – MiR-146a directly represses multiple Tfh cell mRNAs.  
Effects of miR-146a (open bars) and scramble (negative control) RNA (filled bars) expression on 
luciferase reporter constructs containing putative miR-146a target sites shown as relative 
luciferase activity (normalised to the Renilla control). Sequence specificity of miRNA-mRNA 
binding was confirmed by introducing mutations to the predicted target sites at regions 
complementary to the miR-146a seed region. Relative luciferase activity of cells transfected with 
miR-146a is expressed as a percentage of that transfected with the scramble RNA. Data are 
representative of at least two independent experiments. The heights of the bars represent the 
mean, and the error bars represent the s.d. of six technical replicates. Statistical significance 
was determined using unpaired Student’s t test. ns = not significant, **** P < 0.0001.  
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Luciferase assays reveal targets of miRNAs when the miRNA is overexpressed in 
HEK293T cells. To assess which of the above targets are physiologically relevant 
and a direct consequence of miR-146a regulation in CD4+ T cells (naïve, effectors, 
and Tfh cells), we assessed their protein expression in Ly5a+.Mir146a+/+: 
Ly5b+.Mir146a-/- mixed bone marrow chimeras. For this, the geometric mean 
fluorescence intensity (MFI) was compared between Ly5a+ and Ly5b+ cells for each 
target. Of all targets, the only one that appeared to be controlled cell-autonomously 
by miR-146a in all CD4+ subsets examined (including Tfh cells) was ICOS (Figures 
5.5-5.8). None of the other targets was cell-autonomously upregulated in Tfh cells 
(Figure 5.5), but some cell-autonomous upregulation was observed for some targets 
in naïve CD4+ T cells (Figure 5.6: CXCR4, SLAMF1, SLAMF6, and CD84), effector 
CD4+ T cells (Figure 5.7: CXCR4), and Tregs (Figure 5.8: CXCR4, SLAMF1, CD84, 
and STAT1). As expected from the luciferase assay results, neither IL6ST nor IL-21R 
were upregulated cell-intrinsically in any of the Ly5b+.Mir146a-/- T cell subsets 
examined (Figures 5.5-5.8). Collectively, our data suggest that miR-146a acts in T 
cells to directly repress the expression of Icos, Slamf1, Slamf6, Cd84 and Cxcr4, and 
of these, the most striking and consistent T cell-autonomous repression, particularly 
in Tfh cells, is exerted on ICOS. 
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Figure 5.5 – Cell-intrinsic upregulation of ICOS on Mir146a-/- Tfh cells.  
Dot plots showing the MFI values of ICOS, CXCR4, SLAMF1, SLAMF6, CD84, STAT1, IL6ST 
and IL-21R on Tfh cells (CXCR5high PD-1high Foxp3-) from mixed bone marrow chimeras 
generated by sub-lethally irradiating Rag1-/- mice and reconstituting their immune system with a 
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+.Mir146a+/+ and Ly5b+.Mir146a+/+ mice analysed 16 weeks post-reconstitution. Data are 
representative of three independent experiments. Each symbol represents one mouse and the 
numbers below the symbols indicate the difference between the median MFI value of Ly5b+ cells 
and that of Ly5a+ cells in each chimera group. Connecting lines between MFI values in Ly5a+ 
and Ly5b+ cells indicate that they are from the same chimeric mouse. 
Mir146a: 
Mir146a: 
 
	   156 
+/+ +/+ +/+ -/-
0
50
100
150
200
IC
O
S 
M
FI
+/+ +/+ +/+ -/-
0
50
100
150
200
250
C
XC
R
4 
M
FI
 
+/+ +/+ +/+ -/-
0
500
1000
1500
2000
SL
AM
F1
 M
FI
 
+/+ +/+ +/+ -/-
0
5000
10000
15000
SL
AM
F6
 M
FI
+/+ +/+ +/+ -/-
0
500
1000
1500
C
D
84
 M
FI
 
+/+ +/+ +/+ -/-
0
200
400
600
800
1000
ST
AT
1 
M
FI
 
+5 +40 +37 +90 +73 +229 +337 +2600 
+76 +114 
C
X
C
R
4 
M
FI
 
S
LA
M
F1
 M
FI
 
S
LA
M
F6
 M
FI
 
C
D
84
 M
FI
 
IC
O
S
 M
FI
 
+193 +176 +396 +239 +178 +135 
S
TA
T1
 M
FI
 
IL
6S
T 
M
FI
 
IL
-2
1R
 M
FI
 
Figure 5.6 – Expression of putative miR-146a targets on naïve T cells from the mixed 
bone marrow chimeras. Dot plots showing the MFI values of ICOS, CXCR4, SLAMF1, 
SLAMF6, CD84, STAT1, IL6ST and IL-21R on naïve (CD44low) CD4+ T cells from mixed bone 
marrow chimeras described in Figure 5.5. Data are representative of three independent 
experiments. Each symbol represents one mouse and the numbers below the symbols indicate 
the difference between the median MFI value of Ly5b+ cells and that of Ly5a+ cells in each 
chimera group. Connecting lines between MFI values in Ly5a+ and Ly5b+ cells indicate that they 
are from the same chimeric mouse. 
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Figure 5.7 – Expression of putative miR-146a targets on effector T cells from the mixed 
bone marrow chimeras. Dot plots showing the MFI values of ICOS, CXCR4, SLAMF1, 
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experiments. Each symbol represents one mouse and the numbers below the symbols indicate 
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Figure 5.8 – Expression of putative miR-146a targets on Tregs from the mixed bone 
marrow chimeras. Dot plots showing the MFI values of ICOS, CXCR4, SLAMF1, SLAMF6, 
CD84, STAT1, IL6ST and IL-21R on Tregs (Foxp3+) from mixed bone marrow chimeras 
described in Figure 5.5. Data are representative of three independent experiments. Each 
symbol represents one mouse and the numbers below the symbols indicate the difference 
between the median MFI value of Ly5b+ cells and that of Ly5a+ cells in each chimera group. 
Connecting lines between MFI values in Ly5a+ and Ly5b+ cells indicate that they are from the 
same chimeric mouse. 
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Deficiency of miR-146a mildly exacerbates the overexpression of ICOS on 
sanroque T cells 
 
Since ICOS is also a target of Roquin (Yu et al., 2007), we asked whether the loss of 
ICOS repression by miR-146a and Roquin could explain the observed exaggerated 
accumulation of Tfh and GC B cells in Mir146a-/- Rc3h1san/san mice (Figure 4.12). 
Indeed, ICOS expression on naïve CD4+ T cells and Tregs from Mir146a-/- 
Rc3h1san/san mice was slightly higher than that from miR-146a-sufficient sanroque T 
cells or wild-type cells (Figure 5.9). This is likely to contribute towards the severe 
accumulation of Tfh cells in the double-mutant mice. This also suggests that miR-
146a still retains some of its function to repress ICOS in the absence of wild-type 
Roquin. In conclusion, Roquin and miR-146a share and are likely to cooperate to 
repress a common mRNA target, Icos. 
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Figure 5.9 – Deficiency of miR-146a slightly exacerbates the overexpression of ICOS in 
sanroque T cells. Dot plots showing the MFI values of ICOS on naïve, effector, Tregs, and Tfh 
cells from unimmunised 8-week old Mir146a+/+ Rc3h1+/+, Mir146a+/+ Rc3h1san/san, and Mir146a-/- 
Rc3h1san/san mice. Each symbol represents one mouse and the horizontal lines represent the 
median values. Data are representative of two independent experiments. Statistical significance 
was determined using unpaired Student’s t test. * P < 0.05, **** P < 0.0001. 
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Increased ICOS signalling in Tfh cell precursors causes Tfh cell accumulation 
 
In light of the profound cell-autonomous control of ICOS by miR-146a and the known 
roles of ICOS in promoting Tfh cell differentiation (Choi et al., 2013; Xu et al., 2013; 
Yu et al., 2007), we set out to examine the contribution of excessive ICOS signalling 
to the expansion of Tfh cells in the absence of miR-146a. To this end, we first titrated 
anti-ICOSL antibody treatment in mice in search of a dose sufficiently low so as to 
not significantly dampen Tfh cell formation in wild-type mice, but still capable of 
reducing the excess amount of engaged ICOS on the surface of Mir146a-/- T cells. 
Injections of 25 µg of anti-ICOSL antibody given every 3 days to wild-type mice after 
immunisation with sheep red blood cells (SRBC) had no significant effect on the Tfh 
cell response (Figure 5.10a). We then used this anti-ICOSL treatment regime on 9-
week old Mir146a+/+ and Mir146a-/- mice immunised with SRBC. This treatment 
completely and consistently corrected the accumulation of Tfh and GC B cells in 
Mir146a-/- mice and still had no effect on wild-type mice (Figure 5.10b). Of note, the 
increase in Tregs seen in Mir146a-/- mice was not consistently corrected by the 
antibody blockade treatment (Figure 5.10b,b’).  
 
We also used a genetic approach to reduce but not eliminate ICOS expression in 
Mir146a-/- mice. Icos hemizygosity was achieved by crossing Mir146a-/- to Icos-/- mice 
to generate Mir146a-/- Icos+/- mice. As seen with the antibody blockade, lowering Icos 
gene dose reduced the percentage of Tfh and GC B cells in Mir146a-/- Icos+/- mice to 
the amount seen in wild-type Mir146a+/+ Icos+/+ mice (Figure 5.11). Importantly, Icos 
hemizygosity did not rescue Treg accumulation in mice lacking miR-146a (Figure 
5.11), suggesting that dysregulation of Treg numbers is not the cause of Tfh cell 
accumulation. Thus, our data indicate that overexpression of ICOS is likely to be a 
prominent contributor to the Tfh cell accumulation in Mir146a-/- mice. To exclude the 
possibility that the observed effect of Icos gene dose reduction was a consequence 
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of modulating ICOS expression on Tregs, we set out to reduce ICOS overexpression 
only in Tfh cell precursors (i.e. naïve T cells). To do this, we co-transferred sorted 
naïve Mir146a-/- CD4+ T cells, which were either Icos+/+ or Icos+/-, with ICOS-sufficient 
B cells and Tregs (Figure 5.12a). Following SRBC immunisation, recipients of 
Mir146a-/- Icos+/- naïve T cells had a 50% reduction in Tfh cells and GC B cells 
compared with those that received Mir146a-/- Icos+/+ naïve T cells (Figure 5.12b). 
These results suggest that Icos overexpression in Tfh cell precursors is indeed 
responsible, at least in part, for Tfh cell accumulation in miR-146a-deficient mice. 
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Figure 5.10 – Sub-optimal doses of anti-ICOSL blocking antibody correct the Tfh and GC 
B cell accumulation in miR-146a-deficient mice. (a) Percentages of Tfh cells in wild-type 
mice immunised with sheep red blood cells (SRBC) and treated with different amounts of anti-
ICOSL (MIL-5733) blocking antibody on days 0, 3, and 6 post-immunisation. Each symbol 
represents the mean and error bars represent the s.d. of three biological replicates. (b,b’) 
Percentages of Tfh (left), GC B (middle), and Treg (right) cells in 9-week old wild-type and 
miR-146a-deficient mice treated with 25 µg anti-ICOSL blocking antibody or PBS control on the 
same regime as in a. Data shown in b and b’ are from two independent experiments. Each 
symbol represents one mouse and the horizontal lines represent the median values. Statistical 
significance was determined using unpaired Student’s t test (a) or Mann-Whitney U test (b,b’). 
ns = not significant, * P < 0.05, ** P < 0.01. 
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Figure 5.11 – Removal of one allele of Icos is sufficient to correct the Tfh and GC B cell 
accumulation in Mir146a-/- mice. Percentages of Tfh (left), GC B (middle), and Treg (right) 
cells in 9-week old Mir146a+/+ Icos+/+, Mir146a+/+ Icos+/-, Mir146a-/- Icos+/+, Mir146a-/- Icos+/- mice 
following SRBC immunisation. Each symbol represents one mouse and the horizontal lines 
represent the median values. Data are pooled from two independent experiments. ns = not 
significant, * P < 0.05, ** P < 0.01. 
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Figure 5.12 – Icos hemizygosity specifically in Tfh cell precursors is sufficient to reduce 
the percentage of Tfh and GC B cells in miR-146a-deficient mice. (a,b) Adoptive transfer of 
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median values. Statistical significance was determined using Mann-Whitney U test. * P < 0.05. 
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Overexpression of the other putative miR-146a targets may also contribute to 
the accumulation of Tfh cells 
 
To explore the role of other miR-146a targets that may contribute to this effect, we 
investigated the consequences of genetic manipulation of STAT1, SLAMF1, and 
SAP. Mir146a-/- mice were first crossed to mice carrying a loss-of-function mutation 
on the Stat1 gene (Stat1fae; MGI:3611892) to generate Mir146a-/- Stat1fae/+ mice, 
which express normal levels of STAT1 (Figure 5.13a). The percentage of Tfh and 
GC B cells in the Mir146a-/- Stat1fae/+ mice was significantly lower than the Mir146a-/- 
Stat1+/+ mice, but remained about 8-fold higher than those seen in wild-type mice 
(Figure 5.13b).  
 
Through a scientific collaboration with the researchers at James Cook University 
(Margaret A. Jordan and Xuyen T. Dinh), the effect of increased Slamf1 copy number 
in Tfh cell formation was investigated using the NOD.Nkrp1b.Tg(Slamf1)1 (SLAM A – 
6 copies of Slamf1) and the NOD.Nkrp1b.Tg(Slamf1)2 (SLAM B – 44 copies of 
Slamf1) (Jordan et al., 2011) transgenic mice. No differences were identified in either 
Tfh cell or GC formation (Figure 5.14). On the other hand, ablation of SAP, a 
common adaptor molecule downstream of the SLAM family proteins, corrected the 
Tfh and GC B cell accumulation in the Mir146a-/- mice (Figure 5.15). This suggests 
that the combinatorial effect of multiple SLAM proteins, instead of SLAMF1 alone, is 
key for the miR-146a-driven Tfh cell expansion.  
 
Although IL6ST and IL-21R are unlikely to be direct targets of miR-146a (based on 
the luciferase assay data), their increased expression in miR-146a-deficient animals 
may still contribute to the accumulation of Tfh cells. Indeed, the overexpression of IL-
6 and IL-21 receptors on Mir146a-/- T cells correlates with a modestly higher 
sensitivity to their respective cytokines. The amounts of phosphorylated STAT3 
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(pSTAT3) and STAT1 (pSTAT1), generated downstream of IL-6 or IL-21 signalling, 
were higher in T cells lacking miR-146a (Figure 5.16). Furthermore, Mir146a-/- naïve 
T cells upregulated CXCR5 and PD-1 expression when cultured in vitro with low 
concentrations of IL-6 and IL-21 (Figure 5.17). This again indicates that Mir146a-/- T 
cells are more responsive to IL-6 and IL-21 signalling. Collectively, these data 
suggest that overexpression of other miR-146a targets may provide additive effects 
contributing to the accumulation of Tfh and GC B cells in miR-146a-deficient mice. 
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Figure 5.13 – MiR-146a-driven Tfh cell accumulation is partially corrected in the presence 
of Stat1 partial gene deficiency. Dot plots showing the STAT1 MFI on Tregs (a) and 
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Figure 5.14 – Overexpression of SLAMF1 is not sufficient to cause spontaneous Tfh and 
GC B cell accumulation. Dot plots showing the percentage of Tfh (left) and GC B (right) cells 
in NOD.Nkrp1b.Tg(Slamf1)1 (SLAM A), NOD.Nkrp1b.Tg(Slamf1)2 (SLAM B) mice, and control 
wild-type littermates analysed at 16 weeks of age. Each symbol represents one mouse and the 
horizontal lines represent the median values. ns = not significant, * P < 0.05, ** P < 0.01, **** P 
< 0.0001. This experiment was performed by Xuyen T. Dinh and Margaret A. Jordan, James 
Cook University.  
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Figure 5.15 – Ablation of SAP corrects the Tfh and GC B cell accumulation in Mir146a-/- 
mice. Dot plots showing the percentage of Tfh (left) and GC B (right) cells in Mir146a-/- Sap-/-, 
Mir146a-/- Sap+/+, and control wild-type mice analysed at 16 weeks of age. Each symbol 
represents one mouse and the horizontal lines represent the median values. Data are pooled 
from two independent experiments. ** P < 0.01, *** P < 0.001. 
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Figure 5.16 – Mild increase in the responsiveness of miR-146a-deficient T cells to IL-6 
and IL-21 stimulations. Flow cytometric analyses of phospho-STAT3 and phospho-STAT1 
expression on naïve and effector CD4+ T cells after acute stimulation with recombinant IL-6 (a) 
or IL-21 (b). Histograms are pre-gated on wild-type naïve CD4+ T cells. Each symbol 
represents one mouse and the horizontal lines represent the median values. Data are 
representative of three independent experiments. * P < 0.05. 
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Figure 5.17 – Functional consequences of increased expression of IL-6 and IL-21 
receptors on miR-146a-deficient T cells. Percentages of CXCR5high PD-1high cells following 3 
days of in vitro culture under the “Tfh-like” skewing condition based on a protocol modified from 
Lu et al., Immunity, 2011. The starting population of naïve CD4+ T cells were obtained from 
wild-type or miR-146a-deficient mice. Different concentrations (in ng/ml) of recombinant IL-6 (a) 
and IL-21 (b) were added to the cultures as indicated. For “Th0” condition, no IL-6 or IL-21 was 
added to the culture. Each symbol represents one technical replicate and the horizontal lines 
represent the median values. Data are representative of two independent experiments. 
Statistical significance was determined using unpaired Student’s t test. * P < 0.05, ** P < 0.01. 
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MiR-146a limits ICOSL in GC B cells and other antigen-presenting cells 
 
The mixed bone marrow chimera results showed that despite the increase in total 
follicular T cells in the Ly5a+.Mir146a+/+:Ly5b+.Mir146a-/- chimeras (Figure 4.13a), 
only the Ly5b+.Mir146a-/- GC B cells, and not the Ly5a+.Mir146a+/+ B cells, expanded 
(Figure 4.14). One of the plausible explanations is that miR-146a co-ordinately 
regulates a receptor-ligand pair in Tfh and GC B cells, so overexpression of both T 
cell-expressed receptor and GC B cell ligand (or vice versa) are required for Mir146a-
/- GC B cells to accumulate. Since our data revealed ICOS as the most prominent 
target of miR-146a in Tfh cells, and T cell-expressed ICOS interacts with B cell-
expressed ICOS ligand (ICOSL) at different stages of Tfh cell and GC formation 
(Choi et al., 2013; Xu et al., 2013), we assessed whether miR-146a also regulates 
ICOSL in B cells. Although we did not find any predicted miR-146a binding site in 
Icosl 3’UTR, previous studies have shown that Icosl transcription is regulated by NF-
κB signalling (Hu et al., 2011), which is partly controlled by miR-146a (Boldin et al., 
2011; Yang et al., 2012; Zhao et al., 2013).  
 
 
To test whether miR-146a controls ICOSL expression in B cells, we sorted total B 
cells from Mir146a+/+ and Mir146a-/- mice, stimulated them in culture for 8 hours using 
LPS or anti-CD40 antibody, and compared ICOSL expression on either GC or non-
GC B cells. No differences in ICOSL expression were observed in non-GC B cells 
under any conditions (Figure 5.18). On the other hand, the expression of ICOSL was 
consistently higher in Mir146a-/- GC B cells – known to be dependent on NF-κB 
signalling (Chen et al., 2010; Pohl et al., 2002; Tumang et al., 1998) – across all 
conditions (Figure 5.18). Furthermore, an increase in ICOSL expression was also 
observed in miR-146a-deficient CD11b+ and CD11c+ cells following in vitro culture in 
the absence or presence of LPS (Figure 5.19). These results suggest that 
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overexpression of ICOSL on GC B cells and myeloid/dendritic cells are likely to 
enhance the effects of increased ICOS expression on Tfh cell accumulation. They 
also suggest that ICOSL overexpression may be required for Mir146a-/- GC B cell 
expansion when ICOS is concomitantly overexpressed in T cells. 
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GC B cells Non-GC B cells 
Figure 5.18 – MiR-146a deficiency leads to increased ICOSL expression on GC B cells. 
ICOSL MFI on GC B (left) and non-GC B (right) cells from SRBC-immunised wild-type or 
miR-146a-deficient mice following stimulation with LPS, isotype control antibody, or anti-CD40 
antibody. Height of bars represents the mean and error bars represent s.d. of three technical 
replicates. Data are representative of three independent experiments. Statistical significance 
was determined using unpaired Student’s t test. ** P < 0.01, *** P < 0.001. 
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Figure 5.19 – MiR-146a deficiency leads to increased ICOSL expression on CD11b+/ 
CD11c+ antigen-presenting cells. ICOSL MFI on a mixture of CD11b+ and CD11c+ cells from 
SRBC-immunised wild-type or miR-146a-deficient mice before and after 8-hour stimulation with 
LPS. Height of bars represents the mean and error bars represent s.d. of three technical 
replicates. Statistical significance was determined using unpaired Student’s t test. ** P < 0.01, 
**** P < 0.0001. 
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DISCUSSION 
 
We have shown that miR-146a represses multiple mRNAs, including Icos, Slamf1, 
Slamf6, Cd84, Stat1, Cxcr4, and Notch1, which collectively are important to facilitate 
T cell costimulation, Tfh cell differentiation, follicular migration, and interactions 
between T and B cells (Auderset et al., 2013; Bannard et al., 2013; Cannons et al., 
2011; Choi et al., 2013; Dong et al., 2001a; Xu et al., 2013). Although these putative 
targets were upregulated in T cells from miR-146a-deficient mice; ICOS was the only 
target upregulated cell-autonomously in Tfh cells, and the most robustly upregulated 
across all T cell subsets examined. Strikingly, dampening ICOS-mediated signalling 
in Mir146a-/- mice, either by generating Mir146a-/- Icos+/- mice or by injecting a sub-
optimal dose of anti-ICOSL antibody, completely prevented miR-146a-driven Tfh cell 
accumulation. Furthermore, adoptive transfer experiments in which only naïve T cells 
lacked one allele of Icos demonstrated that repressing ICOS signalling in Tfh cell 
precursors themselves, rather than in Tregs or other cells, is required to control Tfh 
cell numbers. This is consistent with previous reports showing that cell-autonomous 
Icos mRNA overexpression due to defective Roquin function contributes to excessive 
Tfh cell numbers (Yu et al., 2007).  
 
Intriguingly, we have also found that miR-146a acts cell-autonomously in GC B cells 
to limit their numbers. Increased expression of ICOSL on GC B cells is a plausible 
contributor to their accumulation in the absence of miR-146a and may explain why 
despite the striking increase of Mir146a-/- Tfh cells in the Mir146a+/+:Mir146a-/- 
chimeras, only Mir146a-/- GC B cells, but not Mir146a+/+ GC B cells, expanded. 
Limiting ICOSL signalling is likely to be important to prevent excessive B cell 
activation. Indeed, mice overexpressing soluble ICOSL-Fc developed 
hypergammaglobulinemia and plasmacytosis (Yoshinaga et al., 1999). Our results 
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suggest that concomitant control of ICOS on Tfh cells and ICOSL on GC B may be 
necessary to control the number of GC B cells. 
 
In addition to ICOS-ICOSL regulation, miR-146a-mediated repression of additional T 
cell-expressed targets that were upregulated to some extent in Mir146a-/- T cells 
might also contribute to limit Tfh cells. Our data suggest STAT1 is such additional 
target: lowering the dose of STAT1 had a significant corrective effect on Tfh cell 
accumulation. This effect is likely to, at least in part, be a consequence of STAT1 
overexpression in regulatory T cells, including Tfr cells (Linterman et al., 2011), 
leading to impaired repressive activity (Lu et al., 2010). In addition, STAT1 is also 
known to function downstream of several Tfh-inducing cytokines, including IL-6, IL-
12, IL-21 and IL-27 (Choi et al., 2013; Ma et al., 2012a), thus STAT1 overexpression 
may enhance the sensitivity of miR-146a-deficient T cells to stimulation by these 
cytokines and increase their propensity to differentiate along the Tfh lineage. 
Nevertheless, we did not observe an increase in IL-6-induced STAT1 
phosphorylation in Mir146a-/- T cells. Another candidate that may contribute to the Tfh 
cell accumulation in miR-146a-deficient mice is IL6ST. We found a subtle increase in 
IL6ST expression on Mir146a-/- T cells; although our luciferase assay data indicate 
that it is unlikely to be a direct target of miR-146a. We speculate that increased 
IL6ST expression in Mir146a-/- T cells might cause the observed heightened 
sensitivity of these T cells to IL-6 signalling as measured by STAT3 phosphorylation. 
 
Although this work has focused on identifying Tfh cell-autonomous targets of miR-
146a, it is possible that T cell-extrinsic factors that regulate early T cell activation also 
contribute to the accumulation of Tfh cells in animals lacking miR-146a. Antigen-
presenting cells that are typically CD11c+ and/or CD11b+ did express increased 
amounts of ICOSL, which may enhance T cell priming and exacerbate Tfh cell 
accumulation in Mir146a-/- mice (Choi et al., 2011). In addition, increased expression 
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of the costimulatory molecules CD80 (Zhao et al., 1996) and CD86 (Li et al., 1999), 
and the reported enhanced sensitivity of T cells to antigen stimulation (Yang et al., 
2012) due to dysregulated NF-κB activation may also contribute to the Tfh cell 
expansion. It has been reported previously that strong TCR signalling can skew the 
differentiation pathway of naïve CD4+ T cells towards the Tfh lineage (Fazilleau et al., 
2009; Tubo et al., 2013). Collectively, all of these miR-146a-mediated effects in 
various cell types are likely to act in concert to cause the florid accumulation of Tfh 
cells. 
 
Several miR-146a putative targets studied here were not identified by conventional 
target prediction algorithms, as they do not have a perfect sequence of 
complementarity to the miR-146a seed region. This ability of miRNAs (especially in 
animals) to bind and repress targets with non-canonical sites has been reported 
previously (Baek et al., 2008; Helwak et al., 2013; Loeb et al., 2012; Selbach et al., 
2008). For example, Rudensky and colleagues found that about 40% of miR-155-
dependent Argonaute binding occurs at sites with extensive complementarity to the 
miRNA seed with one mismatch (Loeb et al., 2012). Hence ideally, future studies on 
miRNA-mediated regulation of gene expression should shift from using bioinformatics 
prediction software to incorporating new technologies, such as high-throughput 
sequencing of RNA isolated by crosslinking immunoprecipitation (HITS-CLIP) (Chi et 
al., 2009) and photoactivatable-ribonucleoside-enhanced crosslinking and 
immunoprecipitation (PAR-CLIP) (Hafner et al., 2010), in combination with the 
generation of animal models overexpressing or lacking a particular miRNA in a 
specific cell type, to experimentally identify and validate target mRNAs. 
 
There are also limitations with regards to the target identification strategy used in the 
current study. Firstly, putative targets were shortlisted based on increased 
expression of their mRNAs in Mir146a-/- mice. Previous high-throughput studies 
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showed that although many miRNA targets are affected by both repression of 
translation and mRNA degradation, a number of targets are predominantly regulated 
by translational repression without detectable changes in mRNA levels (Baek et al., 
2008; Selbach et al., 2008). Secondly, only putative targets that have previously 
known roles in Tfh cell homeostasis were studied further. While this strategy is useful 
to identify “the usual suspects”, novel and potentially crucial regulators of Tfh cells 
were excluded from further analysis. For example, Itch and Foxp1 were recently 
reported as positive and negative regulators, respectively, of Tfh cells (Wang et al., 
2014; Xiao et al., 2014). At first glance, both of these molecules lack obvious 
associations to Tfh cell biology; Foxp1 was previously studied in the context of early 
T cell development (Feng et al., 2010) and maintenance of naïve T cell quiescence in 
the periphery (Feng et al., 2011), whereas Itch was known for its role in repressing 
Th2 cell differentiation (Fang et al., 2002). Thus, an unbiased approach in target 
identification, such as PAR-CLIP, should be used in future studies. 
 
The regulation of both innate and adaptive immune cells by miR-146a makes it a 
promising target for immunotherapy of systemic lupus erythematosus (SLE). There is 
accumulating evidence showing that SLE is a complex systemic inflammatory 
autoimmune disease characterised by pro-inflammatory cytokines (mainly type I 
interferons) secreted by dendritic cells, and also the presence of autoantibodies due 
to defective B cell tolerance (Chan et al., 2012; Kotzin, 1996; Ronnblom and Pascual, 
2008; Yurasov et al., 2005). Of note, miR-146a was found to be expressed at lower 
levels in SLE patients as compared with healthy controls (Tang et al., 2009). Hence, 
administration of miR-146a mimic may prove more efficient in treating SLE than 
combining anti-interferon-α receptor and anti-ICOSL antibody treatments that are 
currently in development (Baccala et al., 2012; Hu et al., 2009; Wang et al., 2013). 
The present discovery of miR-146a-dependent control of Tfh and GC B cells, mainly 
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via ICOS-ICOSL regulation, may therefore contribute to human autoimmunity and 
inflammatory syndromes and may be exploited for therapeutic purposes in the future. 
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CHAPTER SIX 
 
 
General discussion 
 
In the present study, the role of Roquin proteins and microRNA-146a in Tfh cell 
differentiation and germinal centre (GC) biology were investigated. We have shown 
that Roquin and Roquin-2 both repress Icos mRNA in a 3’UTR-dependent fashion. 
Mice harbouring loss-of-function mutations in Roquin and Roquin-2 consequently 
showed elevated ICOS expression on effector CD4+ and Tfh cells compared to wild-
type mice. This was accompanied by increased Tfh and GC B cells upon sheep red 
blood cell (SRBC) immunisation. Also, we have identified miR-146a as the first 
miRNA that limits Tfh cell numbers. Absence of this miRNA led to spontaneous Tfh 
and GC B cell accumulation in 12 to 16-week old mice. MiR-146a repressed several 
Tfh cell-expressed mRNAs, and of these, ICOS was the most strongly and cell-
autonomously upregulated target in miR-146a-deficient T cells. Partial blockade of 
ICOS signalling, either by injections of sub-optimal dose of blocking antibody or by 
halving the gene dose of Icos in miR-146a-deficient Tfh cell precursors, prevented 
the Tfh and GC B cell accumulation. 
 
Overall, these findings highlight the significance of: 1) controlling ICOS expression at 
the post-transcriptional level to prevent excessive B cell responses potentially leading 
to autoimmunity, 2) multiple regulatory mechanisms that may act in concert to 
repress the same target mRNA, and 3) the potential therapeutic relevance of 
targeting ICOS-mediated signalling to treat antibody-mediated autoimmune diseases. 
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LIMITING ICOS EXPRESSION IS ESSENTIAL TO PREVENT TFH CELL 
ACCUMMULATION 
 
ICOS, together with CD28 and CTLA-4, is a member of the CD28-family of 
costimulatory receptors. These molecules have arisen by gene duplication and they 
play important roles in balancing the T cell response. ICOS and CD28 transmit 
positive signals that promote and sustain T cell activation, whilst CTLA-4 mainly 
attenuates TCR signalling (Sharpe and Freeman, 2002). ICOS and CD28 also have 
distinct roles in the immune response. CD28 is essential for T cell priming, whereas 
ICOS is crucial for the effector phase of the immune response. Besides the reported 
difference between these two family members in their ability to recruit signalling 
molecules such as Grb2 (Watanabe et al., 2006), their relatively selective roles 
during different phases of the immune response could largely be attributed to their 
different temporal expression: while CD28 is constitutively expressed, ICOS is 
induced after T cell priming (Beier et al., 2000; Mages et al., 2000; McAdam et al., 
2000) and is expressed at high levels on effector T cells and at highest levels on GC 
Tfh cells (Bentebibel et al., 2011; Hutloff et al., 1999). 
 
The GC reaction is a key example of where ICOS and CD28 perform separate critical 
roles during the same immunological process. Previous studies showed that in the 
absence of CD28, B cells did not undergo proliferative expansion to form GCs after 
immunisation with T-dependent antigens, suggesting that CD28 is essential for GC 
formation (Ferguson et al., 1996). Administration of a CD28 agonist in conjunction 
with protein immunisation revealed that CD28 was absolutely required for the 
initiation of the GC response, but not for GC maintenance (Walker et al., 2003). On 
the other hand, GC formation was observed in Icos-/- mice after protein immunisation, 
although they were reduced in size (Dong et al., 2001a; McAdam et al., 2001; Tafuri 
et al., 2001). These data show that, unlike in Cd28-/- mice, initiation of the GC 
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response is intact in the absence of ICOS, however its progression and/or 
maintenance are disrupted. Data from the present study, together with previous work 
from our group and others, have extended our knowledge on the role of ICOS in the 
GC and this is summarised below. 
 
The role of ICOS in Tfh cell differentiation 
 
A critical role for ICOS in the GC was first suggested following the discovery that 
ICOS is expressed at its highest levels on Tfh cells (Hutloff et al., 1999). Further work 
revealed that ICOS-/- CVID patients have impaired humoral immunity, reduced 
numbers of memory B cells and isotype class switching (Grimbacher et al., 2003; 
Warnatz et al., 2006). They also have defects in GC formation, with only a few, 
rudimentary GCs in the lymph nodes (Grimbacher et al., 2003). Previous work on 
mice where ICOS has been inactivated have similarly demonstrated that ICOS is 
important for T cell-dependent antibody responses, immunoglobulin class switching, 
and cytokine production (Dong et al., 2001a; McAdam et al., 2001; Tafuri et al., 
2001). On the other hand, excessive ICOS expression leads to increased Tfh cell 
numbers and GC overactivity as shown in this thesis. This is consistent with previous 
data from our laboratory and others (Vinuesa et al., 2005a; Vogel et al., 2013; Yu et 
al., 2007). 
 
Studies using ICOS-deficient mice have also shown that ICOS contributes to both the 
formation and subsequent maintenance of Tfh cells as they exhibit impaired Tfh cell 
development in both primary and secondary responses (Akiba et al., 2005; Bossaller 
et al., 2006; Gigoux et al., 2009). Interactions of ICOS on T cells and ICOSL on DCs 
and B cells have been shown to be important for the early (T cell priming) and late 
(T:B interaction at the T:B border) BCL-6 upregulation, respectively (Choi et al., 
2011; Nurieva et al., 2008). Furthermore, ICOS-ICOSL interaction was recently 
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described to play a role in directional motility and follicular recruitment of activated 
CD4+ T cells (Xu et al., 2013). Not surprisingly, similar reductions in Tfh cell numbers 
were also seen in mice that lack ICOSL expression on B cells (Nurieva et al., 2008). 
Of note, ICOS-ICOSL signalling did not seem to be essential for the differentiation of 
other T cell subsets (Bauquet et al., 2009). Thus, ICOS is involved at multiple stages 
of Tfh cell development and maintenance. 
 
In light of the multiple roles of ICOS in the GC, the observed accumulation of Tfh 
cells in miR-146a-deficient mice presented here might be due to both increased 
formation of Tfh cells from naïve T cells and prolonged maintenance of BCL-6 and 
Tfh phenotypes due to ICOS overexpression. Indeed, our adoptive transfer 
experiments showed that, at the peak of the GC, there was an increase in the 
percentage of Tfh cells in mice that received Mir146a-/- naïve T cells, which was 
corrected by deleting one copy of Icos. On the other hand, miR-146a is most highly 
expressed at the late stage of a GC response, thus it is likely to also antagonise the 
function of ICOS in sustaining GCs. In the future, a longitudinal study can be 
performed by transferring Mir146a-/- T cells into recipient mice and monitoring 
whether deficiency of miR-146a causes prolonged GC reactions, and whether this 
can be corrected by reducing the amount of ICOS. In summary, ICOS expression 
needs to be tightly controlled to prevent Tfh cell accumulation. 
 
Post-transcriptional mechanisms to limit ICOS expression 
 
The expression of ICOS is known to be regulated transcriptionally by NFAT and 
MAPK signalling pathways (Tan et al., 2006), as well as by the T helper cell-specific 
transcription factors T-bet and GATA-3 (Tan et al., 2008). Recently, the AP-1 
transcription factor Fra2 was also shown to regulate Icos gene transcription 
(Watanabe et al., 2012). In contrast, relatively little is known about how it is regulated 
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at the post-transcriptional level. 
 
Although transcription is an essential first step in the regulation of gene expression, it 
cannot be rapidly turned off or redirected (Anderson, 2010; Carpenter et al., 2014). 
Certain mRNAs have a long half-life allowing them to continue to synthesise proteins 
long after transcription has stopped. Post-transcriptional gene regulation, can either 
extend protein expression by mRNA stabilisation, or rapidly repress protein 
expression by inducing mRNA decay or disrupting translation, despite ongoing gene 
transcription (Anderson, 2010; Carpenter et al., 2014). The swift effects of post-
transcriptional regulation may be particularly important in the GC reaction. This is 
because Tfh cells need to be able to rapidly migrate in and out of GCs (Shulman et 
al., 2013) – a process that is likely to be accompanied by fast changes in the 
expression of multiple migration and guidance receptors including ICOS (Xu et al., 
2013). Tfh cells also need to interact through repeated transient contacts with B cells 
(Shulman et al., 2014) which undergo fast evolution in terms of their cycling ability 
and acquisition of mutations in their antibody variable region genes, and make rapid 
selective decisions during these T:B cell encounters. Furthermore, timely repression 
of Tfh cell functions might be crucial in certain responses, since prolonged GCs have 
been associated with unintended activation of self-reactive B cells and autoimmunity 
(Vinuesa et al., 2009). 
 
The Icos mRNA has a remarkably long (~2,000 base pair) 3’UTR containing multiple 
regulatory elements that may be subject to post-transcriptional regulation by RNA-
binding proteins or miRNAs (Yu et al., 2007). It is likely that when Icos transcription is 
induced, it synthesises proteins for a short period of time before it is destroyed or 
silenced. Thus far, Roquin is the only post-transcriptional mechanism demonstrated 
to regulate Icos mRNA (Glasmacher et al., 2010; Schlundt et al., 2014; Tan et al., 
2014; Yu et al., 2007). The work presented here adds two more players in the 
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regulation of Icos mRNA at the post-transcriptional level: Roquin-2 and miR-146a. 
Furthermore, experiments using miR-146a-deficient sanroque mice (shown here) and 
parallel related work by other members of our group have suggested a possibility that 
Roquin and miR-146a may interact and work with each other in carrying out their 
function to repress Icos and this is explored further in the next section. 
 
FUNCTIONAL INTERACTIONS BETWEEN ROQUIN AND MICRORNA-146A 
 
Our luciferase assays have identified several potential targets of miR-146a, but only 
ICOS was significantly upregulated in a cell-autonomous manner in all miR-146a-
deficient T cell subsets examined. Moreover, it is not uncommon for top candidates 
of miRNA regulation, as predicted by in silico algorithms, to fail experimental 
validations. Why certain mRNAs are more susceptible to miRNA-mediated regulation 
than others remains largely unknown. Recent developments revealed that interaction 
of RNAs with RNA-binding proteins (RBPs) is an important contributor to this 
phenomenon (Ho and Marsden, 2014). For instance, mRNAs that interact with RBPs 
to form stabilising complexes will be relatively resistant to microRNA-mediated 
inhibition (Ho et al., 2013). 
 
One of the first reports demonstrating that miRNAs and RBPs can target the same 
elements in mRNA 3’UTRs showed that TTP recruits miR-16-containing RNA-
induced silencing complexes (RISCs) to AU-rich elements (ARE)-containing mRNAs, 
including Tnf and Cox2, resulting in mRNA degradation (Jing et al., 2005). In 
addition, HuR has also been implicated in the recruitment of let-7 and miR-19 bound 
to RISCs to target Myc (Kim et al., 2009) and Rhob mRNAs (Glorian et al., 2011) 
respectively. In contrast to the above, HuR has also been shown to protect Cat1 
mRNAs from miR-122-mediated translational repression through its binding to ARE 
sequences, under cellular stress conditions such as amino acid starvation and 
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oxidative stress (Bhattacharyya et al., 2006). Hence, RBPs and microRNAs can 
engage in competition or collaboration with each other. 
 
Pertinent to the present work, our data suggest that miR-146a is likely to cooperate 
with Roquin in repressing Icos mRNA. In another study conducted in our laboratory, 
Icos appeared to be equally de-repressed in vitro when either the Roquin binding site 
or miR-146a binding sites in Icos 3’UTR were mutated, suggesting that Roquin and 
miRNAs act together to regulate Icos (Srivastava et al., 2014). Nevertheless, in vivo, 
the absence of miR-146a resulted in a more exaggerated increase of ICOS 
expression in sanroque T cells compared with that of miR-146a-sufficient sanroque 
cells, suggesting additional functions of miR-146a potentially independent of Roquin 
in Icos mRNA regulation. The nature of the interaction between Roquin and miR-
146a is discussed in more detail below. 
 
Roquin regulates miR-146a expression and function 
 
We have shown that mature miR-146a is present in excess amounts in sanroque 
naïve T cells. Data provided by our collaborator Vigo Heissmeyer (Helmholtz 
Zentrum München, Germany) further showed that miR-146a was also increased in 
Roquin-1/2-deficient T cells (Srivastava et al., 2014), collectively suggesting that 
miRNA dysregulation is due to the loss of Roquin’s function. Work undertaken in our 
laboratory has investigated the cause of this phenomenon. This study demonstrated 
that miR-146a accumulation was not due to increased transcription or processing, 
rather to enhanced stability of mature miR-146a in the absence of wild-type Roquin 
(Srivastava et al., 2014). 
 
Paradoxically, the elevated expression of miR-146a in sanroque T cells is 
accompanied by an increase – rather than the expected decrease – in ICOS 
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expression (a target of miR-146a as shown in this thesis) in the same cells (Vinuesa 
et al., 2005a; Yu et al., 2007). One possibility is that Roquin is a part of general 
cellular machinery controlling expression and/or stability of different RNA species – in 
this case mRNAs and miRNAs. Hence, loss of Roquin’s function may result in the 
dysregulation of multiple RNA species. However, this still does not account for the 
increased ICOS expression in the presence of excess miR-146a, unless Roquin is 
also involved in facilitating miRNA-mediated gene repression and the sanroque allele 
prevents normal miRNA function. 
 
Srivastava and colleagues in our laboratory, together with previous work 
(Athanasopoulos et al., 2010), showed that Roquin binds to Icos mRNA and miR-
146a, and also forms a complex with the RISC component Argonaute-2 (Srivastava 
et al., 2014). Furthermore, crystallisation of the Roquin N-terminus by our 
collaborator Jeff Babon (WEHI, Melbourne) revealed that Roquin contains three 
RNA-binding domains, ROQ, HEPN and CCCH zinc-finger domains. These domains 
give rise to two highly probable RNA-binding surfaces (Srivastava et al., 2014). A 
similar structure of Roquin has been recently reported by an independent research 
group (Tan et al., 2014). It is tempting to speculate that Roquin binds miR-146a-
containing RISCs and Icos via its CDE domain – a conserved stem-loop motif 
previously shown to be recognised by Roquin (Leppek et al., 2013; Schlundt et al., 
2014; Tan et al., 2014) – bringing both miRNA and target mRNA into close proximity, 
in an analogous manner to HuR and TTP mentioned above. Furthermore, as the 
‘san’ mutation is expected to change the surface shape and electrostatic properties 
of the protein but not to disrupt the RNA-binding interface (Tan et al., 2014), it is 
possible that this mutation diminishes Roquin’s interaction with the decapping 
proteins (Glasmacher et al., 2010) or the deadenylase complex (Leppek et al., 2013), 
shown previously to be important in target mRNA degradation. These consequently 
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could lead to the accumulation of both miR-146a and its target Icos when Roquin is 
mutated. 
 
This Roquin-miR-146a cooperation is likely to operate preferentially in T cells, 
whereas miRNA-independent Roquin-mediated RNA degradation, previously shown 
using Dicer-/- mouse embryonic fibroblasts (Glasmacher et al., 2010), is likely to be 
active in other cell types. This is further supported by the observation that the degree 
of Icos repression by Roquin increased with the length of Icos 3’UTR (Glasmacher et 
al., 2010), indicating that multiple sites on Icos 3’UTR, and perhaps several 
mechanisms, may be necessary to induce full repression by Roquin. Also, given the 
very high sequence similarity between Roquin and Roquin-2 in the RNA-binding 
domains, it will be interesting to test whether Roquin-2 also binds to Icos via its CDE 
region and whether Roquin-2 interacts with other regulatory non-coding RNAs to 
repress Icos and its other targets. 
 
MiR-146a potentially regulates Roquin expression 
 
According to a widely used miRNA target prediction algorithm miRanda (John et al., 
2004), miR-146a may target human Roquin (RC3H1) mRNA itself in a 3’UTR-
dependent manner. Although further work is required to experimentally validate this 
observation, it supports the notion that dynamic interactions between different 
regulatory mechanisms are present in the cell and the fate of a specific target mRNA 
lies in the balance between these cellular components. 
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TRANSLATING RESEARCH FINDINGS INTO THE CLINIC 
 
A break in immunological tolerance has detrimental and potentially fatal 
consequences, manifesting as autoimmune disease. Different types of autoimmunity 
can occur depending on where the immunological lesion is; broadly, these are 
divided into systemic and organ-specific. Systemic lupus erythematosus (SLE) is the 
prototypic systemic autoimmune disease, in which the immune system targets 
nuclear antigens causing tissue damage in multiple organs. Our current study is 
particularly relevant to this disease as both miR-146a-deficient mice and sanroque 
mice exhibit increased titres of anti-nuclear autoantibodies in the serum. 
 
SLE is a life-long systemic autoimmune inflammatory disease that can affect many 
parts of the body. A butterfly-shaped rash across the face is a characteristic sign of 
the disease and gave it its Latin name (lupus = wolf). SLE can be mild or life 
threatening, and at least five million people worldwide have a form of lupus according 
to estimates from Lupus Foundation of America. In Australia, it affects about 1 in 700 
people. Both environmental and genetic factors have been implicated in SLE 
pathogenesis (Tsokos, 2011). Twin studies have shown that disease concordance in 
monozygotic twins is greater than 24%, while concordance in dizygotic twins and 
siblings is only 2-5% (Block, 1993; Jarvinen and Aho, 1994; Reichlin et al., 1992). 
Strikingly, nine out of every ten people with lupus are women of childbearing age 
(Guerra et al., 2012) and people from all ethnic backgrounds can develop the 
disease; although it tends to be more prevalent and severe amongst Africans, 
Hispanics, and Asians than other racial or ethnic groups (Tsokos, 2011). 
 
The symptoms of SLE occur largely due to circulating immune complexes consisting 
of anti-nuclear antibodies bound to target antigens being deposited in the skin, joints, 
and kidney, causing inflammation and organ damage (Mok and Lau, 2003; Tsokos, 
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2011). Additionally, these immune complexes have the capability to activate the 
complement system (Cook and Botto, 2006) and antigen-presenting cells (Means et 
al., 2005), which can further activate the immune system in response to self-
antigens. Current treatment options for SLE include the use of corticosteroids, 
hydroxychloroquine, and other immunosuppressive agents (Hahn, 2011; Yildirim-
Toruner and Diamond, 2011). However, these treatments lack specificity, rarely lead 
to disease remission (Urowitz et al., 2005), and broadly suppressing many cell types 
and cellular processes often causing serious side effects (Gordon, 2002; Zonana-
Nacach et al., 2000). Therefore, a deeper understanding of the molecular mechanism 
of SLE and specifically targeting the offending pathway(s) could greatly improve the 
quality of life for people living with the disease. The work presented here, together 
with previous studies, has revealed the importance of Tfh cells and ICOS in mouse 
models of SLE and this is discussed in more detail below.  
 
Impact of excessive Tfh cells in systemic lupus erythematosus 
 
Studies performed in mice have provided extensive insight into the cellular basis of 
autoimmunity that is simply not possible in humans. The sanroque mouse strain 
develops SLE-like symptoms, including the presence of anti-nuclear antibodies 
(ANAs), polyclonal hypergammaglobulinemia, and focal proliferative 
glomerulonephritis with deposition of IgG-containing immune complexes (Vinuesa et 
al., 2005a). Further work showed that the aberrant Tfh cell development in sanroque 
mice is responsible for the autoimmune phenotypes, as selective depletion of Tfh 
cells in sanroque mice by crossing to Sap-/- mice resulted in the remission of the 
autoimmune phenotypes (Linterman et al., 2009b).  
 
ICOS overexpression in Roquin-mutant mice is likely to contribute to Tfh cell 
expansion and a break in T cell tolerance (Vinuesa et al., 2005a; Yu et al., 2007). 
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Excessive signalling through ICOS on naïve T cells upon binding its ligand on resting 
antigen-presenting cells has been shown to override the requirement for CD28-
mediated costimulation for Tfh and GC formation. This would result in aberrant 
activation of T cells, including those recognising self-antigens on immature antigen-
presenting cells (Linterman et al., 2009a). These results are supported by the 
findings that disruption of ICOS-ICOSL signalling could prevent autoantibody 
formation and organ damage in lupus (Iwai et al., 2003) and collagen-induced 
arthritis (Iwai et al., 2002; Nurieva et al., 2003). Nevertheless, there is some evidence 
that ICOS overexpression and spontaneous GCs are not absolutely essential for all 
autoimmune manifestations: Rc3h1san/san Icos-/- mice still develop kidney infiltrates 
and anti-nuclear antibodies (Lee et al., Immunity 2012), and Rc3h1san/san Obf1-/- mice 
that cannot develop GCs, have IgM deposits in the kidneys (Chevrier et al., 2014). In 
summary, tight regulation of Tfh cell numbers and ICOS expression are important for 
maintaining peripheral tolerance, and additional Roquin-regulated molecules 
contribute to prevent autoimmune disease. 
 
Determining whether Tfh cells also play a role in SLE pathogenesis in humans has 
been rather challenging. This is because bona fide Tfh cells are only found within 
GCs in secondary lymphoid organs, which are almost always unavailable for analysis 
in humans. However, recent findings from our laboratory and others have revealed 
the existence of Tfh cell circulating counterparts (He et al., 2013; Locci et al., 2013; 
Simpson et al., 2010). This has provided an opportunity to more easily study Tfh cells 
in human disease by sampling peripheral blood from patients. Flow cytometry and 
gene expression analyses have demonstrated that these circulating cells express 
characteristic molecules found on the Tfh cell subset in secondary lymphoid organs 
albeit at lower levels; amongst them are ICOS, CXCR5, and PD-1 (He et al., 2013; 
Locci et al., 2013). There were marked correlations between expansion of Tfh-like 
cell subsets in lupus patients with increased serum titres of autoantibodies, and the 
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incidence of glomerulonephritis and thrombocytopenia (He et al., 2013; Simpson et 
al., 2010). In addition, increased amounts of ICOS have been found on peripheral 
blood CD4+ T cells from SLE patients (Kawamoto et al., 2006). Pertinent to the 
current study, SLE patients were shown to have reduced levels of miR-146a in their 
peripheral blood leukocytes (Tang et al., 2009), hence it is likely that the cellular 
basis of autoimmunity in the miR-146a-deficient mice closely resembles that of SLE 
patients. Thus, Tfh cells and ICOS may also contribute to SLE pathogenesis in 
humans. 
 
Moving toward new treatments for systemic lupus erythematosus 
 
Findings presented in this thesis indicate that targeting Tfh cells, or more specifically 
ICOS signalling, is likely to improve the current therapeutic approaches for SLE. In 
contrast to the commonly prescribed broad immunosuppressants, targeting the GC 
reaction will keep the other facets of the immune system mostly intact and able to 
respond to environmental threats, which is likely to reduce the disease burden in 
autoimmune individuals. Further work is required to determine if the efficacy of this 
therapeutic strategy is restricted to a subset of patients with elevated numbers of 
circulating Tfh-like cells. 
 
Development of targeted therapies for SLE has been conducted intensively in the last 
decade in conjunction with our increasing knowledge of SLE pathogenesis, albeit 
with a disappointingly low success rate. The approval of belimumab by the US Food 
and Drug Administration in 2011 not only marked the first (and, to date, only) biologic 
agent to be approved for SLE, but also marked the first SLE drug of any type to be 
approved in the last 50 years (Hahn, 2013). Belimumab is a monoclonal antibody 
against BAFF, which is an important cytokine for B cell survival (Davidson, 2010). In 
mice, certain (although not all) autoreactive B cells have a greater dependency on 
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BAFF for their survival than do non-autoreactive B cells (Lesley et al., 2004; Ota et 
al., 2010; Thien et al., 2004), so antagonism of BAFF may preferentially eliminate a 
subset of pathogenic B cells while sparing protective B cells. 
 
Emerging therapeutics is also aimed at targeting the autoantibody-producing B cells, 
as they are central to the pathogenesis of SLE. A number of therapeutics has been 
developed to specifically deplete B cells, including rituximab (anti-CD20) and 
epratuzumab (anti-CD22). The use of rituximab in SLE has had mixed results, with 
some patients of African-American and Hispanic backgrounds responding with 
reduced clinical scores, while others did not show improvements in clinical outcomes 
despite exhibiting reductions in anti-dsDNA and serum C3 and C4 levels (Merrill et 
al., 2010b; Rovin et al., 2012). Preliminary studies of epratuzumab that stimulates an 
inhibitory receptor on B cells (CD22) showed an improvement in disease activity in 
patients with moderately-to-severely active SLE after given a specific dose of the 
drug (Wallace et al., 2014), and larger clinical trials are currently being conducted. 
Hence, although successful treatment with either monoclonal antibody is limited thus 
far, a number of clinical trials with different designs (in terms of the antibody dosage, 
frequency of drug administration, and disease severity of recruited patients) are still 
underway (Stohl, 2013). 
 
As mentioned previously, experiments using lupus-prone mice have demonstrated a 
vital role for T cells, especially Tfh cells, in SLE pathogenesis (Chesnutt et al., 1998; 
Linterman et al., 2009b). Abatacept, a fusion protein composed of the extracellular 
domain of human CTLA-4 and the Fc domain of human IgG1, was developed to 
inhibit CD28-mediated T cell activation. Although the mouse analogue of abatacept 
showed efficacy in a mouse model of lupus (Finck et al., 1994b), results from the 
clinical trials have been disappointing (Furie et al., 2014; Merrill et al., 2010a). 
Another strategy is to disrupt T cell activation by blocking CD40-CD40L engagement. 
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This costimulatory pathway might be especially important in SLE, given that CD40L 
is overexpressed by both CD4+ and CD8+ T cells in SLE patients (Desai-Mehta et al., 
1996). Unfortunately, results from human SLE trials with two different anti-CD40L 
monoclonal antibodies have also been discouraging. In one trial, the tested anti-
CD40L was safe but ineffective (Kalunian et al., 2002), whereas in the other trial, the 
antibody appeared to be effective (treated patients showed decreased anti-dsDNA 
antibodies, proteinuria, and SLE disease activity index) but the trial was terminated 
as two patients suffered myocardial infarctions (Boumpas et al., 2003). Thus none of 
the T cell-targeted therapy in SLE has yielded satisfactory results so far. This is likely 
to be due in great part to the enormous disease heterogeneity [patients have to fulfill 
only 4 out of 11 criteria (Hochberg, 1997) to be diagnosed with this disease], and the 
lack of patient stratification (i.e. testing a T cell-targeted therapy to patients who 
exhibit Tfh cell expansion, whilst a B cell-targeted therapy to those with mature B cell 
accumulation). 
 
The present work warrants further investigation on the efficacy of ICOS-ICOSL 
signalling blockade as a treatment for SLE, particularly in patients that have an 
overactive Tfh pathway as determined by higher numbers of circulating Tfh-like cells. 
ICOSL blockade in a murine model of lupus nephritis has shown promising results 
(Iwai et al., 2003), and it has also consistently reduced the numbers of Tfh and GC B 
cells in the autoimmune-prone miR-146a-deficient mice shown in this thesis. An anti-
ICOSL antibody (AMG557) therapy is currently being evaluated for human SLE 
(Stohl, 2013). 
 
In addition, miR-146a mimic should also be considered as a therapeutic agent for 
SLE as miR-146a level is reduced in peripheral blood leukocytes of SLE patients 
(Tang et al., 2009). On top of targeting Icos mRNA, miR-146a also limits STAT-1 and 
SLAM-family proteins that are important for Tfh cell differentiation (shown here), 
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represses IL-6, a pro-inflammatory cytokine that has been associated with SLE 
(Finck et al., 1994a; Linker-Israeli et al., 1991), and regulates type I interferon 
pathway that has been correlated with active SLE (Tang et al., 2009). 
 
There are still major technical challenges that need to be overcome before miRNA-
targeted therapies can be used in immunological diseases: difficult delivery of 
miRNAs to T cells (Peer, 2013), potential uptake of miRNA by non-target tissues that 
do not normally express it, introduction of miRNA at supra-physiological 
concentration (van Rooij and Kauppinen, 2014), and potential TLR activation against 
double-stranded RNAs (Peacock et al., 2011). Thus, further work is required to 
ensure that targeted delivery of miRNA mimics to the appropriate cell or tissue at a 
physiological level can be achieved. The design and delivery method of miR-34, the 
first miRNA mimic to advance into the clinic for cancer treatment, may be used as an 
example. Systemic delivery of miR-34 mimic blocked tumour growth in mouse 
models of lung cancer (Wiggins et al., 2010) and prostate cancer (Liu et al., 2011). 
Importantly, liposomal encapsulation by neutral lipid emulsion of the miR-34 mimic 
was shown to facilitate cellular uptake by endocytosis and protect the miRNA from 
degradation with minimal toxicities and no significant increases in serum pro-
inflammatory cytokines (Wiggins et al., 2010). 
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CONCLUDING REMARKS 
 
In conclusion, work presented in this thesis explored the role of Roquin-family 
proteins and microRNA-146a in the post-transcriptional regulation of Icos to limit Tfh 
and GC B cell numbers. Data presented here have shown that Roquin-2 is able to 
compensate for Roquin’s function, at least in the repression of ICOS, when Roquin 
fails to localise to stress granules. In addition, this work has demonstrated that miR-
146a is acting in T cells to control ICOS, STAT-1, and, to some extent, sensitivity to 
IL-6 signalling. Also, miR-146a appears to limit ICOSL on GC B cells and other 
antigen-presenting cells, although the exact mechanism of this regulation remains 
unclear. Collectively, these suggest that controlled expression of ICOS within the GC 
is required for maintaining peripheral tolerance. In the context of recent advances in 
targeted therapy for SLE, as well as in miRNA-based therapeutics, characterisation 
of Roquin proteins and miR-146a in mice is an exciting first step in considering them 
as potential therapeutic agents that specifically neutralise Tfh cells. 
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